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Abstract 
Primary progressive multiple sclerosis (PPMS) is a chronic demyelinating disease of the central 
nervous system (CNS) currently lacking any effective treatment. Promoting endogenous brain 
repair offers a potential strategy to halt and possibly restore neurologic function in PPMS. To 
understand how the microenvironment within white matter lesions plays a role in repair I focused 
on neural progenitor cells (NPCs) since they have been found within lesions and influence 
oligodendrocyte progenitor cell (OPC) maturation. To better understand the cellular nature of 
NPCs in PPMS I developed induced pluripotent stem cells (iPSCs) from blood and skin samples 
of PPMS patients and age matched non-disease controls. Using these lines I determined that 
NPCs from PPMS cases provided no neuroprotection against active CNS demyelination and 
failed to promote OPC maturation whereas NPCs from age-matched control cell lines did so 
efficiently. I determined that NPCs from PPMS patients displayed hallmarks of cellular 
senescence, inhibiting their proper functioning. Cellular senescence is a form of adaptive cellular 
physiology associated with aging. Cellular senescence causes a pro-inflammatory cellular 
phenotype that impairs tissue regeneration, has been linked to stress, and is implicated in several 
human neurodegenerative diseases. Senescent NPCs were identified within white matter lesions 
of human progressive MS autopsy brain tissues. Expression of cellular senescence genes in 
PPMS NPCs was found to be reversible by treatment with rapamycin which then enhanced PPMS 
NPC support for oligodendrocyte differentiation. A proteomic analysis of the PPMS NPC 
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secretome identified high mobility group box-1 (HMGB1), which was found to be a senescence-
associated inhibitor of oligodendrocyte differentiation. Transcriptome analysis of OPCs revealed 
that senescent NPCs induced expression of epigenetic regulators mediated by extracellular 
HMGB1. Lastly, I determined that NPCs are a source of elevated HMGB1 in human white matter 
lesions. Based on these data, cellular senescence contributes to altered NPC functions in 
demyelinated lesions in MS. Moreover, these data implicate cellular aging and senescence as a 
process that contributes to remyelination failure in progressive MS which may impact how this 
disease is modeled and inform development of future myelin regeneration strategies. 
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Chapter 1: Multiple Sclerosis (MS) and Remyelination 
 
I. Diagnosis, Clinical Forms, and Treatments for MS 
Multiple sclerosis (MS) was first well defined by Jean-Martin Charcot (1825-1893), a 
French neurologist at the Hôpital de la Salpêtrière in 1868, where he named the disease “la 
sclérose en plaques”, literally meaning a “plaque-like sclerosis” [1]. We now know that the 
presence of sclerotic plaques in the brain pathology from patients who had this disease are 
inflamed and demyelinated areas. Brain lesions remain one of the bases for diagnosis for MS, 
but identification of these lesions has been modernized with imaging techniques such as magnetic 
resonance imaging (MRI). 
MS is currently the most prevalent chronic inflammatory disease of the central nervous 
system (CNS) among young adults, affecting approximately 2.5 million people worldwide [2]. The 
disease is characterized by chronic lesions or plaques of demyelination found throughout the 
brain and spinal cord. The demyelination is a result of death of the myelinating cells, the 
oligodendrocytes (OLs), which renders axons susceptible to injury, without trophic support, and 
without their electrically insulating layer. Axons that are typically myelinated, and then become 
demyelinated with the disease, have deficits in saltatory conduction. At the earlier stages of 
disease, patients most often present with disrupted vision, tingling in their limbs which can be 
accompanied with limb weakness, or ataxia. It is important to point out that the symptoms a patient 
first experiences will vary based on the location of lesions, and the complete disease course for 
any patient is highly individualized and will vary depending on the subtype of MS (Fig. 1.1) [3].  
There is currently no single test that can accurately diagnose MS. It is generally the clinical 
repercussions of the disease that coax someone to come to the clinic. In corroboration with patient 
history and neurological exam, after the presence of symptoms, physicians rely on the use of MRI 
to identify lesions that are disseminated in time and disseminated in space, which have been the 
most important criteria in diagnosing MS [4]. In July of 2000 the International Panel on the 
Diagnosis of MS met and produced what is now called the McDonald Criteria for diagnosing MS 
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[5]. This set of criteria has been evolving and is updated every couple of years due to new 
discoveries and methodologies for diagnosis, and has been most recently updated in 2017. Brain 
and spinal cord MRI still remain the most useful test that aid in the diagnosis of MS. In order to 
distinguish MS from other acute demyelinating conditions, such as acute demyelinating 
encephalomyelitis, repeated imaging is necessary to determine if CNS lesions are disseminated 
in space and time [3]. CNS lesions in MS are typically multifocal white matter lesions in 
characteristic locations, including: periventricular, juxtacortical (next to the cortex), and in the 
spinal cord, close to the pial surface [6]. Examination of the cerebrospinal fluid (CSF) for 
oligoclonal banding, which is the presence of immunoglobulins, is also used to diagnose MS [7]. 
The observation of immunoglobulins in the CSF is indicative of the immune system generating 
antibodies against self, but it is not specific to just MS, therefore CSF testing needs to be used in 
conjunction with other methods of diagnoses [8, 9]. Breakdown of the myelin peptide, myelin basic 
protein (MBP), has also been found to be present in the CSF of patients with MS, but its presence 
does not increase accurate diagnosis [10]. MS is the most common condition that induces 
demyelination, but there are other conditions that can damage myelin including viral infections, 
toxin poisoning, and hereditary disorders, therefore most of these need to be eliminated before a 
diagnosis of MS can be achieved [11]. 
There are various subtypes of MS including: relapsing-remitting MS (RRMS), secondary-
progressive MS (SPMS), progressive relapsing, and primary progressive MS (PPMS) (Fig. 1.1). 
RRMS represents 80-85% of all MS cases, is typically diagnosed in young adults (20-30 years of 
age), and is more common in women with a ratio of 3:1 [12]. The disease is characterized by 
episodic attacks of new or escalating neurological symptoms called “relapses”, which are typically 
followed by periods of remittance, where the disease spontaneously resolves. Symptoms 
generally start with sensory disturbances, such as double vision, which then worsen over time to 
include limb weakness resulting in clumsiness. Over time patients will be encumbered with 
fatigue, display cognitive impairment, and the disease often culminates in progressive disability 
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leading to quadriparesis [13]. The National MS Society currently predicts that 25 years after 
RRMS diagnosis 90% of patients will develop SPMS, generally around 40 years of age [14, 15]. 
SPMS is diagnosed when the patient experiences a worsening disease condition without the 
periods of remission. Unfortunately, when disease advances to the progressive phase current 
immune-modulatory therapies fail to provide any clinical benefit and do not slow down the 
worsening development of the disease (Fig. 1.2).  
PPMS is the most aggressive form of MS and represents approximately 10-15% of all MS 
cases. These patients are typically diagnosed in their 40s and their disease is described as a 
gradual but progressively declining clinical course, which often presents as an upper-motor-
neuron syndrome of the legs [14, 16]. This disease then gradually worsens into quadriparesis, 
with cognitive decline, and eventually cerebellar, bowel, bladder, and sexual dysfunction [13]. 
Unlike relapsing forms of MS, the immune system seems less involved in the brains of PPMS 
patients [16], which makes the current immunomodulatory therapies useless in treating these 
patients (Fig. 1.2). Salient differences between PPMS and RRMS will be discussed further in this 
chapter. 
The majority of MS cases, specifically the RRMS subtype, are believed to be driven by the 
immune system categorizing them as an autoimmune disease. Helper and cytotoxic T cells have 
been found in MS lesions [17], and have been found to be reactive to myelin self-antigens - which 
are used as a diagnostic for MS. It is the development of autoimmunity directed against myelin 
that is currently thought to bring about the eventual destruction of myelin in MS. RRMS patients, 
in particular, have been found to have myelin-reactive T cells that exhibit an activated phenotype, 
measured by an increase in proliferation. In contrast, T cells from healthy controls exhibit a naïve 
phenotype, with a significantly lowered amount of proliferation [18]. Activated T cells can cross 
the blood-brain barrier (BBB) through a step-wise process called extravasation. The BBB in MS 
patients becomes abnormally permeable to immune cell infiltration before inflammatory 
demyelination in MS [19]. Known T cell targets include myelin antigens, such as myelin basic 
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protein (MBP), myelin-associated glycoprotein (MAG), myelin oligodendrocyte glycoprotein 
(MOG), and proteolipid protein (PLP) [13]. In addition, the most common DNA sequence variants 
in patients with MS are those in the human leukocyte antigen (HLA) locus, which code for the cell-
surface proteins responsible for the regulation of the immune system [20]. To support the T cell-
driven theory of MS, a similar experimental disease, called experimental autoimmune 
encephalomyelitis (EAE), can be induced in rodents and primates by immunization with myelin 
antigens. EAE leads to inflammatory CNS demyelination driven by myelin-reactive T cells. Current 
effective treatments for RRMS focus on the activation and migration of immune cells to abate the 
T cell response, such as interferon (IFN)-β (Betaseron), which decreases the expression of T 
helper cells, and natalizumab (Tysabri) which prevents T cell infiltration across the BBB by 
blocking adhesion to the neurovascular endothelium [21]. 
B cells, the professional antigen presenting cells of the immune system, have also been 
implicated in MS, as B cell-depleting antibodies have been found to limit MS lesion formation and 
clinical disease activity [22]. B cells also produce antibodies, which have been found in lesion 
areas, but also produce cytokines, in turn becoming pathogenic [23]. It is becoming increasing 
clear that B cells play an important role other than antibody production in MS, as the amount of 
antibodies are largely unchanged after B cell depletion [24]. Their actions in the development and 
progression of MS are still largely unknown. Ocrelizumab (Ocrevus) is currently the only FDA 
approved therapy for the treatment of progressive forms of MS, which works by targeting B cells 
[25]. Currently the extensive body of work on the immune system in MS, including the diversity of 
cells and cellular response in MS is complex, and while important, exceeds the scope of this 
thesis which is focused on progressive MS.  
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Figure 1.1. Clinical disease courses in the various subtypes of MS. Representative graphs 
of the clinical presentations of the subtypes of MS. Y axis depicts the increase in disability and 
the X axis represents time. Panels are labeled based on the subtype of MS they are representing. 
Figure from the National Multiple Sclerosis Society (https://www.nationalmssociety.org/What-is-
MS/Types-of-MS).   
Relapsing-Remitting (RRMS) Secondary Progressive 
(SPMS)
Primary Progressive 
(PPMS)
Progressive Relapsing
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Currently all treatments for MS predominately focus on the immune system. 
Corticosteroids, such as intravenous methylprednisolone, are initially administered to dampen the 
inflammation that occurs during a MS relapse [26]. It has been proposed that corticosteroids 
reduce the expression of adhesion molecules [27], which helps prevent the extravasation of 
damaging immune cells into the CNS, while also reducing T cell activation and increasing 
expression of transforming growth factor (TGF)-β which is detectable in the CSF [28]. 
Corticosteroids provide a shorter recovery time from relapses, but show no overall long-term 
benefit [29]. 
The first disease-modifying treatment (DMT) for MS, approved by the Food and Drug 
Administration (FDA) in 1993, is interferon (IFN)-β (Betaseron) (Fig. 1.2). Currently, there are five 
formulations of the drug that have been developed to treat RRMS. IFN-β has been shown to 
increase the production of anti-inflammatory cytokines, such as IL-10 and IL-4 [30], decrease the 
production of pro-inflammatory cytokines, such as IL-17 [31], and limit immune cell trafficking 
across the BBB [32, 33]. In placebo experiments IFN-β was shown to be effective in reducing the 
relapse rate in patients with RRMS, but does not alter the progressive disease activity [34]. IFN-
β has no effect on the time it takes for RRMS patients to develop SPMS, instead it only decreases 
rate and duration of relapses, and provides no measurable benefit for PPMS patients [35]. 
Glatiramer acetate (Copaxone) is another immunomodulatory drug made up of a mixture 
of peptides that are found in myelin basic protein (MBP) (Fig. 1.2). The mechanisms of how this 
drug works are not fully understood, but it is believed to be able to promote the shift of pro-
inflammatory T cells to regulatory T cells that suppress an inflammatory response [36]. In clinical 
trials, it prolongs the time to additional relapses and reduces the risk of new lesions, but does not 
alter the development of SPMS [37]. 
Natalizumab (Tysabri) was the first monoclonal antibody that was approved for RRMS, 
which acts by targeting a receptor (α4 integrins) found on activated immune cells, preventing them 
to migrate into the CNS (Fig. 1.2) [21]. Clinical trials have shown that it reduces the number of 
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clinical relapses and treatment resulted in fewer new and enlarging lesions [38]. Although 
natalizumab has been characterized as effective in the reduction of relapses, as well as new 
lesion formation, it leaves the CNS with no immune protection, which may lead to the development 
of progressive multifocal leukoencephalopathy (PML), a fatal demyelinating disease caused by 
the John Cunningham (JC) virus [39]. In a study surveying a large, multinational MS population, 
the JC virus antibody was found to be in 57.1% of the population, eliminating over half of the total 
MS population that could safely take this drug [40]. 
Fingolimod is a sphingosine 1-phosphate receptor (S1PR1) modulator, binding to this 
receptor expressed on immune cells, leading to its internalization and downregulation. The 
internalization of S1PR1 on T cells prevents their release from the lymph nodes and thus dampens 
the immune responses [41]. The mechanism of action of fingolimod may also be CNS mediated 
as S1PR1 expression on astrocytes has been shown to be necessary for the clinical benefit of 
treatment in an animal model of disease [42, 43]. Clinical trials have shown that with early 
treatment it can reduce the risk of disability progression and decreases the number of new or 
enlarging lesions [44]. Interestingly, fingolimod has been shown to have potentially 
neuroprotective effects in the EAE model of MS [45] and may promote the differentiation of 
oligodendrocyte progenitor cells (OPCs) into mature, myelinating oligodendrocytes [46, 47]. 
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Figure 1.2. Timeline of drug developments in the treatment of multiple sclerosis. Milestones 
made in drug approval for the treatment of MS by the FDA. RRMS, relapsing-remitting multiple 
sclerosis; PPMS, primary progressive multiple sclerosis. Figure adapted from Tintore et al., 2018 
[48]. 
  
1993
Subcutaneous 
IFNβ is the first 
drug approved 
for RRMS
1996
Subcutaneous 
glatiramer 
acetate 
approved for 
RRMS
2004
Intravenous 
Natalizumab is the 
first monoclonal 
antibody approved 
for RRMS
2010
Fingolimod is 
the first oral 
drug approved 
for RRMS
2015
First generic drug 
(glatiramer 
acetate) approved 
for RRMS
2017
Ocrelizumab 
becomes the first 
drug to be 
approved for 
PPMS
	 9 
Over the past couple years clinical studies have determined that the earlier DMT  
treatment can begin in patients with RRMS (within 5 years of the diagnosis) the more effective 
these therapies are at slowing the progression of disease into the progressive phase (i.e. SPMS), 
yet treatment does not reduce the progression of disability once SPMS manifests [49]. In contrast 
to RRMS, where there are many anti-inflammatory and immunomodulatory therapies that help 
with the number and severity of relapses, there are very little treatment options available for PPMS 
or SPMS that are effective. In March of 2017 the first drug for the treatment of PPMS was 
approved by the FDA, ocrelizumab, where it only reduced the risk of progression by 24% in 
patients compared with placebo controls [25] (Fig. 1.2). I will discuss these findings further in the 
next section on primary progressive MS. Due to the lack of effective treatments for SPMS and 
PPMS targeting repair strategies via remyelination is an ideal way to develop future treatments 
for MS. 
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II. What causes MS? 
 MS is not considered an inherited genetic disease, but the use of genome-wide 
association studies (GWAS) has identified over 100 genetic regions that are associated with the 
risk of developing MS [50]. These extensive genetic surveys have revealed the presence of 
“genetic susceptibility” for MS but no single genetic locus as a culprit. The majority of the MS-
associated candidate genes are related to immunology and T cell function, which are often 
common to other autoimmune diseases, such as rheumatoid arthritis [51]. These include human 
leukocyte antigen (HLA) genes, which are those that code for cell surface antigen-presenting 
proteins that modulate immune system responses. Polymorphisms in these genes are believed 
to account for 20-60% of the genetic susceptibility in MS [52]. Another gene candidate identified 
is apolipoprotein E (ApoE), which is synthesized in the CNS, has immunomodulatory effects, and 
is involved in lipid and cholesterol transport as well as brain development. A meta-analysis of 
6,977 subjects proposed a mutation in ApoE increased MS risk [53]. However, MS is not carried 
as a Mendelian trait, but there is a higher disease concordance rate within families and different 
ancestral groups [54, 55]. A Canadian twin study, published in 2003, showed a concordance rate 
of MS to be 25.4% between monozygotic twin pairs and 5.4% in dizygotic twins, which suggests 
a genetic component to the disease, but did not account for environmental factors outside of utero 
[56]. There has been no one study which shows a complete dependence on genetics in the 
development of MS, instead it is believed to be caused by a multitude of factors. MS is a 
multifactorial and complex condition, with a heterogeneity of subtypes, and based on current 
GWAS it is not only caused by one or two genetic mutations, but genetics may increase 
susceptibility. 
 Environmental influences such as latitude, vitamin D deficiency, viral or bacterial 
infections, and obesity have been thought to be implicated in the cause of MS. Those living at 
higher latitudes have a higher prevalence in developing MS, which is largely believed to be due 
to UV exposure and vitamin D exposure [57]. Another study demonstrated, by compiling data 
	 11 
from other studies, that insufficient UV light of the correct wavelength, which enables vitamin D 
synthesis, increases the potential of MS prenatally. This study also demonstrated the ‘month of 
birth’ effect, where those born during winter months have a reduced risk of MS, while those born 
in the spring have an increased risk [58]. Maternal vitamin D levels during pregnancy affect the 
immune system of the fetus, which may alter the risk of developing MS [59].  
 For many years studies have tried to determine if a single virus could represent a causative 
agent for developing MS. These investigations have yielded no pathogen link to MS, although 
potentially compelling associations with several agents have been suggested. One aspect of this 
disease where viruses have been implicated is in the severity of relapses [60]. Viral infections of 
the CNS can cause inflammation and damage to oligodendrocytes. The damaged fragments of 
myelin can be recognized by autoreactive T cells that can in turn trigger more inflammation and 
myelin destruction [61]. An additional potential mechanism is that infections outside of the CNS 
can activate T cells with a foreign peptide similar to that of a myelin peptide, which is termed 
“molecular mimicry” [62]. For example, molecular mimicry between myelin basic protein and the 
Epstein-Barr virus (EBV) latent antigen, EBNA1, has been well documented [63]. Interestingly, 
human data has demonstrated that MS risk is extremely low in individuals not infected with EBV, 
and EBV infection increases the risk of MS [64, 65]. EBV-specific T cells have been found to be 
expanded in the CSF of patients with MS [66]. However, EBV, or other viruses, such as influenza, 
are not the sole cause of MS, but may play a role in the severity of disease course and relapses. 
 The cause of MS is not known. It is widely accepted that MS is a multifaceted, complex 
disease. There is no single factor implicated in the cause of MS, instead it may be caused by 
interaction through the various factors mentioned above, including genetic susceptibility and 
environmental instances. Based on the varying subtypes of MS and the constellation of symptoms 
per patient, causal pathways for disease are likely to differ from individual to individual. 
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III. Primary Progressive Multiple Sclerosis (PPMS) 
The clinical features of PPMS are vastly different from the more common RRMS. Patients 
with PPMS, instead of encountering relapses, develop a disease course of chronic unremitting 
worsening disability. This form of MS affects 10-15% of the MS patient population and differs from 
RRMS in that it has no gender bias [67, 68]. What is most striking about PPMS is that patients 
are usually diagnosed in their 40s or 50s which is significantly later in later than RRMS which is 
typically diagnosed in the late 20s [14]. Interestingly, the majority of RRMS patients, after 20-25 
years of diagnosis, advance into a secondary-progressive disease course (SPMS), which is also 
characterized by a clinical phenotype similar to primary progressive disease; persistent 
development of symptoms without relapses [69]. Both PPMS and SPMS are typically diagnosed 
around the same age, suggesting that processes in aging may contribute to the development of 
progression in MS [70]. For instance, eight years after presentation and diagnosis of progressive 
MS, patients generally require assistance for walking, and typically after 18 years patients are 
wheelchair-bound [67]. Most commonly, patients with PPMS present with visual loss but also 
spinal syndrome, reflected in symptoms that include spastic paraparesis and cerebellar 
dysfunction [71]. 
What remains a consistent feature of progressive forms of MS is the presence of white 
matter lesions, along with atrophy and cortical demyelination, while the essential element is “a 
gradual nearly continuously worsening baseline with minor fluctuations but no distinct relapses” 
[72]. Currently, PPMS is diagnosed based on positive MRI lesions, especially in the spinal cord, 
a delayed visual evoked response, and identification of oligoclonal bands in the CSF [73]. There 
is no one blood or CSF marker that can accurately diagnose PPMS, instead, like RRMS, it is 
based on the symptomology experienced by the patient along with MRI lesion evidence. 
Progressive MS is accurately diagnosed post-mortem by analysis of white matter lesions in 
corroboration with patient symptoms. Actively demyelinating white matter lesions, as defined by 
the increased presence of macrophages at the border in and around the lesion area, are more 
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frequently found in RRMS. Lucchinetti et al. identified and described four different patterns of 
lesions found in MS [23]. Patterns I and II share similar features of active demyelination 
associated with the presence of T cells and macrophages. The difference is the presence of 
immunoglobulin deposits at the lesion site, found exclusively in pattern II. Both pattern I and II 
lesions are associated with small veins and venules with active myelin destruction in the plaque 
center. Pattern III lesions are composed mainly of T cells, macrophages, and activated microglia 
without the presence of immunoglobulin deposits. The borders of these types of lesions are ill 
defined, and demonstrate spreading into the surrounding white matter. Lesion patterns I-III are 
associated with shadow plaques, indicating remyelination, and are distributed homogenously in 
RRMS. Lastly, pattern IV lesions are defined by primary oligodendrocyte degeneration, similar to 
a viral infection or toxin and not associated with autoimmunity [23]. It is unknown whether these 
lesion patterns change over the disease course, but pattern IV lesions are exclusive to PPMS 
[16].  
Inactive or chronic active MS lesions are characterized by a rim of microglia and 
sometimes macrophages around the lesion area, and are more common in PPMS [74]. 
Interestingly, inflammation from invading macrophages, such as T cells, is less pronounced in 
progressive MS, suggesting that the inflammation is trapped within the blood-brain barrier [75]. 
Slowly expanding lesions account for approximately half of all lesions found in progressive MS 
[75, 76]. The lesion center is an area of complete demyelination with evidence of profound axonal 
loss and significant astrocytic scarring. Lesions have also been noted to be surrounded by 
activated microglia, which are also scattered diffusely surrounding normal-appearing white matter 
[77]. Besides white matter lesions, another prominent neurological sign in MS patients is the loss 
of overall brain volume [78]. During the progressive stage of the disease there is a gradual 
expansion of pre-existing white matter lesions and widespread cortical demyelination, although 
these changes occur with only mild apparent blood-brain barrier damage [79], making this form 
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of MS significantly different from RRMS, which is primarily T cell mediated with prominent BBB 
breakdown [17, 80]. 
 Histological analysis of demyelinated lesions has found oligodendrocyte progenitor cells 
(OPCs) present within chronic lesions [23, 81]. Since these cells have the capability of 
differentiating into mature, myelinating oligodendrocytes, they offer the potential for brain repair, 
though these cells within lesions exhibit very little to no remyelination activity. Remyelination in 
MS is indicated through the presence of “shadow plaques”, which are partially remyelinated 
lesions and can be identified with luxol fast blue staining [23]. Analysis of post-mortem brain tissue 
found that remyelination in MS patients is variable from patient to patient, yet is significantly 
sparse in progressive MS cases [16, 82, 83]. The mechanisms of myelin repair in patients with 
progressive MS remain elusive and represent a field of intense study. More recently age has been 
proposed as a natural limit on CNS myelination which may have implications for understanding 
the disease-related processes of limited remyelination in MS. 
 Current disease modifying therapeutics used to treat RRMS have little to no therapeutic 
effect in progressive MS. There are no significant treatments that reverses, stops, or even slows 
the progressive disability once it has become established, but for the first time in March of 2017 
a drug for the treatment of PPMS was approved by the FDA (Fig. 1.2) [84]. Ocrelizumab is an 
immunosuppressive drug, a humanized monoclonal antibody, that binds to CD20, only found on 
B cells, and selectively kills them by causing antibody-dependent cell-mediated cytotoxicity. B 
cells have been found to contribute to MS through antigen presentation, the production of 
antibodies, and cytokine secretion. In progressive MS B cells have been found in the meninges 
of patients, where they could be furthering chronic demyelination and inflammation [85, 86]. A 
recently published trial, performed in only patients with PPMS, indicates that ocrelizumab was 
associated with lower rates of clinical and MRI progression compared to those on a placebo [25]. 
Overall, out of the PPMS patient population selected, 32.9% taking ocrelizumab versus 39.3% 
taking placebo had confirmed disability progression after 12 weeks. In addition, the percentage 
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of brain-volume loss was 0.9% with ocrelizumab and 1.09% with placebo [25]. This still leaves 
significant room for improvement in drug therapies to slow progression in these patient 
populations with progressive MS, and suggests that a multifaceted therapy may be best, such as 
a combination of immune suppression and remyelination. 
Despite the increasing knowledge on progression in MS there are still many questions that 
remain unanswered, such as the underlying mechanisms that drive progression. Understanding 
the exact mechanisms involved in the progressive forms of MS will aid in the development of new 
therapeutics that could target multiple aspects of the disease process. One way to model how 
remyelination can be controlled and how progression develops is through the use of animal 
models.  
 
IV. Animal Models of Central Nervous System (CNS) Demyelination 
Since MS is a complex human disease, there is no single animal model that can capture 
exactly what goes on in human MS. Nevertheless, mouse models have become a tremendous 
resource toward understanding how specific aspects of the immune system function and how 
demyelination occurs in MS [87]. Animal models have been used to study disease development, 
test novel therapeutic approaches, and provide a convenient source of CNS tissue in which to 
study demyelination. Currently, the most widely adopted animal models of CNS demyelination 
are: experimental autoimmune encephalomyelitis (EAE), virus induced demyelination (i.e. 
Theiler’s murine encephalomyelitis virus (TMEV) infection), and toxin-induced models 
(cuprizone). 
The most commonly used animal model of MS is EAE. This T cell dependent model of 
CNS demyelination results from an induced autoimmunity evoked by immunization with 
components of myelin. In the 1930s, in an attempt to produce encephalomyelitis Rivers et al. 
immunized monkeys with rabbit brain extracts which were found to induce paralysis associated 
with immune cell infiltration and demyelination in the brain and spinal cord [88]. Now, EAE is 
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induced by injection of specific myelin peptides, specifically antigenic epitopes of myelin proteins, 
such as: myelin oligodendrocyte glycoprotein (MOG) (35-55) peptide, MBP (87-99) peptide, or 
proteolipid protein (PLP) (139-151) which are emulsified in complete Freund’s adjuvant (CFA) 
[89]. While many protocols for induced EAE have been developed, injection of pertussis toxin, 
which has been suggested to transiently enhance the permeability of the BBB, has been found to 
increase the responsiveness of animals to the immunization of self-antigens [90, 91]. EAE in mice 
is characterized by an ascending paralysis, beginning with tail atonia, followed with hind limb 
paresis and paralysis which can advance to involve forelimb paralysis (quadriplegia). Based on 
the genetic background of the mice (SJL/J, C57BL/6, NOD), and on the type of immunization 
(protein vs. peptide) the EAE course will vary. Most commonly, EAE induced using MOG peptide 
(35-55) in C57BL/6 mice is well characterized as a monophasic disease course, without relapses. 
The disease is instigated by autoreactive CD4+ T cells that primarily cause demyelination in the 
spinal cord, unlike human MS, where lesions are primarily in the brain [92]. Other models of EAE 
include MBP-derived peptides or PLP administered to SJL/J mice [93, 94] which induce 
spontaneous relapses and have utility as a model of RRMS.   
The use of EAE has benefited research and patients with MS, as three of six approved 
MS therapeutics showed results with this model: glatiramer acetate, mitoxantrone, and 
natalizumab [92]. However, EAE is not the perfect model as it does not recapitulate the same 
immune mechanisms seen in patients [95]. For example, the lesions in EAE are primarily in the 
spinal cord whereas lesions are more prevalent in the brains of patients, there is difficulty in 
reproducibility of EAE severity, and there is inherent difficulty in studying remyelination processes 
because lesions form sporadically and not in predictable locations. A pharmaceutical example 
would be the use of a TNF neutralizing antibody. In EAE mice suppression of TNF was found to 
ameliorate disease, while in human trials, unexpectedly, it was found to worsen the disease, and 
therefore further study has been discontinued [96, 97]. EAE also provides limited insight into 
understanding the disease-related processes of progression in MS or PPMS pathology as EAE 
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models are primarily T cell dependent, while PPMS is not. In addition, mice with EAE do not 
display additional progression after immunization, instead they typically exhibit robust recovery 
and efficient remyelination, making them unsuitable for studying progressive forms of MS [92].. 
Viruses have a long-standing association with MS [98]. Studies have suggested that viral 
infection(s) early in life, such as EBV, in genetically susceptible individuals may underlie induction 
of an immune-mediated attack against the CNS [99]. Viral infections of the CNS have been found 
to induce demyelination in mice, such as Theiler’s murine encephalomyelitis virus (TMEV) and 
strains of the coronavirus mouse hepatitis virus (MHV) [100]. Through the use of viral models we 
have further elucidated possible mechanisms by which virus infections can lead to delayed CNS 
autoimmunity through epitope spreading [101]. Viral infection models of demyelination all rely on 
the activation of immune cells. Unlike MS the pathogenesis of TMEV-induced demyelination 
requires a persistent viral infection, and TMEV can only induce inflammatory demyelination in 
genetically susceptible strains of mice [102]. Interestingly, in TMEV infection, axonal damage 
precedes demyelination, which is believed to trigger the recruitment of T cells into the CNS, 
causing demyelination through what is called an "inside-out" mechanism [103]. Even though virus-
induced demyelination in mice is significantly different from MS, these models have proven useful 
in testing new therapeutics for targeting axonal degeneration and immunosuppression. 
Immune-mediated models of CNS demyelination all have limited utility for understanding 
how remyelination occurs and how it can be promoted. Targeting remyelination and 
neuroprotection holds the most promise in treating progressive MS. Development of additional 
models of demyelination that involve administration of toxins have enabled researchers to 
accurately time and localize sites of demyelination that allow for study of the endogenous process 
of remyelination. Currently, two models are extensively studied for these purposes: dietary 
consumption of cuprizone (Fig. 1.3), a copper chelator, and direct injection of lysolecithin into 
white matter tracts in the CNS. Cuprizone is fed to mice and causes dysfunction of mitochondrial 
complex IV which selectively kills oligodendrocytes because they are extremely susceptible to 
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oxidative stress [104]. Along with oligodendrocyte cell death, there is significant activation of 
astrocytes and microglia [105]. Cuprizone lesions are similar to human pattern IV MS lesions [23], 
which show very little to no T cell infiltration, and are characterized by significant oligodendrocyte 
death and innate immune activation (microglia) [81, 106]. White matter lesions in the cuprizone 
model are predictable and occur in highly myelinated areas such as the corpus callosum and 
cerebellum (Fig. 1.3). Based on the amount of cuprizone given in the diet, and the length of 
treatment, the amount of total demyelination will vary along with any accompanying behavioral 
deficits, which do not present as an overt phenotype and do not appear until at least 6 weeks of 
toxin treatment [107]. Although demyelination in the cuprizone model is extensive and 
widespread, once cuprizone is removed from the diet, new oligodendrocytes from the pool of 
OPCs begin to fully remyelinate the lesions [104]. Manipulation of this remyelination process has 
been adopted as a means by which to identify mechanisms on how remyelination occurs and how 
it can be promoted endogenously in progressive MS patients [108-110]. Although the cuprizone 
model is not a model to study autoimmune-mediated demyelination, it is widely used as an 
effective system to study the basic mechanisms that occur during demyelination and 
remyelination.  
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Figure 1.3. Representative electron micrographs (EM) of compact myelin in the corpus 
callosum of naïve wildtype mice (left) and mice treated with cuprizone (right). Six week old 
mice were fed cuprizone (0.2% w/v) for 4 consecutive weeks and myelin was imaged in the corpus 
callosum. Scale bar, 2 μm. Images from Nicaise et al., 2017 [111].  
D
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Injection of lysolecithin, an activator of phospholipase A2, into white matter tracts 
represents another model of CNS demyelination. When lysolecithin is injected it focally induces 
demyelination due to the primary toxic effects on oligodendrocytes [112, 113]. Focal injection 
produces a non-immune mediated, rapid and highly reproducible form of demyelination. This 
model allows for analyzing demyelination and remyelination as discrete events with 
“spatiotemporal predictability” [114]. Again, use of this toxin based model since does not involve 
engagement of T cells. When taken together, toxin based models provide systems to study the 
processes of de- and remyelination. Based on the research question, toxin models may provide 
the most appropriate mouse model for study, although it is important to note that no one animal 
model accurately replicates all of the features of myelin damage and immune system biology in 
human MS. 
 
V.  Endogenous Remyelination 
 Remyelination is mediated by a resident population of endogenous stem cells found within 
the brain throughout lifespan called oligodendrocyte progenitor cells (OPCs) and neural 
progenitor cells (NPCs) (Fig. 1.4). Both of these cell populations are widely distributed throughout 
the white and grey matter, and persist throughout adulthood [115]. These are both undifferentiated 
cell types capable of self-renewal, and both can give rise to mature oligodendrocytes if provided 
with the appropriate cues and signals. Neural progenitor cells arise from the adult subventricular 
zone (SVZ), located next to the lateral ventricles, and the subgranular layer of the dentate gyrus 
in the hippocampus [116, 117]. Even though the SVZ expands in response to demyelination and 
NPCs are found to migrate and reside within areas of demyelination, it is clear that remyelination 
fails [118]. The role of NPCs in remyelination failure in MS and in persistent demyelinated lesions 
in progressive MS are unclear [119]. The limited remyelination observed to occur in MS has limited 
long-term benefit due to the recurring inflammation in this disease, and compact myelin resulting 
from remyelination is much thinner than normal appearing white matter myelin [120]. For these 
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reasons the development of therapeutics which can promote healthy and permanent 
remyelination is a high priority. The ways in which NPCs contribute to impairing or promoting 
remyelination will be discussed in the next sub-chapter. 
 Oligodendrocyte differentiation occurs in a sequence of temporally defined steps that can 
be identified by expression of stage-specific markers and dramatic changes in cellular 
morphology. In development, oligodendrocyte differentiation is a highly regulated process that is 
controlled spatially and temporally through tightly controlled signals such as growth factors and 
extracellular matrix molecules. OPCs migrate more extensively compared to astrocytes and 
neurons. They arise from the ventricular zone in the embryonic brain and spinal cord and their 
domains are then defined through the formation of patterns [121]. In early development OPCs 
arrive ventrally, then followed by waves of dorsally derived cells [122, 123]. This long-range 
cellular migration of OPCs, from germinal zones, is critical to development and has been found 
to be regulated by transforming growth factor β (TGFβ), vasculature, and Wnt signaling, among 
other factors [122, 124]. Once they have migrated and populated the white matter, OPCs 
proliferate and mature. The eventual development of OPCs occurs in a series of stages 
dependent on extrinsic factors, such as the environment, and intrinsic factors such as epigenetics 
[124-126]. 
 Immature OPCs have a bipolar morphology and express markers like platelet-derived 
growth factor α-receptor (PDGFR-α), NG2 proteoglycan, and A2B5 that distinguish these 
progenitors from more mature OPC lineage cells [127]. Once OPCs become mature enough to 
start generating myelin they can be identified by expression of myelin proteins such as myelin 
basic protein (MBP), proteolipid protein (PLP), myelin-associated glycoprotein (MAG), and myelin 
oligodendrocyte glycoprotein (MOG) [127]. Morphologically, maturing OLs become much more 
complex and extend numerous processes outward from the cell soma. In vivo, the number of 
myelinating processes vary depending upon the anatomical locus, but on average one 
oligodendrocyte can myelinate up to 40 different axons [128, 129]. 
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Many factors have been shown to be important for the initial maintenance of OPCs in an 
undifferentiated state, while others have been identified as necessary for the differentiation of 
OPCs into mature oligodendrocytes. Bone morphogenic protein (BMP), PDGF, and fibroblast 
growth factor (FGF-2) are necessary in the developing CNS as they keep OPCs in a proliferative 
state and thus immature, ensuring a pool of cells for whenever de novo myelination is needed 
[128, 130, 131]. On the other hand, the thyroid hormone, triiodothyronine (T3), promotes 
differentiation of OPCs into oligodendrocytes [132]. Not only do growth factors have an effect on 
the proliferation and differentiation of OPCs, but these proteins do so by affecting intracellular 
signaling pathways. For instance, NOGO signaling via LINGO-1 has been found to inhibit 
oligodendrocyte differentiation, and Notch-1, which signals developmental fate of NPCs, also 
helps facilitate OPC migration and proliferation [133, 134]. In addition to these factors being 
involved in development, there are factors generated by the tissue damage in MS that also 
influence OPC fate, such as cytokines and chemokines, which impact the ability of OPCs to 
respond to signals and differentiate appropriately. For example, the cytokine TNF-α has been 
found to correlate with the severity of demyelinated lesions, and in EAE mice anti-TNF-α 
neutralizing antibody was found to provide neuroprotection [135-137]. However, remyelination in 
a TNF-α knockout mouse is significantly delayed, indicating that it also plays a role in CNS repair 
[109].  
Both myelination and remyelination occur through the activation of genes that are 
regulated and mediated by transcription factors [138]. These epigenetic events require 
coordinated activation and/or inhibition to appropriately time OPC maturation for myelination and 
remyelination to occur correctly. For example, there is a multitude of evidence that demonstrates 
that histone deacetylase (HDAC) activity is necessary for inhibition of myelin gene expression to 
be removed [139]. Interestingly, a recent study applied transcriptomic analysis to examine 
differences in DNA methylation in the normal appearing white matter of MS patients [140]. This 
report identified gene networks and determined that genes linked to regulating oligodendrocyte 
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survival were downregulated, suggesting that perturbed signaling within OPCs may underlie failed 
OPC differentiation and impaired remyelination in MS [140]. The specific role of the myriad of 
factors that are known to alter remyelination in MS is unknown, and simply inhibiting or 
supplementing expression of any single factor may not be sufficient to efficiently promote 
remyelination in the complex and poorly understood environment of a demyelinated CNS lesion 
in MS (Fig. 1.4). Therefore, greater translational understanding is needed to comprehensively 
address why remyelination fails in disease, and what factors are necessary to develop effective 
regenerative therapies for MS.  
 
VI. Neural Progenitor Cells (NPCs) 
 In adulthood one of the major roles of the SVZ is to generate new neural progenitor cells. 
NPCs are capable of differentiating into neurons, astrocytes, and oligodendrocytes. They have 
the capacity for self-renewal, migrate extensively throughout the CNS, and when given proper 
cues can differentiate for tissue repair [119]. Typically, NPCs are identified using markers of 
pluripotency, such as: Sox2, nestin, and Pax6 [141-143]. This source of potential new cells 
residing within the adult CNS holds hope for repair in a variety of neurodegenerative diseases 
including MS. Interestingly, proliferation and mobilization of NPCs from the SVZ has been 
reported in animal models of seizure, ischemia, brain trauma, and demyelination [118, 144].  
The generation of NPCs and their repair capabilities have been investigated in animal 
models of demyelination [145]. After LPC injection into the rodent corpus callosum the number of 
NPCs in the SVZ was a significantly increased [117]. Thymidine tracing of these cells revealed 
that they differentiated into astrocytes and oligodendrocytes in the lesioned area [117]. NPCs 
derived from the SVZ were also found to proliferate and migrate to lesion areas in the EAE mouse 
model [116]. Analysis of the SVZ in post-mortem MS cases demonstrated a significantly increased 
NPC population compared to age-matched control tissue [118]. In addition to increased 
proliferation, it has also been demonstrated that human NPCs have the capability to migrate to 
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chronic inactive lesioned areas, yet they are somehow inhibited from differentiating into 
myelinating oligodendrocytes [118]. These human data suggest that endogenous human NPCs 
in MS patients have the capability to proliferate and migrate to lesion areas, yet cues from the 
diseased microenvironment could be impeding differentiation, or that there may be inherent 
differences in the potential of NPCs in MS that contribute to poor remyelination in this disease 
(Fig. 1.4).  
 Another way to test NPCs in demyelinating rodent models is by transplanting them and 
then assaying the effect they have on myelin injury and repair. This approach has been 
successfully applied to demonstrate that murine NPCs when grafted into mouse models of 
inflammatory demyelination have been shown to be potently anti-inflammatory and 
neuroprotective [146-148]. In a recent paper from the Pluchino group NPCs transplanted into mice 
in the EAE model were found to ameliorate chronic CNS inflammation by reducing succinate 
levels acting as free radical scavengers [149]. NPCs, when maintained in an undifferentiated state 
and are then grafted into an EAE model have been found to have the capability of inducing 
apoptosis in activated T cells that enter the CNS thereby helping to protect against myelin damage 
[146]. Additionally, NPCs when grafted into demyelinated lesions have been found to promote the 
differentiation of endogenous OPCs, likely through the secretion of pro-differentiation factors such 
as leukemia inhibitory factor (LIF) [150-155]. Previous data from our lab has also demonstrated 
that human embryonic stem (ES) cell-derived NPCs were capable of attenuating demyelination 
in the cuprizone model following intravenous administration [156]. The effect of the human ES 
NPCs in this model were found to be neuroprotective and not limited to cell replacement, 
consistent with the notion that a function of NPCs is to maintain and/or restore homeostatic 
processes. These data all suggest that human NPCs can be studied effectively using murine 
models, and that endogenous NPCs in the MS brain are likely active participants in CNS 
remyelination.  
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Figure 1.4. Remyelination support and inhibition. After demyelination in the CNS a 
demyelinated axon can be remyelinated or remyelination fails, which leaves the axons vulnerable 
to degeneration, associated with the progressive clinical decline in MS. Remyelination occurs 
when OPCs differentiate and wrap demyelinated axons. OPC differentiation can be enhanced 
and promoted by positive factors in the lesion area, remyelinating therapies, the clearance of 
inflammation, and the presence of neural progenitor cells that can be anti-inflammatory, secrete 
factors to promote OPC differentiation, and differentiate themselves into myelinating 
oligodendrocytes. Remyelination is inhibited by inflammation, the presence of myelin debris, 
inhibitory signals, and age. Figure adapted from Franklin and Ffrench-Constant, 2008 [83]. 
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 Lastly, through the technology of induced pluripotent stem cells (iPSCs), NPCs from 
patients with MS can be tested in these mouse models to determine if there are inherent defects. 
Previous work has demonstrated that OPCs differentiated from iPSCs, derived from patients with 
primary progressive MS, are equally capable of maturing into myelin-forming oligodendrocytes 
just as well as age-matched, non-diseased individuals when provided the correct cues in vitro 
[157]. On the other hand, this thesis will further delve into the application of iPS-derived NPCs 
from PPMS patients which I have now determined are less able to provide neuroprotection to 
myelin injury and also fail to support OPC differentiation in vitro [111]. 
 
VII. Emerging Remyelinating Therapies 
 All current disease modifying therapies on the market for treating MS patients only target 
the immune system, and none were developed with the primary mode of action to specifically 
promote remyelination or myelin repair. Considerable research effort has now been focused on 
promoting remyelination and providing neuroprotection in the brain in order to slow progression, 
especially in PPMS and SPMS, where there are very little to no effective treatments. The first 
example of this new approach to treating MS is an experimental antibody drug, anti-LINGO-1 
(also known as opicinumab), which blocks LINGO-1 to promote the differentiation of OPCs. 
LINGO-1 is selectively expressed on OPCs and neurons, where it is associated with the Nogo-66 
receptor complex that when activated inhibits neurite growth and oligodendrocyte differentiation 
[158, 159]. Treatment of mice with the anti-LINGO-1 antibody after focal demyelination in the 
spinal cord using lysolecithin was found to promote faster remyelination and this new myelin had 
increased thickness [160]. Anti-LINGO-1 has also been found to reduce axon degeneration and 
promote regeneration of axons in the EAE model [161]. Unfortunately anti-LINGO-1 failed in 
Phase II trial in patients with MS, where it failed to reach its primary endpoint: an integrated 
measure of MS progression and disability markers [162]. While there was no measurable benefit 
seen in the primary study endpoints, the trial did identify increased percentage of improvement 
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responders at specific doses compared to placebo, which could help identify sub-populations of 
MS patients which would respond well to this drug. The primary indicators of anti-LINGO-1 benefit 
in MS patients included younger individuals who had a shorter disease duration [162].   
 In the last couple of years new technologies have been developed to be able to screen for 
remyelinating therapeutics much faster using automated computer programs. Specifically, the 
Chan lab at UCSF developed an approach to quantify the myelinating potential of OPCs in a high 
throughput manner they call binary indicant for myelination using micropillar arrays (BIMA). This 
approach was developed and validated as a rapid assay to evaluate the effects of compounds 
that can promote OPC differentiation. In BIMA, OPCs are plated at the base of micropillars and 
through confocal imaging concentric wrapping of myelin, seen as rings, can be imaged and 
quantified [110]. By using this method over 1,000 FDA-approved bioactive molecules were 
screened, and a cluster of anti-muscarinic compounds were identified to promote OPC 
differentiation. Using this high-throughput method clemastine and benztropine were identified to 
enhance OPC differentiation in vitro. They are both FDA-approved compounds that readily cross 
the BBB, and were found to promote remyelination in vivo in the cuprizone, EAE, and lysolectithin 
models [110]. Another paper, using a high-throughput method to assay drugs to promote OPC 
differentiation also uncovered benztropine as a potent mediator of differentiation, as well as 
clobetasol and miconazole [163]. These drugs were also shown to enhance maturation of OPCs 
in vivo in the EAE and lysolectithin models and in vitro using human OPCs [163]. Lastly, 
benztropine was also discovered to be beneficial in promoting remyelination in a paper published 
by Deshmukh et al. where another high-throughput assay identified this compound. Again, it was 
shown to decrease clinical severity seen in EAE and help facilitate quicker remyelination in the 
cuprizone model [164]. All of these studies provide promise for development of remyelinating 
therapies for MS, especially for patients with progressive MS. Additionally, all of the studies 
mentioned above used a library of FDA-approved drugs, including compounds known to cross 
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the BBB, therefore the safety profiles of these tested agents are already known, expediting clinical 
development. 
 Clemastine, an FDA-approved antihistamine, was tested in a Phase II trial in patients with 
RRMS along with a chronic demyelinating optic neuropathy [165]. Patients were specifically 
selected with this optic neuropathy, along with RRMS, since the latency delay can be easily 
measured using visual-evoked potentials, and the delay is highly associated with the 
demyelination of the optic nerve [166, 167]. The shorter the delay in transmission, the more 
remyelination that has occurred along the optic nerve. Patients treated with clemastine had a 
reduced latency delay by 1.7 ms/eye, making this the first study that demonstrates the use of a 
drug with a remyelinating effect in humans that has no known immunomodulatory effects [168]. 
The use of high-throughput assays in testing potential remyelinating therapeutics led to the 
discovery of a drug that induced repair in a chronic neurodegenerative condition. A combinatorial 
therapeutic decreasing inflammation and promoting OPC differentiation may be an effective way 
to manage and delay MS progression. 
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Chapter 2: Stem Cells and Disease Modeling 
I. History of Stem Cells 
 Stem cells are defined by their innate potential for regeneration, or self-renewal, where 
they can divide to produce more of the same type of stem cell, or differentiate into a mature cell 
type. Self-renewal is defined as the ability for the cell to go through numerous rounds of 
proliferation while maintaining an undifferentiated state. Stem cells come in different forms. Each 
type of stem cell has a varying potency, which is the capacity to differentiate into a specialized 
cell type. Totipotent stem cells can differentiate and construct a complete and viable organism 
formed during sexual and asexual reproduction, such as a zygote [169]. Pluripotent cells can 
differentiate into cells of any of the three germ layers: endoderm, mesoderm, or ectoderm. 
Multipotent cells can differentiate into only specific cell types. One example of particular interest 
to multiple sclerosis, also the focus of this thesis, is neural progenitor cells, which can differentiate 
into oligodendrocytes, astrocytes, or neurons.  
The first observations of stem cells were in the 1960s and defined as hematopoietic stem 
cells (HSCs). These stem cells give rise to blood cells, including leukocytes, erythrocytes, and 
thrombocytes [170]. HSCs undergo constant self-renewal and can differentiate into multiple 
mature cell types. Since the discovery of HSCs they have been used for transplantation 
procedures in patients with cancers of the blood or bone marrow, where the immune system is 
destroyed and replaced with new HSCs. HSC transplants (HSCT) have been found to ameliorate 
both acute and chronic forms of EAE, through immunosuppression of activated T cells and B cells 
[171, 172]. Like many stem cell studies have found, the impact of stem cells on disease processes 
are manifold: HSCs have been found to suppress CNS inflammation through the secretion of 
soluble factors, cell-contact, and indirectly through actions on other cell types to inhibit T cell 
activation [171, 173, 174]. Based on these positive results in animal studies of MS, HSCT are 
now being conducted in human RRMS patients using their autologous bone marrow in order to 
avoid transplant rejection. To date, even though it is a rough procedure that involves intense 
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immunosuppression, HSCT has been reported to be well tolerated by patients [175]. In an initial 
phase I/II trial, MS patients receiving autologous HSCT did not experience any significant side 
effects or infections, but only a small number of patients felt any benefit from the transplantation 
[176]. An additional HSCT trial using patients with progressive MS also demonstrated that 
autologous HSCT could stabilize lesions after one year post-transplant, although this was 
reported in only half of the patients treated [177]. Overall, the assessment of HSCT as a treatment 
for MS is exploratory and subject to ongoing study. It has been shown to be safe in patients with 
MS, but the overall benefits are at this point limited to a small subset of patients tested and the 
utility of this approach to the wider patient population has yet to be determined. 
 Embryonic stem cells (ESCs) are pluripotent stem cells derived from the inner cell mass 
of a blastocyst. ESCs have the ability to differentiate into the three primary germ layers, making 
them ideal candidates for tissue engineering [178]. For the first time in the 1990s scientists were 
able to generate all of the different cell types of the human body in a dish [179]. These 
groundbreaking studies offered the possibility of using these differentiated cell types to test 
therapeutics, study human tissue regeneration, and/or develop expansive arrays of cells for 
transplantation. Yet, these cells were developed from human embryos which represented a 
significant ethical hurdle for research and mass production. From the perspective of patients with 
MS or Parkinson’s disease, human (h)ESCs offered a way to regenerate new cells to "fix" their 
brains. Whether functional OPCs to recover myelin, or new dopaminergic neurons that could be 
grafted into the brain, the promise of hESCs was widely heralded as a cure for many diseases 
[179]. The first human ESC lines available were originally generated for in vitro fertilization (IVF) 
but were then never used clinically. With consent from the donors the blastocyst was taken to 
generate human ESC lines [180]. Initially, about 20 lines were generated and isolated prior to 
August 2001, when the United States government started to restrict human ESC research due to 
the ethical concerns about the source tissues. At that time, the field had already generated ESC 
lines that the NIH had approved which became the benchmark human lines for research 
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purposes. The small number of hESC lines represented a major impediment to the purported 
future application of ES cell-based therapies. Their use as a clinical reagent was limited as all 
human ESC lines that had been developed were isolated in the presence of animal proteins and 
growth factors which limits their potential for transplant due to immune-rejection [181].  
 The two best examples of successful application of human ESCs in rodent models involve 
the transplant of a differentiated cell type. Transplantation of human ESC-derived dopaminergic 
neurons into a mouse model of Parkinson’s disease successfully reversed behavioral defects and 
grafted long-term in the striatum [182, 183]. Oligodendrocytes, derived from human ESCs, were 
also shown to promote remyelination in animal models of demyelination, and also repair white 
matter lesions after spinal cord injury [184]. Transplantation of NPCs derived from a human ESC 
line were also found to be neuroprotective in the cuprizone mouse model of demyelination [156]. 
Despite these promising results in mouse models of CNS demyelination, translation of ESCs into 
human clinical disease brings with it significant risk, including the caveats associated with 
contamination of these cell lines with animal products which can elicit potent immune reactions in 
humans, immune rejection due to genetic incompatibility of the host with the ESC line, the 
potential for tumor formation if any of the transplanted cells are left undifferentiated, and the ethical 
concerns in derivation of the cells [181].  
 In 2006, a significant development in stem cell research transformed the field. This 
discovery was of genes that can induce pluripotency in somatic cells. First published in 2006, a 
research group at Kyoto University led by Shinya Yamanaka, found that murine somatic cells, 
from adult mice, could revert to an embryonic stem cell-like state by transducing the cells with 
transcription factors Oct4, Sox2, c-Myc, and Klf4 [185]. These induced pluripotent stem cells 
(iPSCs) were found to express the same cellular markers of ESCs, differentiate into a variety of 
cell types like ESCs could and therefore offered potential to make ES-like cells without the ethical 
quandaries surrounding collection of human embryonic tissues [185]. In the following year, two 
groups reported that they were able to generate iPSCs from adult human somatic cells using the 
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same approach, but also using a new combination of transcription factors: Oct4, Sox2, NANOG, 
and Lin28 [186, 187]. Just like the murine cells, the human iPSCs were found to generate all three 
germ layers [178, 186]. Based on this research, the Nobel Prize for physiology and medicine in 
2012 was awarded to Shinya Yamanaka and John Gurdon “for the discovery that mature cells 
can be reprogrammed to be pluripotent” [188]. For the first time, adult somatic cells had the 
possibility to be reprogrammed into an embryonic-like state, without the controversial practice of 
using human ESCs, which has led to a torrent of research using these iPS cells to model human 
disease. With this new approach, disease-specific iPS cells can be used to model the human 
condition, test therapeutics, and generate a source of cells to study disease, a potentially 
unlimited source of transplantable cells, among other possible utilizations.  
 
II. The Use of iPS Cells in Research 
 After the landmark discovery of iPSCs great effort has been made to generate the various 
cells of the human body for purposes such as interrogating the genetics of specific cells, 
performing drug screening assays, and even using them as a cell replacement in humans (Fig. 
2.1). For the purpose of studying multiple sclerosis, protocols for the differentiation of both murine 
and human iPSCs into oligodendrocytes has been established over the last couple of years, and 
have gone from a 3 month protocol to only 28 days [189, 190]. Recently, a protocol for the 
generation of human cortical spheroids, with mature, myelinating oligodendrocytes was 
published, demonstrating their use in testing compounds such as clemastine and ketoconazole 
in promoting myelination [191]. Using iPSCs from patients with Pelizaeus-Merzbacher disease 
(PMD), a genetic leukodystrophy affecting myelin, the human cortical spheroids recapitulated the 
defect in myelination and allowed for screening of various treatments [191]. Interestingly, only 
oligodendrocytes derived from patients with a specific genetic myelin disorder, such as PMD, 
have been found to show deficits [191]. On the other hand, myelinating oligodendrocytes 
differentiated in vitro, with the proper cues, can be generated from iPSC lines developed from 
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patients with PPMS, demonstrating that there is no one genetic defect impairing these cells in 
PPMS, and the defect in patients may be due to epigenetic changes [157]. This study draws into 
question exactly what happens during the reprogramming stage of iPSCs, and if unique 
epigenetic changes are maintained, and exactly what genetic information is retained related to 
cell type, which may be integral to understanding why OPCs fail to remyelinate in progressive 
MS. 
 A large amount of studies have shown that there is interplay between environmental 
factors and individual genetic susceptibility, which is likely to produce a predisposition to MS. It is 
from this standpoint that understanding epigenetics, and epigenetic changes in specific cell types 
is considered crucial to uncovering and developing therapeutics to treat MS patients [192]. 
Epigenetic modifications are changes that affect gene expression, without the alteration of the 
DNA sequence, which includes DNA methylation and histone modification [193]. In this respect, 
some studies that have suggested that cellular reprogramming of somatic cells can alter genomic 
methylation and epigenetic modifications may be cause for concern for using iPS cells to model 
non-genetic disease conditions. However, numerous studies have now demonstrated that even 
with reprogramming cells retain forms of “epigenetic memory”, including in some cases memory 
of the somatic tissue of origin, which suggests that the notion of reprogramming results in 
"resetting" epigenetics or wipes clean epigenetic markers associated with disease is simply untrue 
[194, 195]. For example, murine keratinocytes reprogrammed into iPSCs differentiate more 
readily into fibroblasts, demonstrating a maintained memory through the reprogramming process 
[196]. Analysis of DNA methylation in donor-specific iPSC lines found that these epigenetic 
modifications were unchanged during the reprogramming process from the somatic cell [197]. 
iPSCs have also been used to model nonfamilial, sporadic forms of disease, such as Alzheimer’s. 
Neurons differentiated from iPSCs from patients with genetic, familial Alzheimer’s as well as 
sporadic Alzheimer’s exhibited higher levels of amyloid-β and phospho-tau [198]. In addition, age-
related mitochondrial DNA mutations were found in iPSCs derived from fibroblasts of aged 
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individuals, compared to fibroblasts from young subjects, demonstrating that reprogramming of 
cells does not completely wipe clean epigenetic markers [195]. Using iPSCs as disease models 
reflects individual epigenetic changes unique to each patient or disease state, based on the 
somatic tissue of origin, but differentiation of iPSCs can modify some of these original methylation 
markers [194]. It is important to point out that human iPSCs are known to retain epigenetic 
markers from the patient somatic cell when reprogrammed and differentiated into a cell type of 
interest, but the myriad factors that potentially influence this are as varied as the individual human 
donors. Studies to date have reported that epigenetic differences can depend on exactly how the 
cells were reprogrammed, the cell culture conditions used, the initial somatic cell used for 
reprogramming, the genetics of the donor patient, and cell types that that iPS cell line is then 
differentiated into [194]. In spite of these technical caveats, over the past decade iPSCs have 
made it possible to model "human diseases in a dish" [199]. Although these cells offer the potential 
for novel insights into these enigmatic diseases, our limited understanding as to the exact 
epigenetic changes that can occur with disease or during reprogramming and differentiation need 
to also be considered. 
 Due to the inaccessibility of primary tissues, such as brain, and the limited accuracy of 
animal models for the study of multiple sclerosis, patient-specific iPSCs represent a potentially 
powerful tool to understand the mechanisms underlying this disease. Diseases with full genetic 
penetrance, such as Huntington, display more robust cell-autonomous defects [194], but since 
MS is a complex disorder not caused by any single genetic mutation, it has been much more 
difficult to parse apart possible cellular defects that contribute to the disease phenotype clinically 
defined as MS. One of the main goals of this thesis has been to use iPS cells from MS patients 
to address this important question.  
 Several studies have successfully generated iPSC lines from MS patients with varying 
forms of disease. These studies have also used these cells to generate various differentiated cell 
types [111, 157, 200]. In particular, the generation of oligodendrocyte progenitor cells offered the 
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potential to understand inherent limits on remyelination in MS. A first study generated iPSCs from 
patients with RRMS reported that they were successfully able to differentiate iPS cells into mature 
astrocytes, oligodendrocytes, and neurons and these neurons exhibited electrophysiological 
characteristics no different from differentiated cells from control iPS cell lines [201]. Using a 
different protocol, Douvaras et al. demonstrated that OPCs could be generated from iPSC lines 
derived from patients with PPMS. These OPCs were differentiated in vitro both efficiently and with 
comparable competence to controls when provided the proper growth factors. These cells were 
also found to be functionally viable to provide in vivo myelination when transplanted into the 
forebrain of neonatal shiverer mice, a mouse line that lacks myelin basic protein and thus native 
mature myelin [157]. Thus, these early studies suggested that iPS cells from MS patients when 
differentiated into astrocytes, oligodendrocytes, or neurons were phenotypically "normal". 
 Experimental evidence with rodent neural progenitor cells has demonstrated that when 
these cells are transplanted into mouse models of demyelination they can provide neuroprotection 
and promote differentiation of endogenous OPCs, likely through the secretion of growth factors 
[150-152, 155]. More recently, human NPCs have also been found to attenuate inflammation and 
promote CNS repair in mouse models, [111, 151, 202-204]. Yet, my more recent work has 
demonstrated that NPCs derived from PPMS patients' iPS cells lack neuroprotective properties 
in a mouse model of MS. Based on the data presented in this thesis more needs to be understood 
about NPCs from patient iPSCs with MS before they could be used or autologous stem cell 
transplants into patients. 
 
  
	 36 
 
Figure 2.1. Patient-derived cells are reprogrammed to iPSCs and differentiated towards 
specific cell types to allow for analysis in vitro and well as in vivo. Figure adapted from 
Memorial Sloan Kettering Cancer Center.* 
 
  
																																																						
*	https://www.mskcc.org/sites/default/files/node/35635/images/disesae-modeling.jpg	
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III. Utility of iPS Cells in Disease-Based Drug Screens 
Patient-specific human cells developed from iPSC lines have also been used in order to 
test possible therapeutics (Fig. 2.1). In the context of MS, drugs that promote OPC differentiation 
into functional, myelinating oligodendrocytes have been tested on patient cells, as well as control 
cells, which has led to the discovery of clobetasol and miconazole as promoters of human 
oligodendrocyte differentiation [111, 163]. When human OPCs, derived from patients with MS and 
controls, are given the proper growth factors and cues to differentiate they can myelinate properly 
[157, 205]. The fact that OPCs from patients with MS can be readily generated, and function 
normally in vivo, holds promise as a potential cell replacement strategy. 
 More recently, a new model to study human-iPSC oligodendrocytes called “oligocortical 
spheroids” has been developed. This 3D culture system was found to recapitulate cell-cell 
interactions, microenvironments, and could be used to extend the temporal dynamics of cellular 
interactions in vitro more accurately than a traditional 2D cell culture system [191]. This approach 
was demonstrated using iPSCs developed from patients with Pelizaeus-Merzbacher disease 
(PMD), an X-linked disease associated with defects in myelin production. The oligocortical 
spheroids allowed researchers to understand the developmental errors occurring in 
developmental myelination and were able to correct it with targeted gene therapy and test 
remyelination therapies, such as clemastine [191]. 
Overall, the ability to generate patient specific iPSCs that can self-renew and then 
differentiate into essentially all somatic cell types gives them immense potential for a variety of 
applications. Some include using them to model multitudes of diseases and perform 
pharmaceutical testing and gene targeted therapies, test them in animal models, and analyze 
gene changes in varying cell types among other uses. There are still some challenges that remain 
and need to be addressed before autologous human cell transplants can occur. Improvements in 
differentiation methodologies, and new technologies, such as the 3D cultures, allows for better 
models and platforms that can be combined with traditional drug development to link together 
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genetic patient risk as well as cellular and molecular events that can lead to disease onset and 
progression. Studying MS using patient-specific iPSCs has the potential to reveal epigenetic 
trends within patients, test adult stem cells for the potential to promote brain regeneration, and 
help understand why progression occurs. 
The objectives of this project were to generate neural progenitor cells from patients with 
primary progressive multiple sclerosis in order to determine if there were inherent defects in their 
functioning. I discovered an intrinsic difference in iPS cell-derived NPCs from PPMS patients 
compared to age-matched controls, where they failed to promote endogenous remyelination due 
to a senescent phenotype. This data demonstrates a fundamental difference in the disease state, 
which reflects a central role in NPCs modulating the MS lesion environment. 
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Chapter 3: Aging and the Central Nervous System 
Aging is the main risk factor for many chronic neurodegenerative diseases, including 
Alzheimer’s disease and Parkinson’s, as well as diabetes, arthritis, and cardiovascular disease 
[206]. Overall, aging is associated with a progressive loss in the ability of tissues to recover from 
damage and increased tissue vulnerability to stress [207]. Due to the rise in average life 
expectancy over the past decade, it is estimated that by 2050 two billion people will be over 60 
years of age, drastically increasing the prevalence of chronic diseases [208]. Therefore, it is 
crucial to develop interventions that can promote better tissue regenerative capacity with aging 
that could also extend healthy life span (also referred to as "healthspan"). 
Recent advances in the field of molecular aging have determined that senescent cells 
accumulate with age and disease in various tissues and these cells are believed to be the driving 
force of tissue aging [209, 210]. Cellular senescence is defined as a chronic stress response. It 
can be induced by damage, sometimes associated with growth arrest, such as UV irradiation, and 
this cellular phenotype is often accompanied by a senescence-associated secretory phenotype 
(SASP) [209, 211, 212]. The SASP is generally a collection of pro-inflammatory and matrix-
degrading molecules that are released from senescent cells. It is the result of the SASP factors 
that the function of surrounding cells are affected. Most especially, tissue resident stem cells are 
known to be impaired by the SASP which is thought to underscore the limited regeneration of 
tissues with increased age [213]. This chapter will focus on describing cellular senescence and a 
role for cellular senescence in multiple sclerosis, with the possibility that this process may 
contribute to failure of myelin regeneration in this disease. 
 
I. Cellular Senescence    
The first discovery of replicative senescence in vitro came from Hayflick and Moorehead, 
who demonstrated that normal human fibroblasts exhibited a limited potential for replication with 
time [214]. This observation led to the idea that replicative senescence contributes to aging, where 
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the progressive depletion of cells limits that tissue's potential to replicate, repair, or regenerate 
once damaged [214]. Since these observations of cellular aging are referred to as “replicative 
senescence”, cell cycle arrest has become a model to study aging in vitro. In 1998, it was 
discovered that the attrition of telomeres, the repeating nucleotide sequences at the ends of 
chromosomes, also underlies replicative senescence [215]. The shortening of telomeres triggers 
a DNA damage response (DDR), which recruits the damage sensor ataxia telangiectasia mutated 
(ATM) to stabilize and upregulate expression of proteins p53 and p21 [216]. p21 then prevents 
cyclin-dependent kinase 2 (CDK2) from inactivating the protein retinoblastoma (Rb), which then 
inhibits that cell from entering S phase and thus blocks replication [217]. Another pathway 
overactivated in cellular senescence is the mammalian target of rapamycin (mTOR) pathway. In 
senescent cells, mTOR activity can lead to an upregulation of p16Ink4a which prevents CDK4- and 
CDK6-mediated inaction of Rb, which, in turn, blocks the cell cycle [217]. Both of these 
mechanisms can occur due to a multitude of stressors such as reactive oxygen species (ROS), 
mitogenic/oncogenic signaling, stalled DNA replication, chromatin disruption, and other DNA-
damaging stressors such as ultraviolet (UV) or gamma irradiation, and chemotherapeutics [218-
220].  
 It is important to note that there is increasing awareness that there may be a variety of 
forms of cellular senescence and the specific form of cellular senescence may depend upon how 
this process is initiated. For example, there are differences in expressed proteins and genes 
between stress-induced senescence and replicative senescence [221-223]. Replicative 
senescence causes a total arrest of the cell cycle, while cells with stress-induced senescence 
maintain replicative competence although still express molecular hallmarks of senescence, 
including production of pro-inflammatory SASP factors [223]. Stress-induced senescence is due 
to a gradual and cumulative burden of oxidative damage which occurs with aging, and can lead 
to cell cycle arrest once a theoretical threshold is reached, although cell cycle arrest is not a 
prerequisite for stress-induced senescence [216]. 
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p16Ink4a upregulation is the most common marker used to identify senescent cells. p16Ink4a 
has been used as a biomarker of natural aging as its expression is known to increase with time 
in various tissues [224, 225]. Studies using the BubR1H/H mouse, a model of rapid aging, have 
demonstrated that tissues in these mice exhibit premature aging and increased p16Ink4a 
expression [226]. BubR1 is a mitotic checkpoint protein, and the low levels in the mouse model 
(BubR1H/H), due to two hypomorphic alleles, causes premature separation of sister chromosomes 
inducing aneuploidy and progeriod phenotypes.  Recent studies using mice have demonstrated 
that targeted ablation of p16Ink4a positive cells can be used as a strategy to study cellular 
senescence. One of these models is termed the INK-ATTAC, which selectively expresses a drug-
inducible FKBP-caspase-8 fusion molecule under control of the p16Ink4a promoter, which then 
initiates apoptosis when a specific drug is administered to the mice [227]. Induced deletion of 
p16Ink4a from senescent cells has been shown to extend lifespan and reverse age-related 
functional decline in organs such as kidneys and pancreas [227, 228]. Similarly, targeting of 
cellular senescence by deletion of p16Ink4a positive cells has also been found to mitigate 
accelerated aging in diseases such as progeria modeled in the BubR1H/H mouse, and more 
recently in glia in a model of Alzheimer’s disease (AD); demonstrating p16Ink4a has a central role 
in the functional effects of cellular senescence [224, 227-232]. These studies have demonstrated 
that senescent, p16Ink4a expressing cells drive natural aging, as well as age-related diseases, such 
as atherosclerosis and osteoarthritis [227, 233, 234]. 
There is no single marker that can be used to universally identify senescent cells, and 
p16Ink4a is therefore only part of the process of identifying cellular senescence (Figure 3.1). The 
upregulation and expression of additional proteins such as p53 and p21 are also associated with 
senescence, but these cellular changes can also occur with conditions that are not senescence. 
For this reason, it is has become current standard practice for studies in this field to use multiple 
markers in order to identify and verify cellular senescence [206]. For example, enzymatic activity 
of the lysosomal hydrolase, identified by β-galactosidase activity at pH 6.0, has become an 
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established marker of cellular senescence, which is referred to as senescence-associated β-
galactosidase assay (SA β-gal) [235]. A practical advantage of this marker is that the colorimetric 
assay used to detect it works both on in vitro and in vivo tissues to detect senescent cells [235].  
The most distinguishing feature of senescent cells is the production of a SASP (Table 3.1). 
This aspect of altered cellular function functionally and biochemically distinguishes cellular 
senescence from cellular quiescence. While the specific factors that contribute to the SASP can 
vary depending on cell type, in general, there are several factors consistently produced by 
senescent cells, including those associated with oxidation and inflammation, including interleukin 
(IL)-6, IL-1, MIP1β, MIP1α, MMP-3, HMGB1 as well as growth factors such as FGF2 (Table 3.1) 
[212, 236, 237]. With progressing age, many of these SASP factors have been found to be 
increased on an organism-wide scale, especially IL-6 [238]. Because of the secretion of pro-
inflammatory SASP factors from senescent cells, only a relatively small number of senescent cells 
are necessary to evoke physiological changes and alter function of  a tissue [212]. Chronic 
expression of the SASP impairs the proper function of neighboring cells, and is therefore thought 
to be a major contributor to inflammaging [239]. Inflammaging is a theory that low, but chronic, 
levels of inflammation drives age-related decline in function, which is supported by the presence 
of the SASP [211, 239]. The SASP phenotype is also notable for its absence of several factors 
namely, IFNγ, NGF, and TIMP-1. In fibroblasts, for instance, many factors known to be involved 
in leukocyte recruitment are also reduced, including CX3CL1, PDGF-BB, and anti-inflammatory 
cytokines, such as IL-10 and IL-12 are also not expressed by senescent cells [240]. SASP 
expression is variable between different types of senescence, especially depending on the initial 
causes of senescence in that particular cell population [213, 237, 241]. In addition, the secretome 
of the SASP is highly variable from cell type to cell type, and varies based on how long the cell 
has been senescing, and therefore impacts surrounding cells differently depending on the tissue 
[212, 213]. 
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Factors which comprise the SASP have been found to promote tumor development in 
breast and prostate cancers through the secretion of growth factors, such as GROα and CTGF, 
[242, 243]. These data point to an important contributing role for the SASP in senescence-related 
diseases, which, relevant to this thesis, includes the influence of the SASP on tissue resident 
stem cells and impaired tissue regeneration. Chronic exposure of the SASP factor IL-1 is known 
to inhibit the proper differentiation of hematopoietic stem cells thereby preventing their 
homeostatic roles [244]. Similarly, IL-6 is required for both the induction and continued 
maintenance of pluripotency in stem cells, therefore secretion of IL-6 by senescent cells is thought 
to sustain stem cells in an undifferentiated state and compromise the ability of these cells to 
mediate tissue repair [245]. Senescence has also been shown to trigger cell "reprogramming" in 
vivo, promoting an accumulation of undifferentiated stem cells prevented from differentiating 
[246]. de Keizer has termed this phenomenon the ‘senescence-stem lock’ model, where SASP 
factors keep their neighboring cells locked in a stem-like state, which in the context of aging and 
diseases of injury, would prevent tissue rejuvenation or repair [247]. While these findings point to 
an important function of the SASP as a means by which cellular senescence can impact tissues 
and organ function, our current knowledge of the SASP, and how it varies across different cell 
types, remains quite limited.  Future studies to understand how the SASP is generated, and why 
specific factors are being secreted in senescent states may help improve our understanding on 
why tissue regeneration fails with age and in specific diseases. 
 
 
  
	 44 
 
 
Figure 3.1. Identification of senescent cells. Senescence can be identified by markers 
indicated above. Since senescence is unique depending on the cause as well as the cell type, 
not all senescent cells express each hallmark consistently. Figure adapted from Baker and 
Petersen, 2018 [206]. 
  
Senescent Cell Identification
• Cell cycle arrest (replicative 
senescence)
• SA β-gal expression
• Increased p16Ink4a and p21 expression
• Mitochondrial stress
• DNA damage
• Secretion of the SASP
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II. Cellular Senescence in the CNS 
Cellular senescence has been identified in multiple CNS cell types in aging and models of 
neurodegenerative diseases. Recent studies have identified hallmarks of cellular senescence in 
astrocytes and microglia in models of Alzheimer’s disease (AD) and Parkinson’s disease (PD) 
[229, 248-250]. The chronic low-grade inflammation that occurs in the brain with age, has been 
shown to contribute to the decrease in the numbers of synapses and dendritic spines on neurons, 
both integral to proper neuronal function, which has been suggested to underlie cognitive 
impairment and memory loss with age [251, 252]. While neurons of aged mice are known to 
accumulate high amounts of DNA damage and express pro-inflammatory molecules, which are 
also hallmarks of senescence [218, 253], it has not yet to be determined whether neurons 
themselves become senescent, or if they are subject to senescence from other cell types, and 
whether these changes contribute to the decline in CNS function with age. With age, the human 
brain has been found to develop increased markers of cellular senescence. Human brain tissues 
exhibited increased p16Ink4a positive astrocytes, along with increased levels of MMP-3. While 
these changes are suggestive of cellular senescence, it is currently not known exactly how aging 
drives major features of declining brain function in aging or in neurological disorders such as 
losses in cognitive function, [229]. 
 Microglia are a cell type in which cellular senescence has been identified. In aged mice, 
microglia have been shown to exhibit shorter telomeres and up-regulate the production of pro-
inflammatory cytokines, including: IL-6, IL-1β, and TNF-α [254, 255]. When microglia are kept 
regularly activated in vitro they too express hallmarks of senescence including SA β-gal activity, 
heterochromatic foci formation, and growth arrest [256]. More recently, using a transgenic model 
to delete p16Ink4a+ senescent cells (called the INK-ATTAC mouse model) when crossed with an 
AD tau-dependent mouse (MAPTP301SPS19) it was reported that specific loss of senescent 
microglia and astrocytes preserved cognitive function and prevented gliosis [231]. These results 
show that senescent glia have a prominent role in the progression of tau-mediated AD [231].  
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  Cellular senescence has also been reported in astrocytes. In response to reactive oxygen 
species (ROS) exposure astrocytes exhibit markers of senescence, including growth arrest, SA 
β-gal activity, and increased p16Ink4a and p21 expression [257]. Exposure to the herbicide 
paraquat, an herbicide associated with an increased risk of idiopathic Parkinson’s, has been 
shown to induce senescence in astrocytes which contributes to dopaminergic neurodegeneration 
[249]. In addition, histological analyses of brain tissues from Parkinson’s patients identified 
senescent markers in astrocytes [249]. Therefore, in PD it is thought that the chronic cellular 
stress linked to this disease may evoke cellular senescence in astrocytes that leads to the 
manifestation of disease [206]. Importantly, astrocyte dysfunction, and markers of stress-related 
oxidative stress in astrocytes are found in many neurodegenerative diseases, suggesting that 
cellular senescence in astrocytes may be a component of many neurological conditions. In 
support of this point, current data indicates that cellular senescence can be a pathological gain-
of-function adaptation in chronic neurodegenerative diseases. 
 Aging researchers have begun to examine how cellular senescence contributes to other 
neurological diseases, such as HIV-associated neurocognitive disorders (HAND). While in the 
1990s an HIV diagnosis was tantamount to an early death, the advent of anti-retroviral drug 
therapies have enabled patients to control the levels of HIV. However, longitudinal studies are 
now finding that HIV patients are prone to developing complications associated with premature 
aging, such as HAND, that are believed to be related to highly active antiretroviral therapies 
themselves [258]. Hence, the treatments for HIV may be initiating cellular senescence and an 
aged phenotype in this patient population. Recent studies looking to cellular senescence have 
found that treating astrocytes in vitro with antiretroviral drugs can induce markers of cellular 
senescence, as well as increased ROS production [259, 260]. Microglia are also known to develop 
characteristics of cellular senescence after exposure to HIV itself, but this process is not yet well 
characterized [261]. Based on these findings, our limited understanding of how senescent cells 
contribute to neurodegeneration in disease warrants greater investigation. 
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Table 3.1. SASP Factors. Adapted from Coppé et al., 2010 [212]. 
 
Increased Factors in the SASP 
IL-1, -6, -7, -8, -13, -15 MIP1β FGF 
IL-1a, -b IGFBP-2, -3, -4, -6, -7 HMGB1 
MIP1α MMP-1, -3, -10  
MIF ROS  
VEGF Fibronectin  
Decreased Factors in the SASP 
TIMP-1 CX3CL1 PDGF-BB 
IL-10, -12   
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III. Inhibition of Senescence 
 The INK-ATTAC mouse has provided compelling evidence that specific removal of 
senescent cells can be beneficial in modulating the impact of inflammatory diseases and aging. 
This approach has opened up a novel field of therapeutic pharmacology which seeks to 
specifically eliminate senescent cells as a treatment. Since mice globally lacking p16Ink4a are 
prone to developing tumors, another transgenic model termed p16-3MR was developed [262]. 
These mice express a trimodal reporter construct under the control of the entire p16Ink4a promoter, 
that is coupled to a red fluorescent protein, synthetic Renilla luciferase, and a truncated herpes 
simplex virus thymidine kinase (HSV-TK) [263]. When ganciclovir is given to the mice HSV-TK 
converts it into a toxic compound, triggering apoptosis in p16Ink4a -expressing cells [263]. This 
mouse model has helped to understand, and identify, exactly what cells become senescent in a 
variety of age-associated diseases [233, 234]. Since this mouse model is not widely available, 
current methods to identify cellular senescence rely on expression of markers, in particular 
p16Ink4a, to identify senescent cells. However, some senescent markers are not unique to 
senescent cells and can be expressed by other cell types which has potential for complicating the 
direct elimination of senescent cells and the interpretation of these approaches.  
 In addition, these transgenic approaches to delete senescent cells are not directly 
translatable to humans. Because of this, researches have begun to development a new class of 
drugs called “senolytics”, which pharmacologically target senescent cells for elimination. Many of 
these developed drugs target the antiapoptotic pathway that is known to be upregulated in 
senescent cells [264]. Some of these experimental agents include ABT-737 and navitoclax, which 
prevent the antiapoptotic activity of BCL-2, and thus initiate cell death in senescent cells [265, 
266]. More recently, a combination of dasatinib (D), a tyrosine kinase inhibitor, and quercetin (Q), 
a PI3K pathway inhibitor have been found to be a senolytic combination (D+Q) in animals [267]. 
In aged mice, and mouse models of disease, D+Q treatment effectively reduced the number of 
senescent cells in heart, lung, or adipose tissue, while also reducing inflammation [227, 264, 268, 
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269]. Overall, senolytics have been found to increase health- and lifespan in old mice, yet the 
overall impact on the CNS are incompletely studied [232].  
Rapamycin, an mTOR inhibitor, which was used in my thesis studies, is known to improve 
health in animal models, inhibit cellular senescence in fibroblasts, and prevent the secretion of 
the SASP (Figure 3.2) [270-273]. It is established the rapamycin can increase lifespan and inhibit 
the development of cellular senescence, but the complete mechanism by which rapamycin 
achieves these effects are also poorly understood [274].  
Rapamycin works to block mTOR activity through binding with the FK506-bingind protein, 
FKBP12. mTOR belongs to a family of kinases made up of two catalytic subunits: mTOR complex 
1 (mTORC1) and mTORC2 [275]. mTORC1 suppresses the process of autophagy, which is 
crucial in generating substrates for energy production. Autophagy has been shown to decline with 
age, causing an accumulation of damaged proteins and organelles, especially mitochondria, and 
through inhibition of mTORC1 autophagy can be stimulated [276]. mTORC1 increases 
mitochondrial functions by stimulating mitochondrial biogenesis and controls the metabolism of 
cellular energy, increasing glycolytic flux and limiting oxidative phosphorylation [276]. These 
processes can induce stress in aged cells, and thus lead to senescence, therefore inhibition of 
mTORC1 by rapamycin in aged cells would be expected to attenuate stress and be beneficial. 
Inhibition of mTORC1 with treatment of rapamycin was found to enhance intestinal stem cell 
function by mimicking calorie restriction, allowing them to replicate and differentiate when needed 
[277]. In addition, a study showed age related decline in the function of hematopoietic stem cell 
(HSC) function associated with increased activity of mTORC1 [278]. Rapamycin was found to 
restore self-renewal of HSCs in old mice [278]. Most importantly, rapamycin blunts the pro-
inflammatory SASP secreted by senescent cells and extends lifespan and postpones age-
associated diseases in mice [274, 279]. Metformin, which also leads to indirect inhibition of 
mTOR, can increase lifespan and healthspan in mice by mimicking calorie restriction [280]. 
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Figure 3.2. Inhibition of cellular senescence using rapamycin. Rapamycin inhibits mTOR 
which prevents the development of cellular senescence. Metformin mimics benefits seen in 
calorie restriction by increasing AMPK which improves cellular functioning and inhibits mTOR. 
Both rapamycin and metformin treatment in mice has been found to increase life and healthspan. 
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 While the exploration of challenging and modifying age-related changes is advancing out 
the understanding of aging and age-associated changes in disease, some researchers have 
undertaken studies from quite a different approach. Castellano et al. have been studying how 
youthfulness can promote rejuvenation and counter the aging-related effects on tissues. They 
have found that exposure to factors in young blood can counteract age-related changes in the 
CNS, specifically in the hippocampus of aged mice [281]. Tissue inhibitor of metalloproteinases-
2 (TIMP-2), a secreted protein, was found to be enriched in human cord plasma and increase 
synaptic plasticity and hippocampal-dependent cognition in aged mice [281]. 
 Aging is also known to limit remyelination and aged animals exhibit poor remyelinatng 
potential. The reasons for this are thought to be due to changes within the lesion 
microenvironment, which may also relate to epigenetic changes within OPCs themselves that 
decrease their ability to differentiate and properly myelinate in the milieu of the aged CNS [125, 
282, 283]. Interestingly, Franklin and colleagues have shown that remyelination in aged animals 
can be enhanced using youth: heterochronic parabiosis pairing of an older mouse with a young 
mouse was found to promote myelin repair in the aged CNS. These seminal findings indicate that 
factors present in young blood can help rejuvenate repair and these factors, such as TIMP-2, may 
account for the changes in tissue resilience with age [284].  
 While these data support aging as a process that can impact CNS myelin, cellular 
senescence has yet to be identified in oligodendrocytes or neurons, but the awareness of aging 
in this field is slowly starting to develop. The field of senescence is still in its infancy, but many of 
the typical hallmarks of senescence have been observed in research involving brain aging, just 
not termed “senescent”. Overall, based on what we know about senescence, these cells could 
cause disruptions of the BBB, impaired myelination, and reduced neurogenesis, impairing repair, 
but much more research needs to be done in order to understand exactly how these cells affect 
natural aging and human disease [206]. 
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IV. Cellular Senescence in MS 
 
The concept that cellular senescence may contribute to failed remyelination in MS is 
consistent with the gradual cumulative nature of progressive multiple sclerosis, and that age is 
one of the most influential factors in the progressive of MS [285, 286]. This concept is a central 
idea explored in Chapter 5 of this thesis. While we do not know any specific triggers of MS, chronic 
stress-induced senescence can evoke DNA damage, mitochondrial dysfunction, epigenetic 
stress, reactive oxygen species, and ER stress - all of these have been implicated in MS [287-
291]. In addition, many SASP factors are also known to have elevated expression in MS, including 
a host of oxidative (e.g. nitric oxide) and pro-inflammatory factors (including interleukin (IL)-6, IL-
1, IL-8, MIP1β, MIP1𝝰) and growth factors (e.g. FGF2) [264, 292, 293]. As mentioned in the 
section above, these SASP factors can contribute to disease-related tissue impairment by causing 
a paracrine spread of cellular dysfunction and foster an environment conducive to tissue damage. 
These factors can also disrupt the stem cell niche thereby perturbing endogenous spontaneous 
regeneration of damages or lost tissue [294-296].  
There are several lines of evidence to support a role for cellular senescence in 
experimental models of demyelination. First, it has been recently shown that the cuprizone mouse 
model of demyelination is associated with induced markers of cellular senescence in glia within 
demyelinated lesions†. Second, middle-aged male mice (8 months) have been reported to have 
an increased severity of EAE [297] that is associated with senescence in regulatory T cells [298] 
and increased permeability of the blood brain barrier [299]. Next, senescent CD8+ T cells have 
been identified in the aging human brain, and upregulation of senescence markers and pro-
inflammatory molecules in T cells in response to virus infections have led to the long-standing 
suggestion that pathogens may initiate or promote neurodegeneration under certain conditions 
[300, 301]. The relevance of these findings point to a central role for CD8+ T cells which are found 
																																																						
† Papadopoulos, D; et al., Accelerated cellular senescence in a model of multiple sclerosis 
(S50.004); Neurology, April 17, 2017. http://n.neurology.org/content/88/16_Supplement/S50.004 
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abundantly in MS lesions and where their accumulation has been correlated with the rate of lesion 
damage [302, 303]. Cellular senescence in T cells has been observed in patients with rheumatoid 
arthritis and also in MS, implicating perturbation of immune system function associated with 
senescence in these diseases [304]. Taken together, these findings from mouse models and 
human patients, suggest cellular senescence in T cells may contribute to neuroinflammation and 
neurodegeneration in MS.  
Microglia and macrophages are known to either hasten or hamper oligodendrocyte 
differentiation during CNS remyelination [305]. The clearance of debris by these cells from the 
lesion site is critical in the process of OPC remyelination, but aged microglia demonstrate 
decreased motility and cellular migration when compared to young [306]. When aged these cells 
also show decreased phagocytic function, impairing their ability to clear debris, which may induce 
an arrest in OPC differentiation [307]. Immunosenescence, also termed immune-aging, of both 
microglia and macrophages could be a potential mechanism for the decreased repair seen in 
aging [308]. The age-associated decrease in regeneration proficiency can also be attributed to 
the lessened ability of microglia and macrophages to resolve inflammation. Recently it has been 
determined that cholesterol, from myelin breakdown, overwhelms aged macrophages and 
microglia limiting proper clearance functions [309]. The potential for diverse and in some cases 
opposing role(s) of these cells in natural aging and disease-associated aging has not been fully 
vetted, but current evidence supports both of these phagocytic cells types as actively involved in 
degeneration and remyelination and potentially influenced by cellular senescence. 
The role of senescence in astrocytes in MS has yet to be studied. While contribution of 
cellular senescence in other cell types in MS have been suggested, and cellular senescence in 
astrocytes has been identified in an increasing number of neurodegenerative diseases, including 
Alzheimer’s and Parkinson’s disease [229, 249], a similar role for cellular senescence in 
astrocytes in MS has not yet been reported. Senescent astrocytes are known to express 
increased glial fibrillary acidic protein (GFAP), associated with increased in pro-inflammatory 
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cytokines [310]. Increased levels of GFAP in both human and rodent CSF are correlated with age 
and disease progression in MS, potentially linking senescent astrocytes with progression [311]. 
Clearance of senescent astrocytes in a mouse model of AD demonstrated a reduction in 
inflammation, confirming their potential as mediators in MS progression [231]. However, 
experimental evaluation of the possible roles of senescence in astrocytes will be necessary to 
draw any conclusions about these reported changes in disease or aging. 
OPCs play a crucial role in myelination of the central nervous system. In MS OPCs have 
been noted to be present within demyelinated lesions yet these progenitor cells remain arrested 
in an undifferentiated state. In animal studies age has been shown to limit remyelinating potential 
of OPCs, and in aged rats remyelination can ensue but at a much slower rate when compared to 
younger rats [312]. Other data have shown that aged OPCs also lack the ability to properly migrate 
to infiltrate a white matter lesion in which OPCs have been depleted. These data suggest that 
aging negatively impacts the migratory activities of OPCs, which have been proposed to be due 
to age-related epigenetic changes [313, 314]. Epigenetics is a dynamic process that has also 
been found to orchestrate the proper differentiation of OPCs: distinct epigenetic events need to 
occur for the step-wise progression of OPCs into mature myelinating OLs, and it is now thought 
that these processes are altered with age and disease [138, 140]. Together, these data suggest 
that OPCs do not succumb to replicative senescence, but are sensitive to senescence due to 
chronic stress [315, 316]. 
Most relevant to this thesis is the emerging importance of cellular senescence in neural 
progenitor cells. NPCs have garnered attention for their potential to repair myelin and decrease 
inflammation. NPCs are of particular interest because they have been found within demyelinated 
lesions, among OPCs, astrocytes and microglia [23, 81, 317]. NPCs are found in greater numbers 
within the demyelinated lesion areas, when compared to normal appearing white matter (NAWM) 
or white matter from non-disease individuals. The presence of NPCs spatially related to OPCs in 
the CNS support the experimental evidence that they contribute to regulation of OPC maturation 
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and myelin regeneration [118, 318, 319]. NPCs are active participants within the lesion 
microenvironment and are known to secrete factors that are regenerative, anti-inflammatory, and 
pro-myelinating [146, 149, 319].  
Cellular senescence in NPCs has not been previously explored as a mechanism by which 
myelination may be limited in MS. Several lines of investigation point to cellular senescence in 
MS as a plausible disease-related process and also implicate NPCs as a potential culprit cell type. 
First, the methylation pattern of the p16Ink4a gene has been proposed as an epigenetic risk factor 
for the development of MS [320]. Second, persistent DNA damage has been reported in cells 
isolated from human MS lesion tissue [288]. This genotoxic injury could trigger senescence, and 
the production and secretion of a SASP [321]. Third, inflammation plays a central role in MS and 
inflammation is known to evoke general epigenetic modifications that can leave cells 
hypersensitive to DNA damage, and in turn, senescent [321, 322]. Fourth, the chronic 
demyelination phenotype characteristic of MS and seen prominently in progressive MS patients 
are correlated with signs of long-standing oxidative stress, inflammation, and even somatic 
telomere length shortening [288, 323, 324]. Lastly, as mentioned earlier in the chapter, cellular 
senescence in NPCs provides a mechanism to usurp the expected generation of regenerative 
factors and replace this with secretion of pro-inflammatory SASP factors. These changes would 
serve to promote neuroinflammation and keep OPCs in an undifferentiated state (the ‘stem cell 
lock model’) [247]. Thus cellular senescence provides a reasonable hypothesis to explain the 
continuous inflammation in MS disease which ties together epigenetic changes and limited 
remyelinating potential. 
The data in this thesis focuses on my finding that NPCs derived from PPMS patients 
exhibit cellular senescence not observed in NPCs from aged-matched controls. My data show 
that this senescent phenotype is responsible for impairing differentiation of OPCs via the SASP. 
I also report that SASP from PPMS NPCs induces epigenetic changes in naive OPCs, which 
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account for impaired their proper differentiation. Together, the data in Chapters 4 and 5 of this 
thesis represent novel findings which demonstrate and implicate cellular senescence in NPCs as 
a cellular mechanism limiting CNS myelination in this disease. 
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I. Abstract 
Primary progressive multiple sclerosis (PPMS) is a chronic demyelinating disease of the central 
nervous system (CNS) currently lacking any effective treatment. Promoting endogenous brain 
repair offers a potential strategy to halt and possibly restore neurologic function in PPMS. To 
understand how the microenvironment within white matter lesions plays a role in repair we have 
focused on neural progenitor cells (NPCs) since these are found in lesions in PPMS and have 
been found to influence oligodendrocyte progenitor cell maturation (OPCs). To better understand 
the cellular nature of NPCs in PPMS we developed iPS cells from blood samples of PPMS 
patients and age matched non-disease spouse or blood relative controls. Using these iPS cell 
lines we determined that the NPCs from PPMS cases provided no neuroprotection against active 
CNS demyelination compared to NPCs from control iPS lines which were capable of completely 
preventing injury. Conditioned media (CM) from PPMS NPCs provides no protection to OPCs and 
prevents maturation of OPCs into oligodendrocytes in vitro. We also found that CM from PPMS 
iPS NPCs elicited patient-specific differences in the response to compounds that should foster 
oligodendrocyte (OL) maturation. Together, these data establish a new model for understanding 
the nature of myelination defects in PPMS which may lead to novel targeted approaches for 
preventing demyelination in these patients. 
 
Keywords 
induced pluripotent stem cells, neural progenitor cells, primary progressive multiple 
sclerosis, oligodendrocytes 
Abbreviations 
central nervous system, CNS; conditioned media, CM; cuprizone, cup; embryonic stem 
cells, ESCs; induced pluripotent stem cells, iPSCs; multiple sclerosis, MS; neural 
progenitor cells, NPCs; oligodendrocytes, OLs; oligodendrocyte progenitor cells, OPCs; 
primary progressive multiple sclerosis, PPMS; wild type, WT 
	 59 
II. Introduction 
Primary progressive multiple sclerosis (PPMS) is the most severe form of MS as it is 
distinguished from other forms of this disease by the rapid development of disability often without 
relapses [16, 325]. Disability in all forms of MS is associated with the loss of CNS myelin and the 
ensuing disruption of axon conduction, decline of neuronal functions, and eventual 
neurodegeneration [326]. Promoting remyelination is viewed as a promising approach to restore 
salient brain functions in MS patients [327]. This approach holds particular interest for treating 
PPMS as current immunomodulatory therapies offer little benefit to these patients [328, 329]. The 
efficacy of any prospective remyelinating therapy will rely on the potential of resident OPCs in 
their propensity to differentiate into mature myelinating OLs within the lesioned environment. For 
reasons that remain unclear, OL differentiation in PPMS is interrupted, inadequate, or simply fails, 
resulting in chronically demyelinated lesions. Discerning whether neural progenitor cells from 
PPMS patients can appropriately respond to myelin injury and prevent demyelination is critical to 
the translation of experimental therapies to the clinic.  
Studies of myelin lesion pathology have identified premyelinating OPCs within the lesion, 
suggesting an innate potential for remyelination that is somehow limited by the disease or lesion 
environment. Within a demyelinated lesion there are many cell types, including astrocytes, 
microglia, and neural progenitor cells (NPCs) [23, 81, 317, 330, 331]. NPCs are of particular 
interest in term of understanding innate limits on remyelination because they too are activated 
and recruited into demyelinated lesions in MS, and NPCs as are known to regulate OPC 
maturation and myelin regeneration [318, 319]. This idea is supported by experimental evidence 
that murine NPCs when transplanted into mouse models of demyelination are potently anti-
inflammatory and neuroprotective [146-148], and can also promote OL differentiation of 
endogenous OPCs [319, 332]. These data suggest NPCs are active participants to CNS 
myelination and contribute to the environment of a myelin lesion and its potential for CNS 
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remyelination [319], and yet, in PPMS, remyelination fails. We hypothesized that NPCs are a 
cause of remyelination failure in PPMS. 
Induced pluripotent stem (iPS) cells represent a unique opportunity to study the 
mechanism of pathology involved in PPMS, and to specifically address the functional contribution 
of neural progenitor cells towards demyelination in PPMS. No prior study has previously examined 
NPCs from MS patients, however, patient-derived iPS cells have been recently shown to exhibit 
efficient differentiation into oligodendrocytes in vitro and in vivo using the shiverer mouse model, 
which lacks myelination in the central nervous system [157, 333]. These results indicated that iPS 
cells from PPMS cases have the potential to respond appropriately to the necessary cues required 
for OL differentiation, suggesting that limits on OPC maturation inherent to PPMS may reside in 
the function of other cell types in the lesion. We have previously reported that NPCs derived from 
human embryonic stem (ES) cells were capable of attenuating active demyelination during 
cuprizone-induced demyelination in mice [156]. In the present study we developed NPCs from 
PPMS and control patient blood samples and tested them in the context of an active demyelinating 
lesion. These iPS lines were tested to determine whether NPCs from PPMS patients were equally 
capable of promoting myelination and neuroprotection in vivo. Our results demonstrate a 
dramatically reduced capacity of PPMS NPCs for regeneration in demyelinating lesions, which 
may inform future reparative strategies for treating this disease. 
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III. Materials and Methods 
iPS Cell and NPC Culture Derivation. Procedures involving patients and donors were approved 
by the Institutional Review Boards at both study sites prior to collection of any blood samples 
(Protocol IE-13-069-2). To generate iPS cells, blood samples were collected from patients with 
confirmed diagnosis of PPMS and spouses or blood relatives without any identified neurological 
or autoimmune diseases (control), at either the University of Connecticut Health Center 
(Farmington, CT) or The Mandell MS Center at St. Francis Hospital (Hartford, CT) (Table 4.1). 
Using the Sendai virus, multiple clones of each line were generated by the UConn Health Center 
Stem Cell Core (Supp. Table 1). The iPS cells were then plated onto mouse embryonic fibroblasts 
(MEFs) and were fed iPS cell medium consisting of DMEM/F-12 (Life Technologies), 
supplemented with 20% KnockOut Serum Replacement (KSR) (Life Technologies), 0.5% L-
glutamine (Life Technologies), 1% penicillin/streptomycin (Life Technologies), 8 ng/mL basic 
fibroblast growth factor (bFGF) (R&D Systems), and 0.1 μM/mL 2-mercaptoethanol (Sigma-
Aldrich). The pluripotency and genomic integrity of all iPS cell lines (Table 4.1) was validated by 
immunocytochemical analyses for Oct4 and SSEA4 and karyotyping analyses (Supp. Fig. 4.4A). 
Results indicated successful and uniform reprogramming across all lines with colonies from each 
line exhibiting similar morphology (Supp. Fig. 4.4A). To differentiate the iPS cells to NPCs, neural 
stem cell medium (N2/B27), that consisted of neurobasal medium (Life Technologies), 2% B27 
(Life Technologies), 1% N2 (Life Technologies), 1% L-glutamine, 1% insulin-transferrin-selenium 
(Life Technologies) and 1% penicillin/streptomycin with noggin (Fisher Scientific) (250 ng/mL) 
was applied to the multiple clones of each iPSC line for 10 days. Noggin is then removed, cells 
are plated onto laminin (5 μg/mL, Sigma Aldrich), and fed NPC medium for another 6 to 11 days. 
When NPCs were ready for injection into the mice they were collected and counted in the NPC 
medium right before injection. Immunocytochemistry for the iPS cells was performed by the 
University of Connecticut Health Center Stem Cell Core, including the phase contrast images, 
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and staining for Oct4 and SSEA4. Karyotyping was performed by the UConn Induced Pluripotent 
Stem Cell and Chromosome Core (Supp. Fig. 4.4A). 
 
Cuprizone-induced Demyelination and NPC Administration. All procedures involving the use 
of mice were approved by the Institutional Animal Care and Use Committee at the University of 
Connecticut Health Center, and in accordance with guidelines set forth by the National Research 
Council of the National Academies Guide for the Care and Use of Laboratory Animals. Male 
C57BL/6 mice, between the ages of six to eight weeks, were fed cuprizone (0.2% w/w, Sigma 
Aldrich) in powdered rodent lab chow for four consecutive weeks. Two weeks after the initiation 
of the cuprizone diet, the mice were injected intravenously into the tail vein with either NPC media 
(100 μL), or an equivalent volume containing 5 x 105 control NPCs or PPMS NPCs (n=3-5 mice 
group/line). Multiple clones of either line 1.1 or 2.1 were injected into mice as the control lines, 
and multiple clones of either line 1 or 2 were injected into mice as the PPMS lines. For NPC 
injection clones were grown together with their respective line and injected together. Mice were 
maintained on the cuprizone diet for an additional two weeks after cells were injected and then 
mice were euthanized for brain tissue collection. Brains from saline-perfused animals were fixed 
in 10% formalin for paraffin embedding and histological analyses. Electron microscopy was 
performed on tissues from mice also perfused with 4% paraformaldehyde (Sigma Aldrich) and 
2% glutaraldehyde (Electron Microscopy Sciences) in 0.1 M cacodylate buffer, and their brains 
post-fixed in the perfusion solution.  
 
Immunocytochemistry (ICC). NPCs were plated on laminin-coated coverslips (5 μg/mL, Sigma 
Aldrich), and fixed using 4% paraformaldehyde. Following fixation they were permeabilized using 
triton-X100 (0.5%, Sigma Aldrich). They were then stained using the following primary antibodies: 
GFAP (1:1000; Dako, Carpinteria, CA, USA), Musashi 1 (1:250; Abcam, Cambridge, MA, USA), 
MAP2 (1:1000; Abcam, Cambridge, MA, USA), Tuj1 (1:1000; Abcam, Cambridge, MA, USA), 
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smooth muscle actin (1:100 Abcam, Cambridge, MA, USA), and Oct4 (1:100; Abcam, Cambridge, 
MA, USA). All NPC lines and clones were validated with this staining protocol (Supp. Fig. 4.1 and 
Table 4.1). 
 
Apoptosis Detection (TUNEL). Detection of apoptosis was carried out using an In Situ Cell 
Death Detection Kit, Fluorescein (Roche, Basel, Switzerland) according to the manufacturer’s 
protocol. Sections were deparaffinized in xylene and rehydrated in decreasing concentrations of 
ethanol. Sections were digested with 15 μg/mL proteinase K (BD Biosciences, San Jose, CA, 
USA) for 30 minutes, washed in PBS, and incubated with the label and enzyme solution provided 
in the kit for one hour at 37°C. Sections were washed and then mounted using Cytoseal (Fisher 
Scientific, Pittsburgh, PA, USA). Negative and positive controls were prepared as described. 
Coronal brain tissue sections (between 1.10 mm rostral to bregma and 1.7 mm caudal to bregma) 
were used for all analyses. Sections were examined at 60x magnification and images of the left, 
right, and medial corpus callosum were collected using identical exposure settings using 
computer-assisted image analysis software (Olympus IX71, Northern Eclipse, EMPIX Imaging). 
The number of TUNEL+ cells was determined in each image (n = 2-4 mice/treatment group, n = 
3-5 sections/mouse). 
 
Electron Microscopy (EM). EM was performed on microdissected tissues from the midline 
aspect of the corpus callosum and postfixed in 1% OsO4, as previously described [334]. Samples 
were dehydrated using graded ethanols, stained with uranyl acetate, and embedded in 
Poly/Bed812 resin. Ultrathin (0.1 μm) sections from each tissue block were cut and visualized 
using an electron microscope (80 kV, 5000x magnification). G-ratio analyses were performed 
using ImageJ software (National Institute of Health) [335] to determine axon to myelinated axon 
diameters for each condition.  
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Isolation of Rat OPCs and Treatment with NPC Conditioned Media. OPCs were obtained from 
the cerebral cortices of neonatal rat pups (postnatal day 0-2), and were plated on poly-l-ornithine 
coated coverslips, as previously described [336]. OPCs were then cultured in control or PPMS 
NPC conditioned media (CM) for two days. The conditioned media experiments were performed 
in quadruplicate technical replicates and repeated in triplicate using separately developed cultures 
(i.e. unique biological replicates). Conditioned media was taken from the NPCs after 48 hours on 
80% confluent cells, at least 4 days after passage, and immediately spun down to remove debris 
then frozen at -80°C. OPCs were treated with NPC CM for 48 hours and then were fixed and 
stained for Olig2 (1:500; Millipore, Temecula, CA, USA) and MBP (1:500; Millipore, Temecula, 
CA, USA). In order to test OPC protection by NPC CM during an in vitro stressor OPCs were 
treated with 500 μM of glutamate (Sigma) for 12 hours in NPC CM from control or PPMS patients. 
After 12 hours the cells were washed with PBS and the Live/Dead Viability/Cytotoxicity Kit 
(Invitrogen) was performed according to the manufacturer’s instructions. OPC proliferation was 
measured using BrdU (10 μM, Millipore) applied for four hours at the time of applying NPC CM 
[337]. After treatment, cells were washed, fixed, and stained for Olig2 and BrdU (1:250; 
eBioscience, San Diego, CA, USA). For pharmacological treatments, cultures were grown in NPC 
CM for 2 consecutive days with addition of either benztropine (Sigma, 1 μM), clemastine (Sigma, 
1 μM), clobetasol (Millipore, 5 μM), or miconazole (Sigma, 1 μM). For all experiments five fields 
of view at 20x using identical image capture settings were assessed by an experimenter blinded 
to treatments (Olympus IX71, Northern Eclipse, EMPIX Imaging). For analysis of OPC 
differentiation, all Olig2+ cells and MBP+ cells were counted and the percentage of MBP+ cells 
calculated, for cell death analysis a percentage of dead cells was calculated from the total cell 
number, and proliferation was evaluated by analysis of BrdU positive cells as calculated as the 
percent labeled of total Olig2+ cells (n = 3 biological replicates for each cell line).  
 
	 65 
Statistical Analysis. Data was analyzed by Student’s t-test or one-way ANOVA, where 
appropriate and as indicated, using GraphPad Prism version 6 for Mac OS X (GraphPad 
Software, La Jolla California USA, www.graphpad.com). Differences were considered significant 
when P < 0.05. Data are presented as mean ± SEM. 
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IV. Results 
1. PPMS NPCs Fail to Provide Neuroprotection Against Cuprizone-Induced Demyelination. 
We hypothesized that development of PPMS-patient iPS lines would enable us to evaluate 
and compare the ability of disease-specific cells to foster myelination. To test this hypothesis, we 
examined whether differentiated NPCs from control and PPMS patients could foster CNS 
myelination in vivo. We had previously demonstrated that human embryonic stem cell-line derived 
NPCs potently attenuated demyelination in mice treated with cuprizone [156]. This cuprizone 
model offered several advantages to study the cellular effects of the iPSC-derived NPCs on CNS 
myelination. First, this model induces robust, reproducible, and predictable CNS demyelination 
mediated by OL cell death [156, 338, 339]. Cuprizone-induced demyelination is most notable in 
heavily myelinated areas, including the corpus callosum providing a clearly defined a priori locus 
for analysis [104, 156]. Second, cuprizone-induced demyelination is not dependent on the 
adaptive immune response, which in turn tests the propensity of these cells to foster myelination 
exclusive of their potential to dampen autoreactive T cells which is inherent to other experimental 
models of demyelination [146]. Most importantly, our previous study had validated this model for 
its utility as an acute in vivo assay to test the myelinating potential of human cells [156].  
 Wild type (WT) C57BL/6 mice were fed cuprizone for two consecutive weeks and then 
randomly assigned to receive either NPCs from PPMS patients or control lines (Fig. 4.1A, Table 
1). Control and PPMS NPCs injected into cuprizone-fed mice consisted of three clones per line 
with multiple animals per treatment group (n=3-5 per group/line; Supp. Table 1). Mice were 
maintained on cuprizone for an additional two weeks at which point brain tissues were collected 
for quantitative assessment of myelinated axons in the corpus callosum (Fig. 4.1A). Electron 
microscopy of myelinated axons in the corpus callosum revealed a profound loss of myelination 
in cuprizone-fed mice (Fig. 4.1B), resulting in a significant increase in the axon g-ratio (0.70 naïve 
mice vs. 0.78 cuprizone mice; Fig. 4.1C and D upper panels). Analysis of the corpus callosum in 
cuprizone-fed mice administered control NPCs revealed a marked improvement in compact 
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myelination, while PPMS NPC-treated mice exhibited few compactly myelinated axons, that was 
not different from lesion-control animals (Fig. 4.1B), and exhibited a significant elevation in 
myelinated axon g-ratios (Fig. 4.1C and D lower panels). Analyses on the proportion of axons that 
were unmyelinated in the corpus callosum confirmed a demyelinating effect of cuprizone 
treatment (Fig. 4.1E upper panel). Administration with control NPCs resulted in a marked 
preservation in the number of myelinated axons, while PPMS NPC treatment resulted in 
significantly fewer myelinated axons (Fig. 4.1E lower panel). Cell death analyses within the corpus 
callosum revealed a significant increase in TUNEL+ cells in cuprizone-treated animals, while 
cuprizone-fed animals that were also administered control NPCs did not differ from the naive mice 
(Fig. 4.1F). NPCs from PPMS cases failed to provide neuroprotection from cuprizone treatment 
(Fig. 4.1F). The same amount of human nuclear antigen positive NPCs enter the corpus callosum 
from either the control or PPMS NPC lines (Supp. Fig. 4.5). These results suggest that unlike 
NPCs from control cases which increase the number of myelinated axons in the corpus callosum, 
NPCs from PPMS patients failed to provide any benefit in preserving compact CNS myelination 
during active demyelination produced by cuprizone treatment. 
 We had previously reported that hES-NPCs given to cuprizone-treated mice exhibited 
multiple cell fates in the corpus callosum, including differentiation into GFAP+ astrocytes and O1+ 
mature oligodendroglia [156]. We also examined the cell fates of the NPCs in tissues of control 
NPC and PPMS NPC-treated mice. We determined that the fate of NPCs from control lines tended 
to differentiate towards an oligodendrocyte phenotype, whereas PPMS NPCs exhibited 
significantly fewer oligodendrocytes but significantly more astrocytes (Supp. Fig. 4.5). The reason 
for these differences in NPC fate are not understood but likely relate to the differences in CNS 
myelination observed between control and PPMS NPC-treated groups. 
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2. PPMS NPCs Fail to Protect Rat OPCs from Toxicity and do not Support Oligodendrocyte 
Differentiation in vitro.  
 The failure of PPMS-NPCs to prevent demyelination of the corpus callosum during 
cuprizone-treatment suggested a failure of the NPCs to confer neuroprotection. To test this 
further, we cultured primary rat OPCs, treated these with conditioned media (CM) from either 
control or PPMS NPCs and the applied glutamate as an excitotoxic stimulus to induce cell death 
(Fig 4.2A). Cell death, was measured and compared between treatment groups (Fig 4.2B). 
Application of glutamate (500 μM/12 hrs) [340] was found to induce comparable amounts of cell 
death in both control media (N2/B27 media) or CM from control NPC cultures. In contrast, OPCs 
grown in CM from PPMS NPCs exhibited twice as much cell death in response to glutamate as 
either control condition (Fig 4.2B). These results suggested that PPMS CM exerted a negative 
influence on OPCs which may not be limited to failure to protect against a noxious stimulus. We 
hypothesized that PPMS NPC CM may also negatively impact OPC differentiation. To test the 
possibility that PPMS NPCs differed in their ability to support OPC differentiation we collected 
conditioned media (CM) from PPMS NPC and control NPC cultures. These media were used to 
differentiate primary A2B5+ oligodendrocyte progenitor cells in vitro for two days (Fig. 4.2C). 
Conditioned media collected from control NPCs was found to promote differentiation of A2B5+ 
OPCs into mature MBP+ oligodendrocytes (OLs) (Fig. 4.2D and E), while CM from PPMS NPCs 
failed to promote successful OL differentiation, based on the percentage of MBP positive cells in 
the culture. Out of all three PPMS lines, the NPC CM significantly inhibited differentiation when 
compared to the NPC CM of the spouse or sibling control (Fig. 4.2E). The number of Olig2+ cells 
in each culture condition did not differ (Fig 4.2E), nor did the proliferation of OPCs differ between 
control or PPMS CM treated cultures (Fig. 4.2E). Together, these data indicated that CM from 
PPMS NPCs did not kill OPCs nor did it induce proliferation of OPCs which could have accounted 
for the reduced differentiation in these culture conditions. Thus, PPMS CM was less able to 
promote oligodendrocyte differentiation than control NPCs. 
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3. NPC CM Mediated Oligodendrocyte Differentiation Exhibited Patient-Specific 
Responses Towards Potential Remyelination Compounds.  
We next examined the impact of PPMS NPCs on the efficacy of recently identified 
compounds reported to stimulate remyelination [110, 163, 164]. First we show that in 
unconditioned N2/B27 media there is an increase in MBP positive cells with drug treatment as 
previously reported (Fig. 4.3A). Next, we tested whether conditioned media from our human 
control NPC and PPMS NPC cultures would impact the efficacy of either benztropine[164], 
clemastine [110], miconazole, or clobetasol [163] to stimulate OPC differentiation. To test this we 
employed the same cell culture paradigm as above (Fig. 4.3B), and applied all compounds as 
previously reported. We found that when applied to OPCs grown in CM from control lines 
compounds elicited increased maturation of A2B5+ OPCs to MBP positive cells (Fig. 4.3C and 
D). In contrast, administration of these compounds to OPCs cultured in CM from PPMS NPCs 
exhibited selective effects on OL maturation that varied by patient (Fig. 4.3C and E). In three 
examples, PPMS line 1 only displayed a significant improvement in OPC maturation in response 
to clemastine and miconazole, whereas OPCs grown in CM from PPMS line 2 exhibited modest 
improvement in response to clobetasol but not the other compounds tested, and lastly OPCs 
grown in CM from PPMS line 3 exhibited maturation in response to clemastine, clobetasol, and 
miconazole, but not benztropine (Fig. 4.3C and E). These data indicate that CM from PPMS NPCs 
influence the responsiveness of OPCs to pharmacological stimulation of differentiation observed 
in cells exposed to control NPC CM. 
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V. Discussion and Conclusions 
A therapeutic goal to treat MS is the preservation of CNS myelin and to restore salient 
functions to demyelinated axons in MS patients. Accumulating evidence supports a prominent 
role for NPCs as important regulators of neuroprotection and remyelination in the MS brain. Our 
findings are the first to report that NPCs developed from PPMS patients exhibit inherent defects 
when compared to control NPCs. PPMS NPCs failed to provide neuroprotection during an active 
myelin injury in vivo, and secondly, they were found not to support OPC differentiation in vitro. 
These findings indicate that NPCs from PPMS patients may be inherently different in terms of 
their myelinating support compared to NPCs of control cases. Our findings also demonstrated 
that PPMS NPCs from different patients were inherently distinct from each other in that their 
response to potential pro-myelinating drugs varied from patient to patient, and thus suggests a 
uniqueness to the regenerative potential of each PPMS patient. A future potential development 
of these patient-specific iPS cell lines could be individualized assessment of NPC functions for 
personalized treatment to assess neuroprotection and promote remyelination. Thus, our 
application of iPS NPCs, and CM, may represent a novel approach of discovering patient-specific 
remyelinating therapies when used in conjunction with wider drug screening assays.  
 Studies of myelin pathology in MS cases have identified premyelinating OPCs within 
demyelinated lesions [341]. This observation indicates an endogenous potential for NPCs as a 
source of limiting factors related to disease and/or the lesion microenvironment [342]. That NPCs 
are activated and found within demyelinated lesions in MS has also prompted attention on NPCs 
as possible regulators of myelin regeneration [318, 319]. Experimental evidence using wild type 
(non-disease) murine NPCs has found that when transplanted into mouse models of 
demyelination can have potent anti-inflammatory qualities and provide neuroprotection [146, 147]. 
These wild type murine NPCs can also promote OL differentiation from endogenous OPCs [319, 
332]. The benefit of NPCs in these experimental models of CNS demyelination is (in part) 
mediated by secreted factors [150-153], such as growth factors that can foster myelin repair [154, 
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155]. Consistent with this we have previously demonstrated that human ESC-derived NPCs 
attenuated demyelination in the cuprizone model following intravenous administration [156]. The 
effect of the human NPCs in this model were found to be neuroprotective and not limited to cell 
replacement, consistent with the notion that a function of NPCs is to maintain or restore 
homeostatic processes [343]. Our in vivo fate analysis of injected NPCs in the cuprizone mice 
identified significant differences between control and PPMS lines. We noted that while control 
NPCs differentiated into some astrocytes and mostly oligodendrocytes, PPMS NPCs 
preferentially differentiated into astrocytes only (Supp. Fig. 4.5). While we do not fully understand 
the physiological reasons for these differences, we hypothesize that these differences relate to 
the reduced ability of PPMS NPCs to promote CNS myelination. Astrocytes are known to 
influence the fate of OPCs and myelination and reactive astrocytes are a pathological feature of 
CNS myelin lesions. This may suggest that the bias toward an astrocytic lineage in the PPMS 
lines could reflect a central role for astrocytes in remyelination in PPMS. Alternately, previous 
findings have also shown that genotoxic injury to NPCs can induce a bias toward astrocyte 
differentiation [344]. Within MS lesions DNA damage has been observed [288]. These data may 
suggest that disease-related changes in PPMS could have resulted in a bias of the NPCs from 
these patients to then differentiate towards an astrocytic fate. Future studies should will be needed 
to better understand this difference in cell fate as it relates to the function of NPCs and their 
neuroprotective potential in PPMS. Our results add to this body of work and suggest that NPCs 
in PPMS are fundamentally different and have an effect on mediating changes on the local 
microenvironment through secreted factors that negatively impact OPC maturation. If one were 
to translate these ex vivo findings to an MS lesion microenvironment, our data would suggest that 
NPCs in PPMS are a contributing factor to demyelination that may deplete OPCs and thereby 
limit endogenous remyelinating potential.  
 Our findings using patient specific iPS cells indicate that the function of NPCs in PPMS is 
modified by disease and may be a critical determinant of myelin repair. For instance, we show 
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that PPMS-CM exhibited very little differentiation on OPCs in vitro. This may have been due to 
reduced growth factor production by the PPMS NPCs, which may have then contributed to the 
stunted maturation of MBP+ OLs. One approach we tested was the potential for iPS cells to be 
used to identify personalized remyelinating compounds to treat PPMS. Our data determined that 
four FDA approved drugs recently found to aid OPC maturation had significant differences in 
efficacy when OPCs were grown in conditioned media from PPMS NPCs. Clemastine, one of the 
drugs that was found to enhance oligodendrocyte differentiation, is an antihistamine and 
anticholinergic compound that acts as an antagonist for muscarinic receptors [110, 164], while 
another drug, miconazole, an antifungal agent, acts as an antagonist towards glucocorticoid 
receptors [345]. Based on our results, clemastine may offer therapeutic potential for one patient 
line tested, and yet none of the compounds tested effectively enhanced OPC differentiation for 
the other. These results suggest potentially important differences between patients and in how 
NPCs from these different individuals with PPMS have impaired OPC maturation. Moreover, using 
the NPCs from PPMS iPS cells we also may exploit these individualized differences to better 
identify and understand what process(es) limit remyelination, that may also serve to distinguish 
PPMS from other forms of MS. This NPC-based approach may be adopted to optimize the 
potential of identifying specific compounds for different patients, or groups of patients, that 
effectively stimulate OPC differentiation. Using a personalized iPS-cell based screen would be an 
innovative approach that offers the potential for promoting neuroprotection, fostering 
remyelination and restoring salient functions for PPMS patients. 
 The results of this study complement previous findings by Douvaras and colleagues who 
reported that fibroblast-derived iPS cells from PPMS patients were capable of differentiating into 
myelinating oligodendrocytes in vitro and in vivo, using the shiverer mouse model [157]. Previous 
work had determined that PPMS iPS cells were capable of OL differentiation and maturation [157], 
however our findings reveal restricted and limited promyelinating potential of PPMS NPCs in the 
corpus callosum during active demyelination. It is important to point out that there are several 
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important differences that distinguish this study and the previous report. First, we focused on the 
NPC as the cell type of interest and found that PPMS NPCs exhibited a dramatic effect on 
oligodendrocyte differentiation. Secondly, we challenged PPMS NPCs in the context of an active 
demyelinating lesion and found a significant defect in the neuroprotective potential of PPMS-
derived cells. Third, we reprogrammed cells from blood whereas the previous study used skin 
fibroblasts. Taken together, results from iPS cell studies of PPMS would indicate that cells form 
these patients may have the potential to form myelin but that the potential is limited by the complex 
cellular interplay in the diseased CNS. 
 The cause and biological mechanism underlying the pathology of PPMS is presently 
unknown. Our development and testing of PPMS NPCs provide new information and an important 
opportunity to better understanding PPMS, but perhaps other progressive forms of MS as well. 
Future studies examining the physiological effect of iPS-derived NPCs from secondary 
progressive [346] and also relapsing-remitting forms of MS would be warranted to determine 
whether NPC function is compromised across only progressive forms, or all clinical forms of MS. 
Our data suggest NPCs from PPMS may contribute to an inherent defect in CNS myelination in 
PPMS. It remains unclear whether these important differences in myelinating potential are innate 
to individuals who then develop PPMS, or are a result of maladaptively acquired changes resulting 
from the experience of having PPMS. These findings provide a new perspective from which we 
may better understand this disease and develop new approaches for abating or reversing the 
insidious course of PPMS. 
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VII. Figures 
 
 
Figure 4.1 
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Figure 4.1. Reduced compact myelination in the corpus callosum of cuprizone-treated 
mice administered PPMS NPCs. (A) Experimental timeline for the treatment of cuprizone-fed 
mice with iPS-derived NPCs. Wild type (WT) C57BL/6 mice were fed cuprizone (“cup”) for 2 
weeks, injected with iPS derived NPCs (i.v.), and after an additional 2 weeks of cuprizone 
administration brain tissues isolated for pathology. (B) Representative electron microscopy (EM) 
images (5000x magnification) of compact myelination in the corpus callosum of naïve mice, 
cuprizone-fed mice, and cuprizone-fed mice injected with either control NPCs, or cuprizone-fed 
mice injected with PPMS NPCs. Scale bar, 3 μm. (C) Scatter plots of myelinated axon g-ratios in 
each treatment group comparing naïve vs cuprizone with NPC treatment and both NPC treated 
groups (control NPCs vs PPMS NPCs). (D) Average myelinated axon g-ratios (mean ± SEM) for 
each treatment group (**** P < 0.0001, one-way ANOVA). (E) Quantification of myelinated and 
unmyelinated axons in the corpus callosum of each treatment group, as indicated (** P < 0.01, 
*** P < 0.001, one-way ANOVA). Data points represent individual g-ratios for axons where naïve 
n = 262 axons, cuprizone n = 221 axons, control NPC n = 256 axons, and PPMS NPC n = 303 
axons. (F) Quantification of TUNEL+ cells in the corpus callosum of each treatment group, as 
indicated (* P < 0.05, one-way ANOVA). Naive = mouse fed no cuprizone; Cuprizone = mouse 
fed cuprizone; Cntl = mouse fed cuprizone and injected with control NPCs (either line 1.1, 
consisting of clones 1, 2, and 5 together; or line 2.1, consisting of clones 2, 3, and 6 together]); 
PPMS = mouse fed cuprizone and injected with PPMS NPCs (either line 1, consisting of clones 
1, 4, and 3 together; or line 2 consisting of clones 1, 2, and 4 together). 
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Figure 4.2 
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Figure 4.2. PPMS NPCs do not protect OPCs and do not support oligodendrocyte 
differentiation. (A) Control and PPMS NPCs were grown in culture for at least 48 hours at 80% 
confluency and conditioned media (CM) collected. Primary rat OPCs (rOPCs) were grown in CM 
from control NPCs or PPMS NPCs with 500 μΜ glutamate treatment for 12 hours and cell death 
was assessed. (B) The percent cell death of OPCs treated with either control CM or PPMS CM in 
the presence of glutamate. PPMS CM did not protect OPCs from glutamate toxicity. (* P < 0.05, 
one-way ANOVA). Representative pictures of live cell/dead cell assay. Scale bar, 50 μm. (C) 
Control and PPMS NPCs were grown and CM collected as in A. Primary rat OPCs (rOPCs) were 
grown in CM from control NPCs or PPMS NPCs for 48 hours and OL maturation was assessed. 
(D) Representative images of mature oligodendrocytes (MBP+/Olig2+) resulting from either 
control CM or PPMS CM. Scale bar, 200 µm, magnified panel scale bar, 50 μm. (E) Quantitative 
comparison of OL maturation of OPCs grown in either non-conditioned N2/B27 media, PPMS 
CM, or control CM determined that the proliferation of Olig2+ cells was identical between each 
treatment condition, while OL maturation (Olig2+/MBP+) was significantly lower in OPCs grown 
in PPMS CM. No differences in OPC proliferation (BrdU) was observed in control (N2/B27), or 
CM from either control NPCs or PPMS NPCs.  n = 12 independent cultures per treatment (*** P 
< 0.001, one-way ANOVA). N2/B27 = non-conditioned NPC media; Cntl-CM = CM from control 
lines; PPMS-CM = CM from PPMS lines.  
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Figure 4.3 
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Figure 4.3. Individualized patient-specific differences to promyelinating drugs. (A) 
Quantification of OL maturation in OPCs grown in non-conditioned N2/B27 media with application 
of promyelinating drugs: benztropine (“Benz”), clemastine (“Clem”), clobetasol (“Clob”) or 
miconazole (“Micon”), as indicated. (B) Control and NPC CM was collected after 48 hours at 80% 
confluency. rOPCs were grown in CM from either control NPCs or PPMS NPCs in addition to 
either of the four promyelinating drugs, and after 48 hours OL maturation was assessed. (C) 
Representative images of Olig2+ OPC-lineage cells (green) and MBP+ OLs (red) after 48 hours 
of treatment with either control NPC CM or PPMS NPC CM alone or in combination with 
application of four promyelinating drugs. Scale bar, 200 µm. (D) Quantification of OL maturation 
(%MBP+/Olig2+) in OPCs grown in control NPC CM and the measurable effect on OL maturation 
of the four promyelinating compounds. (E) Quantification of OL maturation in OPCs grown in 
PPMS NPC CM and the measurable effect on OL maturation of the four promyelinating 
compounds. n = 3 independent cultures per treatment from 8 technical replicates/treatment. 
Values are means ± SEM. (* P < 0.5, ** P < 0.01, *** P < 0.001 **** P < 0.0001, one-way ANOVA). 
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Table 4.1. iPS Cell Line Derivation from PPMS Patients and Spousal or Blood-Relative 
Controls. Information on PPMS patients (n = 3), and either their spouses or sibling (n = 3), that 
provided blood samples used to develop new iPS cell lines. Average age of each group did not 
differ (P = 0.876; PPMS mean = 56; control mean = 57). Average duration of PPMS among the 
patient samples at the time of collection was 7.6 years with a mean 5.3 EDSS score. EDSS, 
expanded disability status scale. 
 
Line Gender Age Disease Diagnosis Relationship EDSS 
Score 
1 M 61 PPMS 5 Years  5 
2 F 62 PPMS 14 Years  7.5 
3 F 45 PPMS 4 Years  3.5 
1.1 F 59 No — Spouse — 
1.2 F 66 No — Sibling — 
1.3 M 47 No — Spouse — 
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VIII. Supplement 
Supplemental Methods 
iPS Cell Lines developed from PPMS and Control Blood Samples and NPC Differentiation. 
The stemness and genomic integrity of all iPS cell lines was validated by immunocytochemical 
analyses for Oct4 and SSEA4 and karyotyping analyses. Results indicated successful and 
uniform reprogramming across all lines with colonies from each line exhibiting similar morphology 
(Supp. Fig. 4.4A). Karyotyping of both iPSC line 1 (PPMS) and line 1.1 (control) also revealed no 
chromosomal anomalies (Supp. Fig. 4.4B). NPC differentiation was induced by treating the iPS 
cells with neurobasal media supplemented with noggin (250 ng/mL) for 10 days to promote 
formation of neural rosettes [347]. NPC differentiation was validated by assaying expression of 
Musashi-1 (Msi1), βIII-tubulin (Tuj1), and GFAP (Supp. Fig. 4.4C). NPCs from disease and control 
lines exhibited similar proportions of mature cell types: with the control line expressing an average 
of 8.9 ± 0.9% positive Tuj1 cells and the PPMS line an average of 8.2 ± 0.7% positive Tuj1 cells 
(P = 0.5731; Supp. Fig. 4.4D). A lack of microtubule-associated protein 2 (MAP2), a post-mitotic 
neuronal marker indicated no terminally differentiated neurons in the NPC cultures, and a lack of 
Olig2 expression indicated no oligodendrocyte lineage cells, which supported the characteristic 
early proliferative nature of these cultures. Validation of the restricted potential of these NPC 
cultures was also validated by the lack of smooth muscle actin (SMA) or Oct4 staining, indicating 
that there was no contamination by either mesodermal or earlier stage stem cells in these cultures. 
These data indicate successful reprogramming to iPS cells and equivalent differentiation of both 
control and PPMS cells to NPCs. 
 
Immunohistochemistry. Brain sections were deparaffinized, and immunohistochemical staining 
was performed as previously described using the following primary antibodies [336, 348]: Olig2 
(1:250; Millipore, Temecula, CA, USA), MBP (1:500; Millipore, Temecula, CA, USA), and human 
nuclear antigen (1:150; Millipore, Temecula, CA, USA). Coronal brain tissue sections (between 
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1.10 mm rostral to bregma and 1.7 mm caudal to bregma) were used for all analyses. After 
deparrafinization of the mouse sections, they were either stained using GFAP and human nuclear 
antigen or using Olig2 and human nuclear antigen (hNA). These immunostained sections were 
examined at 20x magnification and images of the medial CC were collected using identical 
settings. Images were viewed and analyzed using computer-assisted image analysis software on 
an Olympus IX71 microscope. For each section the total number of cells positive for GFAP or 
human nuclear antigen were counted, and the cells positive for Olig2 or human nuclear antigen 
were counted. In addition, the cells that were double labeled were also counted. For each animal 
in the treatment groups, three sections were analyzed. 
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Supplemental Figure 4.4 
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Supplemental Figure 4.4. Control and PPMS iPS cells and NPCs exhibit equivalent pluripotency 
and differentiation markers in vitro. (A) Immunocytochemical analyses determined that iPS cells 
from both lines expressed markers Oct4 and SSEA4. No morphological differences were 
observed between the two lines. (B) Karyotype of PPMS line 1 and control line 1.1 indicates no 
chromosomal abnormalities in the iPSCs (Table 4.1). (C) Between D16-D21 of NPC differentiation 
immunocytochemistry was performed to assay for expression of markers indicative of neural 
differentiation, Msi1, MAP2, Tuj1, and GFAP. No positive staining for SMA or Oct4 indicated no 
mesodermal or earlier stage stem cells in these cultures. We also did not detect any Olig2 staining 
in either control or PPMS cultures, which indicated no differences in differentiation potential of the 
NPCs. (D) Both lines of NPCs expressed the same amount of Tuj1 indicating no differences in 
maturity (n = 6 separate coverslips/line). Representative figures in panels A, B, and C are control 
line 1.1 and PPMS line 1. Values are means ± SEM. 
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Supplemental Figure 4.5 
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Supplemental Figure 4.5. Cell fate analysis of transplanted human cells in cuprizone-treated 
mice. Analysis of human cell fates in the corpus callosum of cuprizone-treated mice administered 
control NPCs (Line 1.1) or PPMS NPCs (Line 1). (A, B) Analysis of oligodendrocyte lineage 
(Olig2+) cells in these treatment groups identified a significantly lower percentage of Olig2+ 
staining that colocalized with human nuclear antigen (hNA+) staining in the PPMS NPC injected 
mice. First scale bar, 200 μm; second scale bar 15 μm. (n = 187 hNA+ cells in control NPC 
injected mice, n = 196 hNA+ cells in PPMS NPC injected mice). (C, D) Analysis of hNA+ 
immunostaining with GFAP+ (astrocytes) determined a higher proportion of hNA+/GFAP+ cells 
in PPMS NPC-treated mice than in control NPC-treated mice. (n = 257 hNA+ cells in control NPC 
injected mice, n = 376 hNA+ cells in PPMS NPC injected mice). (E) Quantification of hNA+ cells 
in medial corpus callosum of mice that had been injected with either control NPCs or PPMS NPCs 
(as described). There were no significant differences in number of hNA+ cells per mm2 (P = 
0.3753). Error bars represent SEM. (** P < 0.01, *** P < 0.001, **** P < 0.0001, Student’s t test). 
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I. Abstract 
 
Cellular senescence is a form of adaptive cellular physiology associated with aging. Cellular 
senescence causes a pro-inflammatory cellular phenotype that impairs tissue regeneration, has 
been linked to stress, and is implicated in several human neurodegenerative diseases. We had 
previously determined that neural progenitor cells (NPCs) derived from primary progressive 
multiple sclerosis (PPMS) patient induced pluripotent stem (iPS) cell lines failed to promote 
oligodendrocyte progenitor cell (OPC) maturation whereas NPCs from age-matched control cell 
lines did so efficiently. Herein, we report that expression of hallmarks of cellular senescence were 
identified in Sox2+ NPCs within white matter lesions of human progressive MS autopsy brain 
tissues and PPMS patient iPS-derived NPCs. Expression of cellular senescence genes in PPMS 
NPCs was found to be reversible by treatment with rapamycin which then enhanced PPMS NPC 
support for oligodendrocyte differentiation. A proteomic analysis of the PPMS NPC secretome 
identified high mobility group box-1 (HMGB1), which was found to be a senescence-associated 
inhibitor of oligodendrocyte differentiation. Transcriptome analysis of OPCs revealed that 
senescent NPCs induced expression of epigenetic regulators mediated by extracellular HMGB1. 
Lastly, we determined that NPCs are a source of elevated HMGB1 in human white matter lesions. 
Based on these data, we conclude that cellular senescence contributes to altered NPC functions 
in demyelinated lesions in MS. Moreover, these data implicate cellular aging and senescence as 
a process that contributes to remyelination failure in progressive MS which may impact how this 
disease is modeled and inform development of future myelin regeneration strategies. 
 
 
Significance Statement 
Nicaise et al. identify cellular senescence occurs in neural progenitor cells (NPCs) from primary 
progressive multiple sclerosis (PPMS). In this study, senescent NPCs were identified within 
demyelinated white matter lesions in progressive MS autopsy tissue, and iPS-derived NPCs from 
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PPMS patients were found to express cellular senescence markers compared to age-matched 
control NPCs. Reversal of this cellular senescence phenotype, by treatment with rapamycin, 
restored PPMS NPC-mediated support for oligodendrocyte maturation. Proteomic and 
histological analyses identify senescent NPCs in PPMS as a source of HMGB1 which limits 
maturation and promotes transcriptomic changes in oligodendrocytes. These findings provide the 
first evidence that cellular senescence is an active process in PPMS that may contribute to limited 
remyelination in disease. 
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II. Introduction 
 
Cellular senescence is a component of the aging process that is increasingly recognized 
as an important pathophysiological mechanism associated with a variety of neurodegenerative 
human diseases [216, 349]. Cellular senescence is distinct from cellular quiescence in that 
senescent cells develop a unique level of cellular activity that often exerts a pro-inflammatory 
paracrine effect onto surrounding cells which can impair or alter tissue function, termed the 
senescence-associated secretory phenotype (SASP) [269, 279]. Cellular senescence is linked 
with increased activity of mTOR (mammalian target of rapamycin) [350]. Rapamycin has been 
found to decrease the production of the SASP through inhibition of mTORC1 [279], which has 
enabled studies on cellular plasticity under cellular senescence and the contribution of SASP 
factors to tissue and organ function. One notable influence of cellular senescence is on stem cells 
where senescence has been shown to reduce trophic support and lessen the regenerative 
capacity which can contribute to impaired healing and tissue atrophy in aging and disease [211, 
351, 352]. 
 Progressive forms of multiple sclerosis (PMS) represent a form of this demyelinating 
disease of the central nervous system (CNS) without relapses or remissions. The unabating 
disability in PMS is attributed to demyelination with minimal remyelination [80]. Promoting brain 
repair represents a potential strategy to restore neurologic function in PMS patients [327]. 
However, the success of potential remyelinating therapies relies on endogenous oligodendrocyte 
progenitor cells (OPCs) to differentiate into myelinating oligodendrocytes (OLs) [353]. Therefore 
understanding what limits the potential of endogenous OPCs for remyelination will be required to 
realize remyelination as a therapeutic opportunity for regeneration. 
 Studies analyzing white matter lesion pathology in PMS brain tissues have identified 
immature, premyelinating OPCs in association with neural progenitor cells (NPCs) [319]. NPCs 
have been found to be capable of secreting factors that are anti-inflammatory and support 
remyelination [146], therefore both these cell types could be viewed as capable of promoting 
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regeneration; yet OPC differentiation in vivo is limited and mostly arrested resulting in chronic 
demyelination [23, 80, 81, 318, 319]. We have recently identified that NPCs differentiated from 
iPS cells derived from primary progressive MS (PPMS) patients were less able to provide 
neuroprotection to myelin injury or support OPC differentiation in vitro [111]. Importantly, OPCs 
differentiated from PPMS patient iPS cell lines are equally capable of maturing into myelin-forming 
oligodendrocytes [157], demonstrating that OPCs in this disease have potential that may be 
limited by a disease phenotype in NPCs. 
 In this study, we report new evidence for cellular senescence in NPCs in PMS and 
provide functional evidence that this is a reversible process which is responsible for limiting 
oligodendrocyte maturation. These data suggest that while MS is not a disease of aging, at the 
cellular level, it may be an aging-related disease. 
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III. Materials and Methods 
 
Human Tissue Immunohistochemistry. Unfixed frozen post-mortem tissue was provided by UK 
Multiple Sclerosis Tissue Bank via a UK prospective donor scheme with full ethical approval 
(MREC/02/2/39) and the MRC Sudden Death Brain Bank (ethical approval LREC16/ES/0084) 
(Table 5.1). Colorimetric staining was used to detect labeling in human tissue. 10 μm sections 
were fixed in 4% PFA and antigen retrieval was performed by microwaving sections in Vector H-
3300 antigen unmasking solution (Vector Laboratories, Peterborough, UK). Slides were blocked 
with BloxallTM blocking solution (Vector) then further blocking was performed with 2.5% horse 
serum (Vector). Sections were incubated with primary antibodies HMGB1 (1:500 mouse, 
Biolegend) or p16Ink4a (1:500 mouse, Thermo Fisher Scientific, Paisley, UK) in antibody diluent 
(Spring Bioscience, Abcam, Cambridge, UK) overnight at 4°C. Sections were incubated with 
ImpressTM HRP anti-mouse then colorized with DAB (Vector). Sections were washed and blocked 
in 2.5% horse serum (Vector) then incubated with Sox2 (1:500 rabbit, Reprocell, Glasgow, UK) 
overnight at 4°C. Sections were incubated with ImpressTM AP anti-rabbit and colorized with Vector 
Blue alkaline phosphatase then mounted in Fluoromount-G (Southern Biotech, Birmingham, AL, 
USA). Sections were imaged on a Zeiss Axio Scan.Z1 and processed using Qupath software 
[354]. Four areas measuring 0.37 mm2 each were counted within both the lesion and NAWM in 
MS tissue and white matter of control tissue.  
 
iPS Cell and NPC Culture Derivation. Induced pluripotent stem (iPS) cells and NPCs were 
generated as described previously [111], and iPSC lines from the Fossati lab were derived as 
described previously [157] (Table 5.2). Cell colonies were passaged manually when needed, and 
NPC passage number was kept consistent between lines, similar by at least 5 passages for all 
experiments described. 
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Isolation of Rat Oligodendrocyte Progenitor Cells (OPCs) and Treatment with NPC 
Conditioned Media (CM). OPCs were obtained from the cerebral cortices of neonatal rat pups 
(postnatal day 0-2), and were plated on poly-L-ornithine coated coverslips, as previously 
described [336]. OPCs were cultured in varying conditioned mediums for 48 hours. CM was taken 
from the NPCs after 48 hours on 80% confluent cells, at least 4 days after passage, and 
immediately spun down to remove debris then frozen at -80°C. The conditioned media 
experiments were performed in quadruplicate technical replicates and repeated in triplicate using 
separately developed cultures (i.e. unique biological replicates). For the HMGB1 blocking 
experiments, CM was collected then incubated with 1 μg/mL of function blocking αHMGB1 
antibody (BioLegend, San Diego, CA), or the appropriate isotype control (IgG) for 1 hour at 37°C 
on a shaker. The treated CM was then applied to OPCs for 48 hours, and then differentiation was 
assayed. For recombinant HMGB1 treatment, OPCs were grown in differentiation media 
(neurobasal media [Thermo Fisher, Waltham, MA], 2% B27, 2 mM L-glutamine, and 10 ng/mL 
T3) and treated with recombinant human HMGB1 (R&D Systems, Minneapolis, MN) every 24 
hours for 48 hours, for a total of two doses. Doses consisted of: 0.5, 5, 50, 500, and 5000 ng/mL. 
OPCs were then fixed and differentiation assayed. Oligodendrocytes on coverslips were fixed and 
stained for Olig2 (1:500; Millipore, Temecula, CA, USA) and MBP (1:500; Millipore). For all 
experiments five fields of view at 20x using identical image capture settings were assessed by an 
experimenter blinded to treatments (Olympus IX71, CellSens Software, Olympus, Center Valley, 
PA). For analysis of OPC differentiation, all Olig2+ cells and MBP+ cells were counted and the 
percentage of MBP+ cells calculated. Data is represented as the percent of MBP+/Olig2+ cells 
relative to the control condition set to 100%.  
 
Neural Progenitor Cell Treatments. NPCs were treated with rapamycin (12.5 nM, daily for 48 
hrs) once cells became 80% confluent. After treatment, conditioned media was collected, and 
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cells collected in either TriReagent (Millipore Sigma, Burlington, MA) for RNA isolation, RIPA 
buffer for protein isolation, or fixed (4% paraformaldehyde) for immunocytochemistry. 
 
Immunocytochemistry (ICC). NPCs were plated on laminin-coated coverslips (50 μg/mL, Sigma 
Aldrich), and fixed using 4% paraformaldehyde (PFA). Following fixation they were permeabilized 
using triton-X100 (0.5%, Millipore Sigma). Cells were then stained using the following primary 
antibodies overnight: p16Ink4a (1:500; ThermoFisher, Rockford, IL, USA) and Sox2 (1:250; 
Stemgent, San Diego, CA, USA), and then appropriate secondary antibodies were applied. 
 
Quantitative Real-time Polymerase Chain Reaction (qRT-PCR). Total RNA was isolated from 
NPCs plated on laminin as described previously [348], and converted into complementary DNA 
(cDNA) via reverse transcription (iScript cDNA synthesis kit, BioRad, Hercules, MA), according to 
the manufacturer’s protocol. Synthesized cDNA samples were amplified for qRT-PCR using 
primer pairs for human p16Ink4a (F: 5’ GAAGGTCCCTCAGACATCCCC 3’; Rev: 5’ 
CCCTGTAGGACCTTCGGTGAC 3’), human p53 (F: 5’ CCCCTCCTGGCCCCTGTCATCTTC 3’; 
Rev: 5’ GCAGCGCCTCACAACCTCCGTCAT 3’, human HMGB1 (F: 5’ 
ACATCCAAAATCTTGATCAGTTA 3’; Rev: 5’ AGGACAGACTTTCAAAATGTTT 3’), and human 
β-actin (F: 5’ GGACTTCGAGCAAGAGATGG 3’; Rev: 5’ AGCACTGTGTTGGCGTACAG 3’) 
using the SsoAdvanced Universal SYBR Green Supermix (BioRad) according to the 
manufacturer’s protocol. The PCR cycle conditions were 1 cycle at 95°C for 2 min, 40 cycles of 
95°C for 5 s, and 40 cycles at 60°C for 30 s run on a BioRad CFX96 Touch Real-Time PCR 
Detection System. Relative expression of mRNA was calculated relative to β-actin using 
comparative cycle threshold analysis. 
 
Senescence β-Galactosidase Staining. NPCs were plated onto laminin-coated coverglass at 
equal densities (2 million cells/35 mm well), and β-galactosidase staining was performed 
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according to the manufacturer’s instructions (Cell Signaling Technology, Danvers, MA; Supp. Fig. 
5.6). Images were captured at 10x using identical phase contrast settings (Olympus IX71, 
CellSens Software, Olympus). 
 
Immunoblots. Cells were lysed in RIPA buffer, and protein content determined by BCA, and 20 
μg of protein was separated by electrophoresis and transferred to nitrocellulose membranes. 
Membranes were blocked in tris-buffered saline (1% tween-20) (TBST) + 5% bovine serum 
albumin (BSA), incubated overnight with primary antibodies: phosoho-mTOR (Ser2448) (Cell 
Signaling Technology, Danvers, MA) and GAPDH (Cell Signaling), washed in TBST, and 
incubated with the appropriate HRP-conjugated secondary antibody for an hour. Proteins were 
visualized by chemiluminescence. 
 
Mass Spectrometry. Conditioned media from iPS-derived NPCs from either non-disease control, 
PPMS, or PPMS lines treated with rapamycin were collected and sent to the Mass Spectrometry 
and Proteomics Keck Laboratory at Yale University where LC-MS/MS analysis was performed 
was performed on a Thermo Scientific Q Exactive Plus with a Waters nanoAcquity UPLC system, 
using a Waters Symmetry® C18 180 µm x 20 mm trap column and an ACQUITY UPLC PST 
(BEH) C18 nanoACQUITY Column 1.7 µm, 75 µm x 250 mm (37ºC) for peptide separation. 
Trapping was done at 5 µl/min, 97% Buffer A (100% water, 0.1% formic acid) for 3 min. Peptide 
separation was performed at 330 nl/min with Buffer A: 100% water, 0.1% formic acid and Buffer 
B: 100% acetonitrile, 0.1% formic acid. A linear gradient (90 minutes) was run with 3% buffer B 
at initial conditions; 5% B at 1 minute; 35% B at 50 minutes; 50% B at 60 minutes; 90% B at 65-
70; and back to initial conditions at 71 minutes. MS was acquired in profile mode over the 300-
1,700 m/z range using 1 microscan; 70,000 resolution; AGC target of 3E6; and a full max ion time 
of 45 ms. MS/MS was acquired in centroid mode using 1 microscan; 17,500 resolution; AGC 
target of 1E5; full max IT of 100 ms; 1.7 m/z isolation window; normalized collision energy of 28; 
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and 200-2,000 m/z scan range. Up to 20 MS/MS were collected per MS scan on species with an 
intensity threshold of 2E4, charge states 2-6, peptide match preferred, and dynamic exclusion set 
to 20 seconds. Data was viewed using Scaffold Viewer (Proteome Software, Portland, Oregon). 
Analysis of protein lists was performed using the DAVID bioinformatics database [355, 356], and 
the percentage of proteins from the varying mediums associated with disease was analyzed using 
the Genetic Association Database disease class. Percentages shown in the pie graph are the 
percent proteins involved in that disease category over total proteins. 
 
RNA sequencing. OPCs were plated out and treated with NPC CM from control, PPMS, and 
PPMS + αHMGB1 CM as described above. After 48 hours the OPCs were collected in Trizol, and 
RNA was isolated as described previously [348]. RNA was given to Jackson Laboratories 
(Farmington, CT) where 1 μg of total RNA was processed using the TruSeq RNA Library 
Preparation Kit v2 (Illumina, RS-122-2001) according to the manufacturer’s instructions. The 
protocol starts from using oligo-dT attached magnetic beads to purify the poly-A containing mRNA 
molecules. The purified mRNA was fragmented and reversed to first stand cDNA. Then second 
strand cDNA was synthesized. After end repair and a single ‘A’ nucleotide was added to the 
3’ends, cDNA was ligated to its indexing adapter. Four cycles of PCR were used to enrich the 
adapter ligated DNA fragments. Following bead purification, libraries were quantified and equally 
pooled together. The pooled libraries were sequenced on the Illumina HiSeq 4000 platform using 
a 75 base paired-end protocol and sequenced to a depth of approximately 40M reads per library. 
The RNA-seq samples were processed using the in-house pipeline at The Jackson Laboratory. 
The reference for rat (version 6.0.91) was obtained from Ensemble. Alignment estimation of gene 
expression levels using the EM algorithm for single-ended and paired-end read data was 
performed using RSEM (package version 1.3.0); default settings were used for alignment. Data 
quality control was performed using Picard (version 1.95) and qualimap (version 2.2.1). Qualimap 
output was utilized to examine the alignment data and to detect potential biases in mapping data; 
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this was computed using two analyses types: 1) BAMQC; 2) RNA-seq QC within the tool. BAMQC 
provides basic alignment statistics (e.g. coverage, GC content). RNA-seq QC provided quality 
control metrics, bias estimations, transcript coverage and 5’-3’ bias computation. Analyses of 
aligned reads were performed using the edgeR (v3.30.7) and Biobase (2.38.0) packages in R 
(v3.4.3). Following normalization, read counts were filtered to include genes with counts per 
million (CPM) greater than one in at least two samples. The quantile-adjusted conditional 
maximum likelihood (qCML) method was used to determine differentially expressed genes 
between libraries as follows: 1) control and PPMS; 2) control and PPMS + αHMGB1; 3) PPMS 
and PPMS + αHMGB1. Genes with FDRs < 0.05 were sorted by gene ontology using Gene 
Ontology Consortium and PANTHER analysis to get varying clusters, including: myelin, oxidative 
stress, epigenetics, and senescence. All heatmaps were made in RStudio (V. 1.1.419) using 
packages “gplots” and “RColorBrewer” and organized by gene log fold change. 
 
Statistical Analysis. Data were analyzed by Student’s t-test or one-way ANOVA with Tukey’s 
multiple comparisons test, where appropriate and as indicated, using GraphPad Prism version 7 
for Mac OS X (GraphPad Software, La Jolla California USA, www.graphpad.com). Differences 
were considered significant when P < 0.05. Data are presented as mean ± SEM. 
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IV. Results 
Cellular Senescence is Present in NPCs of Progressive MS Brain Tissue and in iPS-derived 
NPCs from PPMS Patients.  
Age is recognized as an irreversible process that limits tissue regeneration and impairs CNS 
remyelination [206, 284]. We hypothesized that the process of cellular aging called cellular 
senescence may contribute to differences in support for myelination previously reported by NPCs 
derived from PPMS and non-disease control iPS cell lines [111]. Human autopsy brain tissue 
samples from confirmed progressive MS patients and age matched controls were immunostained 
for the NPC marker Sox2 along with p16Ink4a, a cyclin-dependent kinase inhibitor and an 
established marker of senescence [357]. Within the progressive MS brain we found there to be a 
significant increase in the number of Sox2+ NPCs in white matter lesions when compared with 
either normal appearing white matter (NAWM) or white matter of control brain samples (Table 
5.1; Fig. 5.1A, B). This increase in NPCs within demyelinated lesions was consistent with 
previously reported observations [118]. However, when co-labeled with p16ink4a, we identified that 
the majority of Sox2+ NPCs within the progressive MS brain expressed this senescence marker 
(Fig. 5.1A, C). These data indicated the presence of elevated cellular senescence in NPCs in the 
progressive MS brain. 
 To further characterize cellular senescence in PPMS NPCs, and to interrogate a functional 
role for this aging process in human NPCs, we differentiated NPCs from iPS cell lines of PPMS 
patients and age-matched control donors. We first determined whether the expression of the 
lysosomal enzyme β-galactosidase, also a marker of cellular senescence [358], was present in 
the iPS-derived NPCs (Supp. Fig. 5.6A). Elevated activity of senescence associated β-gal (SA-β 
gal) in PPMS NPCs was observed while little to no activity was detected in any NPCs from non-
disease control iPS cell lines (Fig. 5.1D, E, Supp. Fig. 5.6A demonstrates quantification 
methodology). We then examined by quantitative PCR (qPCR) the expression of p16Ink4a a well-
known tumor suppressor gene also known as a marker of cellular senescence [209, 359]. 
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Significantly higher mRNA expression of p16Ink4a was measured in PPMS NPCs when compared 
to control NPCs (Fig. 5.1F) [360]. Since cellular senescence is known to be associated with cell 
cycle arrest [212], we performed cell cycle analysis and examined the proportion of NPCs in 
G0/G1, G2/M, and S phase. We found no significant differences between control and PPMS 
NPCs in terms of cell cycle indicating that evidence of senescence in PPMS NPCs was not 
accountable to replicative senescence (Supp. Fig. 5.6B). Collectively, these independent markers 
of cellular senescence identified increased senescence in PPMS NPCs when compared to the 
age-matched control NPCs, even though the chronological age of the human donors in both 
groups did not differ (Table 5.2). We also considered whether these changes may relate to 
differentiation. To test this, we assayed p16ink4a expression in the undifferentiated iPS cell state 
for each iPS cell line. Interestingly, we found no differences in p16Ink4a mRNA expression among 
the different cell lines (Supp. Fig. 5.7), suggesting that these early passage iPS cell lines adopted 
a cellular senescent phenotype only when differentiated. 
 
Reversal of Cellular Senescence in NPCs Promotes OPC Maturation.  
The identification of cellular senescence in PPMS NPCs led us to hypothesize that this intrinsic 
process may underlie the failure of PPMS NPCs to support OPC maturation we had previously 
reported [111]. Given that a senescent phenotype also contributes to a secretory phenotype, we 
selected to affect cellular senescence in PPMS NPCs using rapamycin, which would also block 
the senescence-associated secretory phenotype, or SASP. We first confirmed that treatment of 
PPMS NPCs with rapamycin (12.5 nM, 48 h) resulted in decreased mTOR phosphorylation in 
PPMS NPCs, as determined by Western blotting (Fig 5.2A, B). We then assayed expression of 
senescent markers. This brief rapamycin treatment of PPMS NPCs decreased p16Ink4a mRNA and 
protein expression assayed by qPCR and immunocytochemistry, respectively (Fig. 5.2C, D). SA-
β gal staining also decreased in intensity to that observed in non-diseased control NPC following 
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rapamycin treatment (Fig. 5.2E). These findings demonstrated that rapamycin effectively reduced 
expression of key cellular senescence markers p16ink4a and SA-β gal, in PPMS NPCs. 
 We next determined whether rapamycin affected the potential for PPMS NPCs to support 
OPC differentiation. To test this, we collected conditioned media (CM) from PPMS NPC cultures 
that had either been treated with rapamycin or vehicle, and these media were separately applied 
to oligodendrocyte progenitor cell cultures (OPCs). Consistent with our previous work [111], we 
found that CM from PPMS NPCs did not promote the differentiation of OPCs, when compared to 
control NPC CM, and did not alter OPC numbers (Fig. 5.2F, G, H). In contrast, OPCs grown in 
CM from rapamycin-treated PPMS NPCs were found to differentiate into MBP+ oligodendrocyte 
at a rate comparable to OPCs grown under control NPC CM conditions (Fig. 5.2 H). Treatment of 
the control NPCs with rapamycin did not negatively affect their ability to promote OL maturation 
via CM (Fig. 5.2G, H). This effect of rapamycin on human NPCs contrasts with previous studies 
examining the direct effects of mTOR signaling on OPCs [361, 362], indicating that rapamycin 
was not transferred to the OPCs in the CM. However, to verify that this was the case, we also 
tested whether carry over of rapamycin could have independently promoted OPC differentiation 
in OPCs grown in PPMS CM. OPCs were treated directly with the same concentration of 
rapamycin used to treat the NPCs (12.5 nM) and we found no increase in differentiation (Supp. 
Fig. 5.8). This was consistent with previous work that had shown direct treatment of OPCs with 
rapamycin may actually inhibit OPC differentiation [363]. Hence, reversing senescence in PPMS 
NPCs using rapamycin was found to provide not only a change in senescence marker expression 
but also result in a significant improvement in PPMS NPC function reflected by enhanced OPC 
differentiation. Importantly, treatment of OPCs under any of these media conditions tested did not 
result in differences in cell death, as the number of Olig2+ cells did not differ among any of the 
experimental treatment conditions (Fig. 5.2H). 
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Proteomic Analysis of Neural Progenitor Cell Secretome Identified HMGB1 as a Potent 
Inhibitor of OL Differentiation.  
To identify what factor(s) in the NPC conditioned media were responsible for impaired OPC 
differentiation, we performed mass spectrometry (LC-MS/MS) on the CM from control NPCs, 
PPMS NPCs, and also rapamycin-treated PPMS NPCs to identify and compare peptides from 
each of these conditions (Fig. 5.3A). For this analysis we exploited the heterogeneity of the human 
donors to provide higher stringency to the comparisons where only factors found in all samples in 
a treatment group were considered valid targets. From these proteomic analyses we identified 
several factors uniquely expressed by PPMS NPCs. Many of these peptides represented secreted 
proteins previously known to be associated with cellular senescence, including heat shock 
proteins 90 and 60, DJ-1, and HMGB1 (high mobility group box 1) (Fig. 5.3A). Importantly, these 
factors were not found to be produced by either the control NPCs or when PPMS NPCs had been 
treated with rapamycin (Fig. 5.3A). Ontology analysis of the identified peptides using the DAVID 
bioinformatics database revealed that 14.5% of proteins secreted by PPMS NPCs were 
associated with “aging”. This “aging” profile was reduced to only 4.8% of peptides identified from 
PPMS NPC that had been treated with rapamycin, which represents a decrease of 67%. No aging 
ontology was identified from the secretome of control NPCs (Fig. 5.3B). These findings lend 
further support to cellular senescence as a feature of NPCs in PPMS and rapamycin as a 
pharmacological means to affect the SASP of NPCs. 
 Of the candidate proteins secreted by PPMS NPCs, we focused our attention on HMGB1 
for several reasons: it is produced at higher levels in demyelinated lesions in MS brain tissues 
[237, 364], produced at higher levels by senescent cells [364], and has been implicated as a 
mediator of neuroinflammation [365]. We evaluated HMGB1 gene expression and found 
significantly increased mRNA expression in PPMS NPCs which was also down-regulated by 
rapamycin treatment (Fig. 5.3C). To address the contribution of extracellular HMGB1 to impaired 
OPC differentiation, we repeated the OPC differentiation experiment using CM from PPMS NPCs 
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but added a well characterized function blocking antibody to inhibit HMGB1 (αHMGB1) (Fig. 
5.3D). Maturation of OLs in the αHMGB1-treated PPMS CM was significantly higher when 
compared to OPCs grown in CM with serotype-matched IgG antisera (control) (Fig. 5.3E). 
Blocking HMGB1 was not found to affect either Olig2+ cell proliferation or cell death (Fig. 5.3F). 
To test whether extracellular HMGB1 was acting directly as an inhibitor of OPC differentiation we 
applied recombinant human (rh)HMGB1 to cultures of differentiating OPCs and measured the 
proportion of OL maturation (Fig. 5.3G). Extracellular rhHMGB1 had a concentration-dependent 
effect on reducing OPC differentiation in vitro (Fig. 5.3H). Lastly, we determined whether NPCs 
could be a source of HMGB1 within demyelinated lesions in human MS brain tissues. 
Immunohistochemistry identified a significantly increased proportion of Sox2+/HMGB1+ NPCs in 
demyelinated white matter lesions when compared with NAWM (Fig. 5.3I, J). These data provide 
the first direct evidence that extracellular HMGB1 produced by senescent NPCs can act to directly 
suppress OPC maturation. 
 
HMGB1 Mediates Senescence-related Transcriptomic Changes in OPCs  
To better understand how cellular senescence of NPCs and their production of extracellular 
HMGB1 affects the potential for OPCs to mature into MBP+ OLs with myelinating potential, we 
performed transcriptomic analyses of OPCs. Specifically, collected cultures of primary OPCs that 
had been grown in CM from either PPMS NPCs, non-disease control NPCs or CM from PPMS 
NPCs that had been treated with αHMGB1 antisera. OPCs were grown for 48 hours and then 
collected for RNA sequencing analyses (i.e. RNAseq, Fig. 5.4A). Genes were filtered for a false 
discovery rate of <0.05. Substantial transcriptome changes were seen in the OPCs treated with 
either control CM, PPMS CM, or PPMS + αHMGB1 (Fig. 5.4B, C, D). Out of all genes filtered, 
Cd99l2 and Wdr54 were found to be some of the most upregulated genes in the OPCs treated 
with PPMS CM compared to the OPCs treated with control CM (Fig. 5.4B). Cd99l2 has been 
found to allow for the entrance of leukocytes into the CNS in the experimental autoimmune 
	 104 
encephalomyelitis (EAE) mouse model of MS, and when knocked out leukocyte entry is inhibited 
and disease ameliorated [366]. Treatment of the PPMS CM with αHMGB1 did not decrease 
Wdr54 and Cd99l2 to levels found in OPCs treated with control CM (Fig. 5.4C). Treatment of the 
OPCs with PPMS + αHMGB1 CM did increase expression of Map2k3 (Fig. 5.4B), which was 
found to be significantly decreased in OPCs treated with PPMS CM (Fig. 5.4D). Map2k3, a dual 
specificity kinase, has been found to be associated with a resolution in inflammation [367]. Our 
data therefore implicate HMGB1 in perpetuating inflammation in OPCs. 
 Our first step in curating these data was to identify differentially expressed genes (DEGs), 
which defined several notable ontological differences between the treatment groups. Senescent 
cells also are known to induce senescence through the secretion of the SASP as a paracrine 
effect, so we examined markers of senescence in the OPCs. Overall, we found an increase in 
senescence-associated genes, such as Mmp2, p16Ink4a (Cdkn2a), and Igfbp2 when OPCs were 
treated with PPMS CM, which was reduced close to normal in PPMS CM containing HMGB1 
blocking antibody (Fig. 5.4E). We also investigated expression of epigenetic modifiers since 
epigenetics plays a pivotal role in determining the potential for OPC differentiation [138]. We found 
that PPMS CM significantly induced expression of numerous epigenetic regulators in OPCs (Fig. 
5.4F). Interestingly, when HMGB1 was functionally blocked from the PPMS NPC CM most of 
these changes in epigenetic-associated genes were normalized to levels observed in control NPC 
CM (Fig. 5.4F). These RNA sequencing data indicate that the expression and production of 
HMGB1 by NPCs plays an important role influencing the potential for OPCs to mature by 
modulating gene expression. Moreover, these differences in senescence-associated and 
epigenetic modifier genes in OPCs demonstrate that it is likely locally produced factors from NPCs 
within demyelinated lesions that contribute to the microenvironment that determine OPC fate. 
These observations provide a novel and compelling link between the presence of senescent 
NPCs in demyelinated lesions in progressive MS and ascribe a deleterious role for cellular 
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senescence in NPCs which we have functionally characterized using iPS cells from PPMS 
patients. 
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V. Discussion and Conclusions 
 
Our data provide a new perspective on the pathophysiology of demyelinating lesions in 
MS. We have identified cellular senescence in Sox2+ NPCs which influence, through paracrine 
activity, the maturation of OPCs with myelinating potential. We determined that cellular 
senescence is potentially reversible, or amenable to therapeutic intervention, using rapamycin as 
a prototypic compound. We also determined that senescent NPCs secrete extracellular HMGB1 
which leads to altered gene expression and impaired maturation of OPCs (Fig. 5.5). Age is 
recognized as a process that limits the myelinating potential of the CNS [284]. Although MS is not 
typically considered a disease of aging, because it is generally diagnosed in early-to-mid 
adulthood, the functional impact of cellular senescence in NPCs we report here may indicate that 
advanced cellular aging is an important component of this disease, particularly in the progressive 
phase. 
 Neural progenitor cells are of particular interest because they have been found within 
demyelinated lesions, along with astrocytes and microglia [23, 81, 317]. As our data support, 
NPCs are found in greater numbers within the lesion area, when compared to NAWM and control 
white matter, where they contribute to regulation of OPC maturation and myelin regeneration [318, 
319]. Data would suggest that NPCs are active participants in the lesion environment and could 
secrete regenerative, anti-inflammatory, and promyelinating factors [146, 149, 319]. However, our 
data would suggest that in progressive MS, endogenous NPCs are or become senescent and 
their participation in the lesion is pro-inflammatory and actively suppresses OPC maturation 
through the secretion of factors (the SASP), HMGB1 in particular. These findings contribute to 
our understanding of the lesion microenvironment and may explain why immature OPCs within 
lesions fail to remyelinate in progressive MS.  
 Our data demonstrate that NPCs from patients with PPMS display key hallmarks of 
senescence, including SA-β gal staining and increased p16Ink4a. p16Ink4a is a cyclin dependent 
kinase inhibitor that has become a hallmark for identifying senescent cells [228]. p16Ink4a acts 
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through the retinoblastoma pathway, which inhibits the action of cyclin dependent kinases [368]. 
Up-regulation of p16Ink4a results in chromatin reorganization, which leads to changes in genes 
related to inflammation and oxidative damage, including COX1 and COX2 enzymes, as well as 
other inflammatory mediators [368, 369].  We have shown that rapamycin effectively reduced the 
expression of p16Ink4a in PPMS NPCs and this was reflected in a functional change in the NPC 
secretome by enhanced OPC maturation. Recent studies using mice have demonstrated that 
targeted ablation of p16Ink4a positive cells can be used as a strategy to study cellular senescence. 
Induced deletion of p16Ink4a from senescent cells has been shown to extend lifespan and reverse 
age-related functional decline in organs such as kidneys and pancreas [227, 228]. Similarly, 
targeting of cellular senescence by deletion of p16Ink4a positive cells has also been found to 
mitigate accelerated aging in diseases such as progeria, and more recently in glia in a model of 
AD; demonstrating p16Ink4a has a central role in the functional effects of cellular senescence [224, 
227-232]. Interestingly, the methylation pattern of p16Ink4a has been proposed to be an epigenetic 
risk factor in the development of MS [320]. Our study is the first to implicate cellular senescence 
as a feature of NPCs in MS. As current mouse models of induced demyelination do not reflect the 
unique aging characteristics of the human disease, the utility of these models to explore the 
effects of cellular senescence on demyelination is limited. This emphasizes the utility of the 
approach we have taken here – the use of patient iPS cells and study of human autopsy tissues 
- to address the question of cellular aging and demyelination. 
 Whether NPCs in PPMS acquire senescence because of the disease, or are somehow 
predisposed to developing senescence which promotes the disease is presently unclear. It has 
been shown that the DNA damage response (DDR) is strongly linked to senescence in other cell 
types where mitochondrial dysfunction has also been implicated [237]. Cells with damaged 
mitochondria more easily acquire a senescent phenotype and secrete factors such as CCL27, 
TNF-α, and HMGB1 [237]. We found HMGB1 only in CM from PPMS cells, and after treatment 
with rapamycin HMGB1 secretion was abrogated. Extracellular HMGB1 acts as a cytokine and 
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generates inflammatory responses such as the production of additional cytokines and 
chemokines, continuing the cycle of chronic inflammation [365]. Interestingly, extracellular 
HMGB1 has also been found to act as a chemokine specifically for neural progenitor cells, which 
may further facilitate the senescent microenvironment in the lesion area [370]. HMGB1 can also 
be secreted by activated astrocytes and microglia in lesion areas, this has been proposed to help 
recruit NPCs to facilitate repair [371]. However, as our data indicate, if NPCs become senescent 
and begin secreting HMGB1, this impairs OPC differentiation, and thus is deleterious. Our findings 
demonstrate HMGB1 as a potent suppressor of oligodendrocyte differentiation. We found a 
significant increase in NPCs expressing HMGB1 in lesions from progressive MS autopsy tissue. 
A report has also found increased HMGB1 in MS lesions associated with an elevated expression 
of HMGB1-binding receptors [372], making it a potential target for progressive MS treatment. 
 Senescence is not only induced from aging (termed replicative senescence), where cells 
wear out their capability of replicating, but also from constant inundation of inflammation, which 
leads to stress-induced senescence [237, 373-375]. The majority of senescent cells release a 
heterogeneous secretory profile, SASP, that consists of pro-inflammatory cytokines that can 
disrupt tissue microenvironments and molecules that have paracrine effects on surrounding cells 
[212, 213, 237, 376]. Changes in senescent gene expression depend on the cell type, which 
makes the SASP unique to the specific cell of interest [213]. In performing RNA sequencing on 
the rat OPCs treated with PPMS CM we found an induction of senescence genes. When cross-
referencing upregulated genes found in OPCs treated with PPMS CM with those in genome-wide 
association studies (GWAS) performed on patients with MS we identified VCAM1, STAT3, and 
MYB(AHI1) [377]. Interestingly, these genes found in MS GWAS studies have also been found to 
be implicated in senescence [378-380]. Senescent stem cells have been shown to secrete IL-6 
which maintains neighboring stem cells in a pluripotent state [245, 381]. Therefore, senescent 
PPMS NPCs may be affecting other stem cells in the lesion microenvironment by preventing 
differentiation through the secretion of the SASP. This concept has been termed the “senescence-
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stem lock model” [211]. This model demonstrates how senescent cells reduce tissue regeneration 
and promote aging. 
 Persistent DNA damage to cells, which has been reported in human MS lesion tissue 
[288], triggers senescence, and with that, the secretion of the SASP [321]. Consistent 
inflammation leads to general epigenetic modifications that can leave cells hypersensitive to DNA 
damage, and in turn, senescent [321, 322]. The chronic demyelination seen in progressive MS 
patients triggers the brain microenvironment, and the blood, to show persistent signs of oxidative 
stress and inflammation [288, 323]. This continuous inflammation induces epigenetic changes 
reflected in the patient NPCs making them more susceptible to DNA damage, and therefore 
senescent. We found that when HMGB1 was blocked in PPMS CM the effect of the SASP on the 
OPCs was greatly diminished, and this effect was reflected in changes in the OPC transcriptome. 
In particular, we identified unique gene expression profiles in OPCs when exposed to CMs from 
senescent (PPMS) NPCs. For example, we observed a significant up-regulation of both 
senescence and epigenetic-associated genes in OPCs treated with the PPMS CM. Importantly, 
we identified extracellular HMGB1 as a mediator of these transcriptional changes associated with 
impaired or reduced OPC differentiation. Our data demonstrated that HMGB1 had a significant 
impact on the expression of key epigenetic regulators in OPCs, such as helicase [382, 383], and 
the histones: H2afz, H2afv, and H2afx [384]. Previous research has targeted HMGB1 as a 
modifier of gene promoters and repressors involved in pro-inflammation [385]. Overall epigenetic 
modification of OPCs has been identified as a critical determinant in promoting differentiation and 
eventual remyelination in mouse models [125, 386, 387]. 
 The cause of progressive MS is not known. Based on these data we hypothesize that 
cellular senescence in NPCs secrete factors which impair the regenerative potential of the lesion 
microenvironment. Current treatments for MS suppress inflammation and block access of immune 
cells into the CNS, yet this does not fully prevent demyelination and axonal degeneration [388]. 
Additionally, current disease modifying therapies for MS do not benefit patients with progressive 
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MS [328]. Therefore, targeting and stimulating OPC differentiation has important therapeutic 
potential, but candidate remyelinating therapies do not take into account the lesion environment. 
The efficacy of these candidate drugs relies on the differentiation of resident OPCs within the 
lesioned microenvironment yet if senescent NPCs are not also addressed then therapeutic 
efficacy may be reduced. Rapamycin is a known immunosuppressant and is currently used to 
prevent organ transplant rejection, but it has never been investigated in treating PPMS. 
Interestingly, rapamycin had been tested in clinical trials (NCT00095329, NCT00228397) for 
patients with relapse-remitting MS, but progressive MS patients were not included and thus the 
potential of its anti-senescence impact on PPMS patients remain untested. At present, it is unclear 
whether cellular senescence is present in other types of MS, such as RRMS, but future study 
would be expected to extend our findings herein and address salient questions regarding whether 
cellular senescence is found in all forms or MS or perhaps only in progressive forms of MS, and 
whether predisposition to developing cellular senescence is a risk factor for developing this 
disease.  
 In summary, our identification of cellular senescence within the MS brain provides a 
mechanism by which aberrant cellular aging silently subverts natural aging by impairing OPCs 
and promoting chronic demyelination. Targeting cellular senescence in NPCs, as a means by 
which to unlock the differentiation potential of endogenous OPCs, may represent a novel 
therapeutic approach to promote remyelination in MS. 
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VII. Figures 
 
Figure 5.1 
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Figure 5.1. Senescent markers identify neural progenitor cells within demyelinated lesion 
of human progressive MS brain tissue and in NPCs derived from PPMS patients. (A) Human 
brain tissue from the frontal lobe, subcortical white matter was stained for Sox2 (NPC marker) 
and p16Ink4a (senescence marker) in control and progressive MS patients neurospecimens. 
Representative image from control is (60 y.o. female), and representative images from MS NAWM 
and MS lesion (69 y.o. female; SPMS disease duration of 40 years). MS lesion is from a female, 
46 year old patient with SPMS and a disease duration of 25 years. Arrows point to cells double 
positive for Sox2 and p16Ink4a. (Scale bar, 20 μm.) (B) Increase in total number of Sox2 positive 
cells in MS lesion compared to control and MS NAWM area. Individual points are individual 
patients and matching colors between MS NAWM and MS lesion samples represent the same 
patient (*, P < 0.05, ** P < 0.01, ANOVA, Tukey’s). (C) Percent of Sox2+ NPCs co-labeling with 
p16Ink4a in both MS NAWM and MS lesion areas in same patients identified by color coding (P = 
0.1644, two-tailed t test). (D) Senescence-associated β galactosidase (SA-β gal) staining in 
control NPC and PPMS NPC cultures revealed LacZ activity in PPMS NPC cultures. Figures show 
representative lines 3.1 and 3. (Scale bar, 400 µm.) (E) Quantification of SA-β gal staining in 
control and PPMS NPCs show an increase in LacZ in PPMS cultures (**, P < 0.01, t test). (F, G) 
p16Ink4a and p53 mRNA expression by qPCR in control NPC and PPMS NPC cultures revealed a 
significant increase in p16Ink4a and p53 mRNA levels in PPMS NPCs (***, P < 0.001, **, P<0.0022, 
unpaired t tests). All qPCR data normalized to control NPC lines. Each data point represents 
individual sample from varying lines and clones. 
 
  
	 114 
 
Figure 5.2 
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Figure 5.2. Cellular senescence phenotype in PPMS NPCs is reversed by treatment with 
rapamycin. (A) Western blot of protein lysates from control NPCs, PPMS NPCs, and PPMS 
NPCs treated with rapamycin for 48 hours probed for phospho-mTOR (Ser2481), mTOR, and 
GAPDH. (B) Densitometry of pmTOR over mTOR shows a significant decrease in pmTOR after 
rapamycin treatment (*, P < 0.05, t test). (C) p16Ink4a and Sox2 staining in control, PPMS, and 
PPMS NPCs treated with rapamycin shows a decrease in p16Ink4a protein expression in the PPMS 
NPCs. Figure shows representative lines 1 and 1.1. (Scale bar, 50 µm.) (D) Decrease in PPMS 
NPC p16Ink4a mRNA expression after treatment with rapamycin for 48 hours (PPMS vs. PPMS + 
Rapa [****, P < 0.0001], control vs. PPMS [***, P < 0.001]; control vs. PPMS + Rapa [P = 0.6418], 
ANOVA, Tukey’s). (E) Quantification of SA-β gal staining in control NPC, PPMS NPC, and 
rapamycin-treated PPMS NPCs (PPMS vs. PPMS + Rapa [**, P < 0.01], control vs. PPMS [**, P 
< 0.01], control vs. PPMS + Rapa [P = 0.7483], ANOVA, Tukey’s). All qPCR data normalized to 
control NPC lines. Each data point represents individual sample from varying lines and clones. 
(F) Quantitative analysis of oligodendrocyte maturation (MBP+/Olig2+) resulting from culture of 
OPCs in various CM conditions, as indicated, after 48 hrs of treatment. Conditioned media 
conditions were control NPC CM, control NPC + rapamycin CM, PPMS NPC CM, and PPMS + 
rapamycin CM. All conditions were quantified relative to differentiation under N2/B27 
(standardized control) unconditioned media as set to 100%. (Cntl CM vs. PPMS CM [*, P < 0.05], 
Cntl CM vs. PPMS + rapa CM [P = 0.9974], ANOVA, Tukey’s). (G) Quantification of total Olig2+ 
cells under each treatment condition showing equivalent densities of cells under all conditions 
indicating that differences in differentiation were not a result of cellular proliferation or cell death. 
Each data point represents individual sample from varying lines and clones. Values are means ± 
SEM. 
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Figure 5.3  
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Figure 5.3. Proteomic analysis of the NPC secretome and characterization of HMGB1 as a 
directly acting inhibitor of OPC differentiation. (A) Venn diagram of comparison strategy for 
proteomic data analysis from control CM, PPMS CM, and PPMS + rapa treatment CM. Peptides 
identified by LC MS/MS from each treatment group. Protein threshold was set at 95% confidence 
of identification. (B) Functional classification of secreted peptides from PPMS NPCs and non-
disease control NPCs as determined by the DAVID bioinformatics database 
(https://david.ncifcrf.gov/). Pie graphs depicting the proportions of peptides identified associated 
with disease classifications as determined by Genetic Association Database disease class. (C) 
Increased HMGB1 mRNA expression in PPMS NPCs was decreased with rapamycin treatment 
(Cntl vs. PPMS [**, P < 0.01], Cntl vs. PPMS + rapa [P = 0.4182], ANOVA, Tukey’s). (D) Human 
tissue staining for Sox2 and HMGB1 in control and progressive MS patients in the frontal lobe, 
subcortical white matter. Representative image for control is from an 82 year old male who died 
from myelodysplastic syndrome and rheumatoid arthritis, and representative images for MS 
NAWM and MS lesion is from a female, 69 year old patient with SPMS and a disease duration of 
40 years. Arrows point to cells double positive for Sox2 and HMGB1. (Scale bars, 20 μm.) (E) 
Increase in percent of Sox2 positive cells expressing HMGB1 in MS lesion compared to MS 
NAWM. Individual points are individual patients, and matching colors between MS NAWM and 
MS lesion samples represent the same patient (** P < 0.01, two-tailed t test). Values are means 
± SEM. (F) Experimental design to test whether functional blocking antisera against HMGB1 (1 
μg/mL) in PPMS CM (or IgG control; 1 μg/mL) affected OPC maturation (rOPCs, rat OPCs). (G) 
Quantification of OL maturation in experiment “E”. All conditions relative to Cntl + IgG, set to 100% 
(PPMS + IgG vs. PPMS + αHMGB1 [****, P < 0.0001], ANOVA, Tukey’s). (H) No significant 
differences in Olig2+ cells were observed from the varying treatments on the OPCs. (I) 
Experimental design to test whether recombinant human (rh)HMGB1 affected OPC maturation 
(rOPCs, rat OPCs). (J) Treatment of OPCs with increasing doses of rhHMGB1 (ng/mL) decreases 
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OL differentiation after 48 hours in the presence of differentiation media. All conditions relative to 
PBS, set to 100% (PBS vs. 5000 ng/mL rhHMGB1 [* P, < 0.05], ANOVA, Tukey’s).  
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Figure 5.4 
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Figure 5.4. Transcriptomic analysis of OPCs treated with human NPC conditioned media 
(CM) identifies marked differences in expression of cellular senescence genes (E) and 
epigenetic regulators (F) regulated by HMGB1. (A) OPC RNA was collected after 48 hours of 
treatment with control CM, PPMS CM, or PPMS + αHMGB1 CM, and RNAseq was performed. 
Image generated using BioRender. (B, C, D) Volcano plots of gene expression changes in the 
OPC transcriptome after treatment with control CM, PPMS CM, or PPMS + αHMGB1 CM. The x-
axis specifies the log of the fold changes (FC) and the y-axis specifics the negative logarithm to 
the base 10 of the p-vales. Vertical lines reflect a FC of ±2 and the horizontal line reflects a P 
value of 0.05. (B) reflects gene expression changes in control vs. PPMS CM treated OPCs, (C) 
reflects gene expression changes in control vs. PPMS + αHMGB1 CM treated OPCs, and (D) 
reflects gene expression changes in PPMS vs. PPMS αHMGB1 CM treated OPCs. (E) Heatmap 
of expression differences in senescence-associated genes in OPCs after treatment with CM. (F) 
Heatmap of expression differences in epigenetic-associated genes in OPCs after treatment with 
CM. Three individual control and PPMS lines were selected and are demonstrated individually in 
the heatmaps. RNA was aligned to the latest version of the rat genome (version 6.0.91). Heatmap 
for each class of genes, as indicated. Genes with FDRs < 0.05 were sorted by gene ontology 
using Gene Ontology Consortium and PANTHER analysis to get the varying clusters. 
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Figure 5.5 
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Figure 5.5 Schematic diagram outlining hypothesized impact of senescent NPCs on 
remyelinating potential in the MS brain. The recruitment and presence of senescent NPCs in 
demyelinated white matter lesions exert a negative impact on the differentiation of OPCs, also 
within the demyelinated lesion, by modifying the transcriptional activity of OPCs via secretion of 
factors in the SASP such as HMGB1. Collectively, this model suggests that cellular senescence 
in NPCs, either acquired as a result of disease or as a predisposing feature of individuals that 
develop MS, contributes to the limited potential of OPCs to foster remyelination in the MS brain. 
Image generated using BioRender. 
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Table 5.1. Patient information for histology data.   
Table 1. Patient information for histology data.

MS 
Patient
Sex Age Disease Disease 
Duration 
(Years)
Post 
Mortem 
Delay 
(Hours)
Graph 
Color
MS 100 M 46 SPMS 8 7 Gray
MS 121 F 49 SPMS 14 24 Black
MS 207 F 46 SPMS 25 10 Pink
MS 640 F 69 SPMS 40 26 Red
MS 641 F 69 PPMS 19 24 Green
Control 
Patient
Sex Age Cause of Death Post 
Mortem 
Delay 
(Hours)
SD21/17 M 67 Ischaemic heart disease 68
SD22/16 M 39 Ischaemic heart 
disease, coronary artery 
atherosclerosis
86
CO25 M 35 Carcinoma of the 
tongue
22
CO28 F 60 Ovarian cancer 13
CO39 M 82 Myelodysplastic 
syndrome, rheumatoid 
arthritis
21
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Table 5.2. Induced pluripotent stem cell lines from PPMS patients and controls.  
Table 2. Induced pluripotent stem cel lines from PPMS patients and controls.

Line Sex Age Disease Relationship 
(if known)
Cell Line 
Source
Cell 
Origin
1 M 61 PPMS Crocker blood
2 F 62 PPMS Crocker blood
3 F 45 PPMS Crocker blood
104 F 62 PPMS Fossati fibroblast
Average Age 57
1.1 F 59 Spouse Crocker blood
2.1 F 66 Sibling Crocker blood
3.1 M 47 Spouse Crocker blood
130 M 52 Fossati fibroblast
598 M 53 Fossati fibroblast
Average Age 55
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VIII. Supplement 
 
Cell Cycle Analysis. Neural progenitor cells were plated at 750,000 cells per line and then 
collected and resuspended in PBS 24 hours later. The cells were then incubated in 70% ethanol 
for 30 minutes at 4°C to fix and permeabilize. The cells were then spun down and washed with 
PBS. After pelleting the cells they were resuspended in the DAPI stain solution (1 μg/mL DAPI in 
PBS) and analyzed on an LSR II with the flow rate on slow, and at least 20,000 events were 
collected. Using FlowJo software the data was analyzed using the Watson (pragmatic) approach 
to fit Gaussian curves to G1 and G2/M phases and the percent of cells in each phase was 
calculated. 
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Supplemental Figure 5.6 Method for quantification of senescence associated β-
galactosidase (SA-β gal) staining and cell cycle analysis of NPCs. (A) Phase contrast 
representative images of control and PPMS NPCs with SA-β gal staining. Yellow shading 
highlights cell bodies and asterisks indicate cells positive for the blue color indicative of SA-β gal 
staining. (B) Representative plots of DAPI cell cycle analysis and graphs of percent of NPCs 
positive for the G0/G1, G2/M, and S phase. Data demonstrates 4 control NPC lines and 3 PPMS 
NPC lines. All values are means ± SEM.  
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Supplemental Figure 5.7. No significant change in p16Ink4a mRNA expression between 
control and PPMS iPSC lines. All qPCR data normalized to control iPSC lines. Values are 
means ± SEM. n = 3 iPSC lines / disease condition. Student’s t test, P = 0.6850.  
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Supplemental Figure 5.8. Directly added rapamycin does not increase OPC differentiation. 
Quantitative analysis of mature OLs after direct treatment with media plus rapamycin (12.5 nM) 
after 48 hours. Direct treatment of rapamycin to OPCs inhibits OL differentiation (****, P < 0.0001). 
Values are means ± SEM. 
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Chapter 6: Discussion and Future Directions 
 Since the discovery that induced pluripotent stem cells can be derived from somatic cells 
they have been used to model a wide range of diseases enabling study of disease-specific 
processes in a culture dish, testing of new therapeutics, and even have the potential to be used 
for cell replacement strategies in the future. In my thesis I characterized and analyzed neural 
progenitor cells derived from iPSCs of patients with primary progressive multiple sclerosis and 
age-matched controls. My data have demonstrated that NPCs from patients with PPMS display 
a premature senescent phenotype which impairs their ability to support endogenous 
remyelination, both in vitro and in vivo, which was found to be reversed by treatment with 
rapamycin. My thesis work can be broadly applied to a variety of CNS disorders where age and 
neurodegeneration is involved, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). 
 
I. Genetic Caveats of Modeling Multiple Sclerosis with iPSCs 
 Classically, iPSCs have been used to model diseases of monogenic origins such as 
Huntington’s disease, caused by the genetic defect of CAG expansion in the huntingtin gene, and 
familial amyotrophic lateral sclerosis (ALS), with mutations in SOD1 [389]. iPSCs from these 
patients retain their somatic genetic traits and are more likely to display cell-autonomous cell 
defects using stem cell-based modeling [389]. More recently, the use of mutation-defined iPSCs 
have been used to generate models of neurodegeneration for AD. For example, studies have 
generated iPSC lines with familial mutations in APP and PSEN-1, known to be involved in AD, 
not a monogenic disease [198]. Using this type of disease modeling in iPSCs has helped develop 
drug screening methodologies which can help determine how certain patients will react to various 
treatments [198]. 
 On the other hand, iPSCs have been recently used to understand non-familial, or sporadic 
forms, of diseases including sporadic AD and ALS which do not have a defined, specific genetic 
mutation. Neurons differentiated from iPSCs generated from patients with genetic, familial AD 
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and those with sporadic AD exhibited higher levels of amyloid-β and phospho-tau compared to 
non-diseased cells [390]. In another example, astrocytes derived from patients with sporadic ALS 
were found to be as toxic as those derived from patients with familial, causative mutations [391]. 
Both these studies have important implications for diseases such as MS, where there is no single 
mutation known to cause disease. Thus, the potential to model human diseases using the 
approach of patient iPSCs may help uncover pathological phenotypes that may not have as of 
yet been identified in patients. Moreover, these data clearly demonstrate that iPSC technologies 
are not limited to monogenic diseases and have widespread utility for studying complex diseases 
under defined conditions. 
 MS does not have defined somatic mutations, and is instead a complex disorder that has 
been associated with susceptibility genes linked to immunity and environmental factors. 
Significantly, the current disease modifying therapeutics only work to target the immune 
component in the disease, which become ineffective once the patient has reached the progressive 
phase of the disease, or if the patient has always had PPMS. iPSCs have allowed for the modeling 
of hard to reach cells in the CNS which hold potential for lesion regeneration. Therefore in using 
patient-specific iPSCs one can model the cells involved in the lesion to understand where 
regeneration can be targeted. In my thesis I interrogated NPCs derived from iPSCs of patients 
with PPMS as well as age-matched controls to determine if there were differences in their support 
of remyelination. I found that NPCs derived from PPMS patients failed to support oligodendrocyte 
maturation and failed to provide remyelination support in vivo due to a premature aging 
phenotype. Even though PPMS has no specific identified culprit gene and no single genetic 
mutations are linked to risk for this condition there are clear, reproducible inherent defects in 
NPCs derived from these patients. Since MS is a disease that involves the interplay between 
environmental factors and individual genetic susceptibility, epigenetic changes likely underlie the 
phenotype I have defined using iPSC PPMS NPCs.  
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 The reprogramming process of somatic cells has been suggested to reset genomic 
methylation and epigenetic modifications. However, it is becoming increasingly clear from reports 
in the literature that this is not always the case. For example, fibroblasts which have been 
reprogrammed into iPSCs have been found to differentiate more readily back into fibroblasts [194, 
196]. In addition, analysis of DNA methylation in patient-specific iPSC lines has found that 
epigenetic modifications remained unchanged during the reprogramming process [197]. Patient-
derived iPSCs retain epigenetic modifications from the original donor which may explain why the 
NPCs from PPMS patients demonstrate significant defects. Using iPSCs from patients 
incorporates environmental risk factors, vitamin D deficiency, smoking, and exposure to the 
Epstein-Barr virus which have been found to exert epigenetic changes and be involved in the 
pathogenesis of MS [392]. Hence, accumulating data about reprogramming, including my own, 
have demonstrated a clear functional distinction between disease and control iPS cells, and 
support the growing awareness that iPSC reprogramming does not wipe clean the epigenome. 
Another way to study various cell types from patients with MS, that could be used to extend 
my findings, is using the new method of direct reprogramming. It is now possible to take patient 
fibroblasts and directly reprogram them to the cell type of interest. Currently, direct reprogramming 
can generate neurons, astrocytes, and NPCs [149, 391, 393, 394]. Direct reprogramming avoids 
the expensive and laborious process of making iPSCs and has been shown to retain a more direct 
epigenetic profile of the patient [393]. Using this method may help further parse out epigenetic 
changes in NPCs from patients with PPMS. Future studies expanding on the epigenetics of NPCs 
derived from PPMS patients are further warranted to understand the role it may play in the 
development of defective NPCs. 
 
II. Neural Progenitor Cells and Senescence 
 The processes of natural aging may be an underlying risk factor for progression in MS, 
and the cause of failed remyelination. This hypothesis is supported by aging as a natural limit on 
	 132 
remyelination potential in people with progressive MS and rodent models [14, 108, 312, 395]. The 
data in this thesis demonstrates that NPCs from patients with PPMS fail to foster remyelination 
as well as neuroprotection due to a premature aging phenotype, senescence. Chronic 
mitochondrial oxidative stress is a major trigger of cellular senescence [237, 241]. Markers of 
cellular senescence have been shown to increase in NPCs with normal aging, and are associated 
with diminished regenerative capacity. Importantly, mitochondria are critical for the development 
of pro-inflammatory and tissue-damaging senescence [241, 396]. Mitochondria are essential 
organelles for the generation of cellular energy through signaling and metabolism. Mutations in 
genes that encode subunits of oxidative phosphorylation complex I, part of the electron transport 
chain (ETC), have been identified in PPMS, as well as altered enzyme activities, increased free 
radical production, and oxidative damage [397]. Using MitoSox staining to measure the 
generation of ROS production, I found a significant increase in the production of ROS in the PPMS 
NPCs compared to the age-matched controls (Fig. 6.1). This data potentially implicates 
mitochondrial dysfunction in producing the senescence phenotype in the NPCs from primary 
progressive MS patients. 
 The process of aging has been directly characterized by DNA damage and overall 
genomic instability, which is reflected in somatic DNA mutations in aged human iPSCs [195]. The 
rate of mitochondrial DNA mutations is at least 10-20 fold higher than that of the nuclear genome, 
increases with age, and the age-related decline of mitochondrial DNA copy number is associated 
with late-onset progressive MS [398, 399]. In sequencing patients with progressive MS Ban et al. 
found a trend in the representation of mitochondrial haplogroup U in those with MS, which is 
associated with the oxidative phosphorylation complex I [400]. A publication from Tranah et al. 
found an elevated risk for progressive MS in those with the mitochondrial haplogroups J and T 
[397]. These single nucleotide polymorphisms within J and T occur in genes that encode subunits 
of oxidative phosphorylation complex I, which when deficient, is the most frequent cause of 
bioenergetic dysfunction [401]. Future studies performing mitochondrial sequencing on the NPCs 
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from PPMS patients could reveal potential underlying genetic abnormalities that lead to the 
dysfunction of mitochondria, and the ensuing increase of ROS. 
 In 2016 it was recently discovered that mitochondrial dysfunction can lead directly to 
cellular senescence and secretion of the SASP [237]. Additionally, absence of mitochondria 
prevents senescence, closely linking mitochondrial dysfunction to senescence [241]. The factors 
produced in the SASP of the senescent PPMS NPCs initiated a self-amplifying feedback loop by 
inducing senescence in healthy OPCs through a paracrine fashion and inhibiting their 
differentiation into oligodendrocytes. Mitochondrial aging defects have also been found to emerge 
in directly reprogrammed neurons from aged human fibroblasts, where they showed reduced 
energy production and increased ROS [393]. My own data have also suggested that iPS-derived 
NPCs from PPMS patients exhibit evidence of elevated oxidative stress (Fig 6.1). These data 
insinuate the possibility of mitochondrial defects in the PPMS NPCs that may underlie the 
senescent phenotype. 
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Figure 6.1. NPCs from PPMS patients display increased mitochondrial stress. Increased 
MitoSox intensity quantified in NPCs from PPMS patients relative to total cell number quantified 
(Sox2+ cells) (n = 3 lines/group). t-test, **, P < 0.01. 
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In my studies we also applied proteomics to identify HMGB1, high mobility group box 1, 
as secreted by senescent PPMS NPCs which, in turn, functioned to inhibit OPC differentiation. 
HMGB1 is a chromatin-associated protein which helps maintain nuclear homeostasis by bending 
DNA to provide transcription factor access to promoter regions [402]. When secreted it plays a 
role in inflammation as an alarmin, where it can provoke an innate immune response by binding 
to cell surface RAGE (receptor for advanced glycation end products) and TLRs (toll-like receptors) 
[364]. HMGB1 is secreted by senescent cells, and therefore in senescent cells it translocates from 
the nucleus to the cytoplasm in order to be secreted [364]. Disruption of HMGB1 from the nucleus 
has been found to induce mitochondrial fragmentation as well as deficits in mitochondrial 
respiration [403]. Thus, my findings implicate HMGB1 as a putative mechanism contributing to 
mitochondrial dysfunction which may underlie defects in support of oligodendrocyte growth and 
maturation evident from the PPMS NPCs. 
An important aspect of my studies was the finding that cellular senescence in NPCs was 
amenable to therapeutic manipulation by rapamycin. Rapamycin is a direct inhibitor of mTOR and 
my results showed that rapamycin effectively reversed the senescent phenotype in the PPMS 
NPCs and recovered their ability to support OPC differentiation. Further studies are needed to 
determine whether rapamycin reversal of cellular senescence is a transient event or may result 
in a permanent reversal of senescence in the PPMS NPCs. In addition, studies are planned to 
determine if reversing senescence using rapamycin in iPS-NPCs affects their function when 
administered to cuprizone treated mice [111]. Importantly, rapamycin has been found to alter 
mitochondrial dynamics by increasing mitochondrial respiration, decreasing ROS production, and 
inducing autophagy [404, 405]. In analyzing all facets of the data in this thesis, as well as the 
literature, including the increased ROS production, senescence, reversal of senescence with 
rapamycin, and increased mitochondrial DNA mutations in aged progressive MS patients, 
mitochondrial dysfunction is highly implicated to be the reason for the defects in these cells. 
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Besides the secretion of HMGB1 that directly inhibits OPC differentiation, it is still unknown 
exactly how senescent NPCs alter the lesion microenvironment. Overall, the SASP limits tissue 
regeneration through the secretion of oxidative and pro-inflammatory factors and can induce 
senescence in surrounding cells [212]. Injected senescent NPCs in the cuprizone mouse model 
could be inducing senescence in the host tissue, in turn inhibiting endogenous OPC 
differentiation. Analysis of the mouse lesion sites need to be performed in order to determine if 
the human cells are conferring senescence locally. In addition, the cuprizone model allows for the 
study of endogenous remyelination. Determining if senescent NPCs impair endogenous CNS 
remyelination will help further examine the role of NPCs in the lesion environment. This 
experiment can be performed by injecting NPCs after cuprizone withdrawal. Treatment of mice 
with cuprizone for 4 weeks depletes the myelinating oligodendrocytes, but after cuprizone is 
removed from the diet the resident OPCs will remyelinate [338]. Injection of the PPMS NPCs at 
this time point will determine if they hinder endogenous remyelination after demyelination. The 
lysolecithin model could also be used to study remyelination in the presence of senescent NPCs 
since the key steps in the timeline of the remyelination process is known [305]. Understanding 
how senescent NPCs affect the lesion microenvironment would potentially open opportunities for 
identifying new therapeutic targets which would be expected to promote brain repair in 
progressive MS patients.  
 
III. Do all Subtypes of MS have Senescent NPCs? 
 Based on the data presented in this thesis there are senescent cells in both primary 
progressive and secondary progressive forms of the disease. We identified senescent NPCs 
secreting HMGB1 in lesions from patients with PPMS as well as SPMS. Further characterization 
of cells from patients with the relapsing-remitting forms is needed. The RRMS form of the disease 
is much different to the progressive form as it is diagnosed earlier in life, early 20s, and can be 
treated with immunomodulatory therapies, while the progressive forms have no current 
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treatments. We hypothesize that due to a shift in age of diagnosis, patients with RRMS will not 
have a senescent phenotype in the NPCs. By accident, we obtained a single line of iPSCs from 
a patient with RRMS, line 102. The cells were differentiated into NPCs and assayed for 
senescence markers. p16Ink4a, p53, and HMGB1 were not significantly increased in the NPCs 
from the RRMS line (Figure 6.2A, B, C). In addition, treatment of OPCs with CM from line 102 did 
not significantly decrease differentiation into mature OLs (Figure 6.2D). These preliminary data 
indicate that there are no significant markers of senescence in this line from one RRMS patient, 
but in order to have a definitive conclusion more lines from varying patients need to be assayed. 
A more thorough analysis of post-mortem brain tissue from patients with RRMS would also yield 
more results as to if the NPC population in these tissues are senescent.   
Overall these data suggest a previously unrecognized mechanism occurring in 
progressive forms of MS but not in RRMS, the presence of senescent NPCs inhibiting 
oligodendrocyte differentiation. The model for our current understanding is that with aging, along 
with epigenetic factors altering the risk of MS, NPCs become senescent due to the inflammatory 
lesion environment in progressive MS. Once senescent they no longer can support proper 
remyelination, and instead secrete the SASP inhibiting regeneration. Further study is needed to 
explore and better understand this process and define how this may help with the development 
of new drug targets to induce regeneration. 
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Figure 6.2. No change in senescent markers in neural progenitor cells from an RRMS 
patient line. (A, B, C) p16Ink4a, p53, and HMGB1 mRNA expression by qPCR in control NPC and 
RRMS line 102 NPC cultures revealed no significant changes (unpaired t tests). All qPCR data 
normalized to control NPC lines. (D) Quantitative analysis of oligodendrocyte maturation 
(MBP+/Olig2+) resulting from culture of OPCs in either N2/B27 (unconditioned NPC media), 
control NPC CM, or line 102 RRMS NPC CM after 48 hours. No significant changes in OPC 
differentiation were identified between the conditions (ANOVA). 
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IV. Application of this Data for the Development of New Therapeutics 
 The data presented in my thesis opens the potential for new therapeutic avenues to 
pursue in patients with progressive forms of MS. Currently, there is only one drug that has been 
approved by the FDA to treat PPMS, ocrelizumab. This recombinant antibody selectively targets 
B cells. However, the data supporting its benefits are limited: compared to the placebo group, 
those taking ocrelizumab had a 24% decrease in disability progression after 12 weeks [25]. 
Progression was defined as an increase in the EDSS score of at least 1 point compared to that 
of baseline that was sustained after subsequent visits for at least 12 weeks. This study also 
assayed the patients in their performance on a timed 25-foot walk, the change in total volume of 
brain lesions on T2-weighted MRI, change in total brain volume, and change in the Physical 
Component Summary score of the Medical Outcomes Study 36-Item Short-Form Health Survey, 
which all were assayed to define progression of the disease [25]. No significant changes were 
seen in the Physical Component Summary scores in the two groups after 120 weeks, but 
significant decreases (3.4% decrease compared to baseline) were seen in the total volume of 
brain lesions, and overall brain-volume loss in the ocrelizumab treated group [25]. That only a 
single drug may be useful for PPMS patients leaves significant room for improvement in drug 
therapies to slow progression.  
 New remyelinating therapies, such as clemastine, benztropine, clobetasol, and 
miconazole have been proposed to promote OPCs to differentiate and remyelinate lesion areas, 
but the identification of these compounds did not take into account that the microenvironment of 
the MS brain may affect the ability to translate these findings to patients [110, 163, 164]. Data I 
presented in Chapter 4 demonstrated that a screen which encapsulates the nuances of lesions, 
specific to individuals may impact the quest for potential remyelinating drug candidates. Here, I 
treated OPCs with conditioned media from the individual PPMS patient lines and demonstrated 
that each of the new remyelinating drugs have a patient dependent effect in promoting 
differentiation of OPCs [111]. A combinatorial approach may be beneficial in treating patients with 
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progressive MS. For example, a combination of drugs that target and reverse senescence along 
with remyelinating therapeutics may be warranted. As the technology for the development of 
autologous stem cells becomes more rapid and cost-effective the screening of patient cells and 
how they respond to specific drugs may be an opportunity to develop catered therapies in the 
hopes of slowing progression. Clemastine has been tested in patients with RRMS along with a 
chronic demyelinating optic neuropathy, where it has been shown to induce remyelination of the 
optic nerve, but a more in-depth clinical trial is needed to determine if it can manage and delay 
MS progression [165]. 
 The progressive forms of MS have always been associated with an increase in age, but 
for the first time my thesis studies show the functional consequences and identify NPCs in the 
disease as senescent. This discovery of senescent cells inhibiting the differentiation of OPCs in 
the lesion area opens up new therapeutic avenues. Rapamycin was found to reverse senescence 
of PPMS NPCs and restore their normal functions in supporting OPC differentiation. Rapamycin 
is used for its immunosuppressive effects but has never been used to target cellular senescence 
in patients with progressive MS. A recent clinical trial from Iran demonstrated that after 6 months 
of rapamycin treatment in patients with RRMS there was a decrease in lesion area size measured 
by MRI due to a decrease in immune cell populations [406]. While we know that rapamycin acts 
on mTOR signaling, it can have varying impacts on cells. For instance, even though there is only 
a small immune component to progressive MS, it may be beneficial through the reversal of 
senescence in NPCs. Senescent NPCs were also found to secrete HMGB1, a pro-inflammatory 
alarmin, that directly inhibited the differentiation of OPCs. Through the use of a blocking antibody 
in the PPMS NPC CM the ability of OPCs to differentiate was improved. Determining where 
HMGB1 binds onto OPCs, and how exactly it is inhibiting differentiation could discover a 
mechanism by which to target remyelination. HMGB1 binds to RAGE, TLR2, and TLR4 which 
have all be found to be expressed by OPCs, but the exact downstream mechanism is unknown 
[407, 408]. Total RNA sequencing of OPCs after treatment with PPMS CM and PPMS CM with 
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HMGB1 blocking antibody revealed significant differences in epigenetic regulators, demonstrating 
that HMGB1 has a substantial effect on the development of OPCs. Further experiments delving 
into the exact genetic changes, and when they occur in OPCs, can help better explain why 
differentiation is halted in the presence of PPMS NPC conditioned media. Sequestering HMGB1 
in lesion areas, inhibiting its effect on OPCs, and reversing senescence in NPCs could possibly 
enhance regeneration and slow progression of the disease. 
 Drugs are currently being developed to eliminate senescent cells, called senolytics, to 
restore natural regeneration.  A combinatorial approach using dasatinib (D) and quercetin (Q) has 
been found to specifically eliminate senescent cells in multiple tissues of aged mice, reduce 
inflammation, and increase health- and lifespan [264, 267]. The overall effects of senolytic therapy 
on the aged human CNS is currently unknown, but in a mouse model of Alzheimer’s clearance of 
senescent cells through transgenic targeting ameliorated neurodegeneration [231]. The 
elimination of senescent NPCs may be beneficial in patients with progressive MS by decreasing 
inflammation and allowing for regeneration. Currently, the side effects of eliminating a specific cell 
population through apoptosis in the CNS is unknown and a better understanding is merited before 
human clinical trials.  
 Since the development of stem cells their use in transplantation has been studied, 
especially in neurodegenerative diseases. Work by the Pluchino group has demonstrated that 
NPCs possess therapeutic potential that is distinct from that of small molecules, as they can sense 
diverse signals, migrate to specific biological niches, and execute complex behaviors [147, 149, 
331]. NPCs have been shown to graft and replace lost cells when transplanted into mouse models 
of demyelination, but also act by buffering inflammation and stimulating endogenous 
remyelination [149, 152]. To date, only HSCT has been used in patients with MS, where only a 
small number of patients benefited from the transplant [176]. Transplantation of NPCs may 
provide a greater impact by repairing lesion area by buffering inflammation and through the 
secretion of promyelinating factors [151]. Based on the data presented in this thesis autologous 
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transplant in patients with progressive MS will not be beneficial due to the senescent phenotype. 
Autologous transplant avoids the possibility of rejection, but may not be feasible in patients with 
progressive MS. If specific mutations are identified within the progressive MS NPCs they could 
be targeted using CRISPR gene editing technology before transplantation. Still, these 
technologies are expensive and take time, which limits their use in the clinical setting. On the 
other hand, if healthy NPC transplants in progressive MS patients are found to be beneficial, the 
generation of a large pool of NPCs from healthy donors could be stock pilled for transplantation. 
We still have a long way to go before NPC transplants can be used in the clinic as their efficacy 
and safety in humans is still unknown, and the production of a mass scale of NPCs would be 
costly, as would the quality control of each batch. Studying how transplantation of NPCs into 
mouse models of MS ameliorates disease can help uncover new targetable mechanisms to 
modulate disease progression. 
 
V. Concluding Statement 
My thesis demonstrates for the first time a cell autonomous defect in iPS-NPCs derived from 
patients with primary progressive MS. These cells failed to promote remyelination and provide 
neuroprotection in a demyelinated mouse model due to a senescent phenotype. Senescent NPCs 
were identified in post-mortem progressive MS tissue, associated with HMGB1, a pro-
inflammatory factor that inhibits OPC differentiation. Rapamycin treatment ameliorated the 
senescent phenotype in the NPCs, allowing for oligodendrocyte differentiation. This research 
opens up new therapeutic avenues to pursue in the treatment of progressive MS, such as 
targeting senescent NPCs to promote remyelination. These data implicate cellular aging and 
senescence as a process that contributes to remyelination failure in progressive MS which may 
impact how this disease is modeled and inform development of future myelin regeneration 
strategies. 
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